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Abstract
Cancer-induced muscle wasting, otherwise known as cancer-cachexia, is a wasting
syndrome that occurs in approximately 80% of cancer patients that is the primary cause of death
for 22%-30% of cancer cases. Cancer-cachexia may be metabolically induced; therefore, the
central hypothesis of this dissertation is mitochondrial degeneration occurs before cancercachexia, and increased oxidative stress because of mitochondrial degeneration in muscle may
instigate cancer-cachexia. Lewis Lung Carcinoma cells (LLC) or PBS (control) were injected
into the hind-flank of C57Bl6/J mice at 8 wks age, and tumor allowed to develop for 1, 2, 3 or 4
wks. Mitochondrial quality, function, ROS emission, protein synthesis and protein breakdown
were assessed. LLC Conditioned Media (LCM) treatment of C2C12 myotubes was used to
analyze cancer-cachexia in-vitro. Data were analyzed by one-way (animal experiments) or twoway (cell culture experiments) ANOVA with Student-Newman Kuels post hoc test. Cachectic
muscle loss and decreased oxidative capacity was evident only at 4 wks post-tumor implantation.
Mitochondrial function decreased by ~25% by 3wks after tumor implantation. Mitochondrial
degeneration (MitoTimer) was evident by 2 weeks LLC compared to PBS control. Mitochondrial
ROS production was elevated by ~50% to ~100% when compared to PBS at 1-3 wks post-tumor
implantation. Mixed FSR Protein synthesis was ~40% lower in 4 wk tumor-bearing mice when
compared to PBS controls. Mitochondrial quality control and protein turnover signaling were
dysregulated throughout the progression of cancer-cachexia. Ubiquitin content was elevated by
~50% 4wks after tumor implantation. ERK and p38 MAPK phosphorylation was 4 and 3 fold
greater than control muscle 4 wks following tumor implantation, respectively. MitoT treatment
and inhibition of p38 MAPK ameliorated LCM-induced loss of myotube diameter. These data
provide novel insight into mechanisms which may induce cancer-cachexia.
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Chapter 1
Review of Literature
Cancer is one of the leading causes of death with the World Health Organization reporting 8.2
million deaths and 14.1 million new cancer cases in 2008 worldwide [1]. Moreover, half of the
people that are affected by cancer will die as a result of the condition [2]. In fact, between 1970
and 2008, mortality rates from heart disease, cerebrovascular disease, and accidents declined
62%, 73%, and 38%, respectively [3], but in the same period, cancer mortality rates declined just
12%, mostly since 1990 [3]. One problem associated with cancer is cancer-cachexia, a wasting
syndrome that occurs in approximately 80% of cancer patients [4, 5]. Cancer-cachexia is the
primary cause of death for 22%-30% of cancer patients [4, 5]. Not only is cancer-cachexia
behind an escalation in cancer associated mortality, it also increases the cost of health care [6].
Based on these findings, it is clear that cancer-cachexia is a major health care concern that lacks
adequate therapies.
The syndrome of cancer-cachexia is multifactorial, cannot be fully reversed by nutritional
support and is triggered by a combination of reduced food intake and abnormal metabolism,
seemingly induced by tumor- and host-derived factors [4]. Skeletal muscle atrophy is instigated
by an imbalance of protein turnover favoring protein degradation over protein synthesis;
however, mechanisms behind this imbalance of protein turnover vary depending on the
(patho)physiological circumstance [7, 8]. Overall, metabolic derangements inducing cancercachexia are not fully elucidated in scientific literature; however, mitochondrial degeneration
may contribute [9]. This review of literature will outline cellular processes that contribute to
cancer-cachexia [10].
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Cancer-Cachexia: Mechanisms of Muscle Atrophy
Cancer-cachexia is a prevalent problem which lacks adequate therapies. Current therapies
for cancer-cachexia are focused on increasing energy intake of patients whether from
pharmacological interventions or diet modifications [11]. While hypophagia may influence
skeletal muscle loss, other cellular processes contribute to cancer-cachexia [4]. Cancer-cachexia
is associated with reduced muscle protein synthesis and increased muscle protein breakdown [7,
8] which promotes loss of skeletal muscle mass [10]. Numerous molecular substrates and
mechanisms underlie the dysregulation of skeletal muscle protein turnover associated with
cancer-cachexia [12, 11]. These pathways/molecules include protein synthetic pathways,
autophagy pathways, proteasome pathways, inflammatory cytokines, myostatin pathways and
myogenesis [11-14].
A. Protein Synthesis
Protein Synthesis is a highly controled process that is predominantly regulated at the
stage of initiation [15]. Translation initiation can be divided into three stages: the binding of
initiator methionyl-tRNA (met-tRNA) to the 40S ribosomal subunit to form the 43S preinitiation
complex, the binding of mRNA to the 43S preinitiation complex to form the 48S preinitiation
complex, and the binding of the 60S ribosomal subunit to the 48S preinitiation complex to form
the active 80S initiation complex [15]. Translation initiation is predominantly regulated by signal
transduction [16] (Figure 1). Many factors regulate signal transduction pathways that influence
skeletal muscle’s ability to synthesize protein. This includes energy status, anabolic hormones,
catabolic hormones and mechanical stimuli [17]. The most important signal transduction event
involved in the regulation of protein synthesis is the Akt/mTOR pathway [18]. Insulin and IGF-1
are both major activators of the Akt/mTOR pathway [18]. mTOR regulates translation initiation
2

primarily through the inhibition of eIF4E-BP1 (hereafter 4EBP1) via hyper phosphorylation and
the activation of p70S6K via phosphorylation [19, 20].
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Figure 1-1: Schematic of mTOR and AMPK regulation of protein synthesis and
autophagy.
In cancer-cachexia literature, there is an ongoing debate as to whether a decrease in
protein synthesis, upregulated protein degradation or both play a bigger role in the onset of
cancer-induced muscle wasting [21]. There appears to be discrepancies based on both the type of
model used and the methodology for measuring protein synthesis [21-25]. Current measurements
of protein synthesis in cancer-cachexia literature use acute measurement techniques (3 hours or
less); therefore, there is a key need to explore protein synthesis over a larger range of time.
Protein synthesis may be decreased in cancer-cachexia through a variety of mechanisms
[26, 27]. Both circulating IGF-1 and IGF-1 expression from skeletal muscle is impaired in
cancer-cachexia [28]. Furthermore, both early and late stage cancer-cachexia exhibit diminished
mTOR activation [29, 30]. Many cellular processes can inhibit mTOR activation; however, in
cancer-cachexia both 5′-adenosine monophosphate-activated protein kinase (AMPK) and
inflammation are likely candidates [31, 26]. AMPK becomes active when cellular energy levels
are reduced and upon skeletal muscle contraction [32]. AMPK directly and indirectly through
3

TSC2 activation inhibits mTOR signaling (Figure 1). Specifically, AMPK prevents interactions
between mTOR and 4EBP1 and p70S6K1 [33]. In the early stages of cancer-cachexia, muscle
protein synthesis has been reported to be suppressed by 19% [27]. As cancer-cachexia
progresses, muscle protein synthesis is further decreased by ~50% [27]. Cancer induces a proinflammatory environment which alters skeletal muscle protein turnover. Inflammatory
molecules such as IL-6 reduce phosphorylation of mTOR and 4EBP1 in a dose dependent
manner while increasing the phosphorylation of AMPK [26]. Glycoprotein 130 (GP130) is
critical for fascillitating IL-6 signaling [24]. While GP130 knockout (KO) mice attenuated
cancer-cachexia by ~15%, GP130 KO did not prevent increased AMPK expression and reduced
mTOR phosphorylation which suggests that GP130 is responsible for these alterations in cancercachexia [24]. This suggests that IL-6 partially suppresses protein synthesis in cancer-cachexia
through pathways that are not mediated by GP130.
B. Autophagy
Autophagy is another mechanism which influences protein turnover that appears to be
dysregulated in cancer-cachexia [14]. Autophagy is a process involving the formation of an
autophagosome in order to facilitate lysosomal clearance of proteins and organelles in response
to stress [34-36]. Autophagy in most cases is inversely regulated from protein synthesis [35].
More specifically, autophagy is induced by lack of nutrients, hormones, oxidative stress and
energy balance [36], while mTOR activation inhibits autophagy [37, 35] (Figure 1). Recent
evidence has revealed autophagy may be dysregulated in cancer-cachexia [14]. Promotion of
autophagy via cancer-cachexia related stimuli is evidenced by increased LC3 II: LC3 I ratio;
however, lysosomal clearance may be impaired indicated by increased p62, an autophagy cargo
protein [14]. Likely mechanisms for the induction of autophagy as it relates to cancer-cachexia
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are mTOR inhibition and AMPK activation [36, 38, 9]. Excess oxidative stress may also
upregulate autophagy in cancer cachexia; however, skeletal muscle reactive oxygen species
(ROS) production has not been adequately examined [36, 38]. Autophagy is one of many
processes that influence protein breakdown. To current knowledge, other cellular processes such
as proteasomal degradation are likely more involved in cancer-cachexia than autophagy;
however, autophagy enables the cell to remove damaged organelles such as the mitochondria
which may influence cancer-cachexia. Autophagic removal of mitochondria will be discussed at
a later section in this literature review.
C. E3 Ligases and Proteasome
The proteasome is essential for cellular function as demonstrated by the onset of
oxidative stress and apoptotic cellular death following the administration of proteasome
inhibitors [39]. Despite the proteasome’s essential function for cellular health, in skeletal muscle
over-activation of proteasomes induces skeletal muscle wasting [40]. In late stage cancercachexia, proteasome-induced muscle atrophy is clearly prevalent [7, 41].
The ubiquitin proteasome system works via a complex series of reactions which transfer
activated ubiquitin to protein substrate via E1, E2 and E3 ligases. The 26S proteasome which
consists of a 20S catalytic core and 19S regulatory subunits [42] will then degrade the ubiquitin
tagged proteins. Specifically, the 19S subunits are responsible for recognizing ubiquitin-tagged
proteins, while the 20S catalytic core is responsible for protein degradation [42]. In order to load
ubiquitin onto a protein substrate, ubiquitin-activating enzymes (E1s), ubiquitin-conjugating
enzymes (E2s), and ubiquitin-protein ligases (E3s) perform a series of high energy reactions [43]
(Figure 2). Briefly, the process begins with the ATP-dependent activation of ubiquitin (Ub) by an
E1, which results in a high-energy thioester linkage between the COOH terminus of ubiquitin
5

and the active site cysteine of the E1 [44, 45]. The activated ubiquitin is then transferred to an
E2, again forming a thioester bond [44, 45]. The final step is the transfer of the ubiquitin from
the E2 to a substrate via an E3 ligase [44, 45]. E3 ligases facilitate poly-ubiquitination in order to
tag a protein for the proteasome by the formation of isopeptide bonds on lysine residues [46, 47,
45] [48, 45].
In skeletal muscle, there are two muscle specific E3 ligases that are particularly involved
in the induction of skeletal muscle wasting [49]. Specifically these ligases are Muscle Atrophy FBox Protein-1 (Atrogin-1) and Muscle Specific RING Finger-1 (MuRF-1) [49] (Figure 2). Under
normal conditions, Atrogin-1 and MuRF are scarcely expressed; however, expression rapidly
increases following atrophic stressors [50]. Atrogin-1 and MuRF facilitate the ubiquitination of
many proteins involved in hypertrophic programing including proteins involved in ATP
generation, protein synthesis, myogenic regulatory factors and myofibrillar proteins [51-54].
Both Atrogin-1 and MuRF-1 are regulated by FOX-O1/3, members of the fork head family of
transcription factors, in skeletal muscle [55, 56]. Fork head family of transcription factors have
the ability to be translocated into the nucleus upon phosphorylation and bind to a distinct fork
head DNA binding domain to influence transcriptional activity [56]. FOX-O1/3 signaling
appears to interact with protein synthetic signaling demonstrated by the inhibition of FOX-O1/3
activation via AKT phosphorylation [57, 58]. Cellular stress seems to promote FOX-O1/3
signaling [59]. FOX-O1/3 signaling upregulates the process of autophagy as well [59, 60].
Intriguingly, FOX-O1/3 promotes cellular ROS detoxification by increasing the transcription of
the antioxidant enzymes MnSOD and Catalase which will be discussed in subsequent sections in
the literature review [61].
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When cancer-cachexia occurs, the expression of both Atrogin-1 and MuRF dramatically
increase mediated by FOX-O1/3 signaling [27]. Chronically elevated cytokines such as IL-6 are
involved in promoting the upregulation of both Atrogin-1 and MuRF [7]. Considering the
regulation of Atrogin-1 and MuRF is multifaceted, multiple cellular signals other than
inflammation stimulate increased expression of these E3 ligases. Pathways associated with
energy levels and stress related signaling which induce Atrogin-1 and MuRF are likely behind
the induction of these E3 ligases in cancer-cachexia [62, 63].
D. Pro-inflammatory Cytokines
Cachexia is a systemic problem with the presence of an inflammatory response and
profound metabolic derangements in not only muscle and fat, but in hypothalamus, liver, heart,
blood, spleen and likely other organs [64]. This global response is orchestrated in part through
circulating cytokines that rise in conditions of cachexia [9, 65, 66, 64]. Cytokines implicated to
induce negative metabolic effects in cancer cachexia are IL-6 and TNFα [67].
Exogenous IL-6 and related cytokines can induce most cachexia symptomatology,
including muscle and fat wasting, the acute phase response and anemia, while IL-6 inhibition
reduces muscle loss in cancer [64]. In tumor bearing mice, there is a dramatic increase in plasma
IL-6 [68]. Downstream of IL-6, GP130 KO mice exhibit attenuated cancer-induced muscle and
fat loss and reduced pathological phosphorylations of STAT3, p38 and FOX-O3 [24]. Moreover,
IL-6 reduces protein synthesis by indirectly inhibiting mTOR [26], a key regulator of protein
synthesis [69], signaling likely mediated through upregulated AMPK expression and induces
cellular proteolysis [70, 66]. Furthermore, recent evidence suggests IL-6 represses Pgc-1α4
mRNA, a regulator of skeletal muscle hypertrophy [71], content by signaling through ERKMAPK [72]. STAT3 signaling is causally linked to phenotypes of cancer-cachexia including
7

skeletal muscle wasting, cardiac dysfunction and hypothalamic inflammation [64, 9, 26, 73].
Intriguingly, the induction of cancer-cachexia is IL-6 independent in female mice [74].
TNF-α is an inflammatory mediator present in the tumor microenvironment that has been
implicated in carcinogenesis, especially in the early stages, including angiogenesis and invasion
[75]. As far as muscle atrophy is concerned, TNF-α is involved in the promotion of apoptotic
signaling of Type II muscle fibers, which can induce muscle atrophy [76]. Furthermore, TNF-α
has been shown to increase the expression of ubiquitin and key E3 ligases (Atrogin-1 and MuRF1) leading to an accumulation of ubiquitin tagged proteins which will prompt skeletal muscle
atrophy [77, 78]. This is mediated through the activation and translocation of transcription factor
NFκB [79]. Intriguingly, TNF-α also decreases food intake by acting on the hypothalamus to
modulate expression of neurotransmitters dealing with energy balance [80]. TNF-α further
modulates energy balance by increasing the gene expression of uncoupling proteins 2 and 3 in
skeletal muscle, leading to inefficient mitochondrial energy production [81].
E. Myostatin
Myostatin (Mstn) is another heavily researched target for the promotion and prevention
of cancer-cachexia. Mstn is a highly conserved member of the TGF-β superfamily of proteins,
and is considered to be a master regulator of skeletal muscle mass that promotes/inhibits many
protein turnover processes [82]. Mstn acts in an autocrine/paracrine manner by binding to type-II
activing receptors ActRIIA and ActRIIB, which then recruit and activate type-I activin receptors,
also known as activin receptor-like kinase (Alk) 4 and 5 [83]. This, in turn, causes
phosphorylation of Smad2 and Smad3, the association with Smad4 into a Smad2/3/4 complex,
which then enters into the nucleus to trigger gene transcription [83]. Smad 2/3/4 complex
stimulates FoxO-dependent transcription and enhanced muscle protein breakdown via the
8

ubiquitin-proteasome system and autophagy [83]. In addition, Smad activation inhibits muscle
protein synthesis by suppressing Akt signaling [83]. Due to Mstn’s vast role in the regulation of
skeletal muscle mass, it has garnered attention in the prevention of cancer cachexia [84].
Intriguingly, cancerous Mstn KO mice live longer than cancerous wildtype mice [84]. Mstn KO
mice also exhibit the ability to repress tumor growth [84]. These mice prevent atrophy inducing
pathways such as FOXO3 mediated induction of Atrogin-1 and MuRF-1 and autophagy [84].
Moreover, Mstn KO mice prevent cancer-cachexia associated reduction of protein synthesis [84].
Also, inhibitors for myostatin pathways appear to diminish cancer-cachexia [85, 22]. Though
Mstn exhibits these effects, tumor burden does not appear to alter myostatin expression and
signaling in skeletal muscle, therefore cancer-cachexia is likely mediated through other
mechanisms [84].
F. Myogenesis
Myogenesis is the formation of muscular tissue and is especially important for postnatal
skeletal muscle regeneration that is necessary for muscle repair. Myogenesis is primarily
regulated by four myogenic regulatory factors (MRF): MyoD, Myf5, Myf 6 and myogenin [86].
Muscle repair coincides with injury induced inflammation, and the induction of some proinflammatory cytokines [87]. Satellite cells, which lie under the basal lamina of muscle fibers
and are marked by the expression of Pax7, also provide a crucial role in skeletal muscle
regeneration [88]. In certain diseased states such as aging, muscular dystrophy and cancer,
satellite cell numbers and proliferative potential decreases, which may induce a failure to
maintain muscle homeostasis [89, 90]. In the process of skeletal muscle regeneration, satellite
cells become activated and shift from expressing Pax7 to MyoD and Myf5 [91]. Upon activation,
satellite cells transmigrate through the Extra Cellular Matrix (ECM) to the outside of the muscle
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fiber [91]. Progenitor cells within the satellite cell pool proliferate into myoblasts stimulated by
signals induced from MyoD and Myf5 [92, 91]. The accretion of myoblasts to preexisting
myofibers is essential for hypertrophic muscle growth [73]. These myoblasts will then
differentiate into myotubes from signals induced from Myogenin [92, 91].
It is clear that myogenesis is involved in the regulation of muscle mass [73]. It is
postulated that impaired myogenesis does not directly influence muscle atrophy; however, this
may be due to a compensation by protein synthetic programing that is not present in cancercachexia [93, 94]. In cancer, the sarcolemma becomes damaged due to factors secreted by the
tumor. This is problematic because cancer is associated with impaired myogenesis in skeletal
muscle, which is linked to dysregulated differentiation and muscle loss [95]. NFκB is activated
in muscle progenitor cells during cachexia leading to sustained Pax7 expression [94]. In turn, a
self-renewing signal in myogenic cells is likely propagated that results in their inability to
progress through a differentiation programing (Figure 3) [94]. NFκB mediated Pax 7 expression
has been linked to impaired MyoD synthesis [96]. In fact, cancer decreases the expression of
MRFs despite the induction of satellite cells or other resident progenitor cells in skeletal muscle
[97, 94]. Furthermore, the process of myogenesis may have a more direct effect on promoting
skeletal muscle atrophy [98, 99]. Myogenin seems to upregulate both Atrogin-1 and MuRF-1 to
elicit a proteolytic response [99, 98].
G. Apoptosis
It is theorized that there is a linear relationship between the link between cell volume and
DNA content of cells [100]. Muscle fibers are the largest volume animal cell requiring multiple
nuclei to support the amount of tissue [101]. There is a correlation between the nuclei present
and the size of the muscle tissue in young (less than 2 months of age) and old mice (greater than
10

23 months of age), but not middle aged mice [102]. Based on this principle, a loss of myonuclei
could lead to smaller muscle fibers.
It has not been proven that myonuclear apoptosis does occur in permanent fibres
undergoing atrophy [102]. Using TUNEL staining, nuclear apoptosis appears to occur in atrophic
conditions [103]; however, it is not clear whether the myonuclear apoptosis occurs in satellite
cells or myonuclei [102]. In cancer-induced muscle wasting, severe cachectic phenotype shows
an increase of up to 1.5% tunel + nuclei [104]. Moreover, prior literature showed a 9.8 fold
increase in skeletal muscle DNA fragmentation of LLC tumor-bearing mice when compared to
control mice utilizing scanning densitometry [105]. Also in more severe cachectic phenotypes,
literature suggests that cleaved caspase 3 may be upregulated in LLC tumor-bearing mice [106].
It is still not clear whether myonuclear apoptosis has a role in the onset of cancer-cachexia due to
lack of data.
MAPK signaling in cancer-cachexia.
A mitogen-activated protein kinases (MAPKs) are involved in directing cellular
responses that promote survival [107]. Specifically, MAPKs coordinately regulate proliferation,
gene expression, differentiation, mitosis, cell survival, and apoptosis among other things [107].
MAPK family of proteins includes extracellular signal-regulated kinases 1 and 2 (ERK1/2), cJun amino-terminal kinases 1 to 3 (JNK1-3), p38 (α, β, γ, and δ), and ERK5 families [108].
Typically, MAPKs are activated by a number of phosphorylation events on both threonine and
tyrosine residues, and are inactivated by a variety of phosphatases [109, 110]. MAPK literature
indicates a wide array of regulatory functions; however, future research needs to further elucidate
MAPKs role in the regulation of skeletal muscle mass in atrophic conditions.
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Recently, MAPKs have been implicated as critical controllers of skeletal muscle mass
[111, 112], and are potential theraputic targets for multiple muscle wasting conditions [113-117].
MAPKs regulate skeletal muscle programs such as ubiquitin proteasome system [118], extra
cellular matrix processes, myogenic programing [119], fibrosis, lipid accumulation,
inflammation [112], and morphological changes [64] all of which are involved in the
maintenance of skeletal muscle mass. A few specific examples of MAPK inhibition attenuating
muscle loss include models of endotoxin, musclular dystrophy, inflammation and chemotherapy
mediated muscle wasting [115, 114, 120, 121]. Both p38 MAPK and ERK MAPK seem to be the
major controllers of processes which regulate proteostasis in these studies.
In models of cancer-cachexia, it appears that p38 MAPK expression is induced in
response to tumor burden [113], which may be from associated inflammation [122].
Furthermore, there is evidence that inhibition of p38 MAPK in myotubes and skeletal muscle
prevents upregulation of E3 ligases [117, 123, 124]. Moreover, experimental evidence suggests
inhibition of ERK MAPK signaling may help prevent cancer-induced muscle wasting [116].
Furthermore, pharmacological inhibition of both p38 and ERK 1/2 MAPK may attenuate cancerinduced muscle loss [123]. Based on these reports, p38 and ERK 1/2 MAPK could be potential
targets for new therapeutic strategies to treat cancer-cachexia.
Denervation in Skeletal Muscle
A neuromuscular junction is a synapse formed by the contact between a motor neuron
and a muscle fiber [125]. The neuron releases acetycholine into the synaptic cleft using
microvesicles which fuse to the neuronal membrane [125]. The acetylcholine then travels down
the acetylcholine receptor (AChR) enriched synaptic cleft to bind to AChR and elicit a
contractile response in skeletal muscle [125]. Normally AChR density is higher than needed for
12

efficient capture of the acetylcholine released [126]. In fact, blockade or removal of ∼80% of
receptors is required to reduce the response to acetylcholine by 50% [126]. Therefore, it is
unlikely that downregulation of AChR results in functional denervation. The expression of
AChR is partially mediated through ERK 1/2 [127]. AChRs are concentrated at the synaptic
cleft, with a receptor density of ∼10,000–20,000 AChRs/μm2 [128].
It is well established that denervation will induce skeletal muscle wasting by both the
downregulating protein synthesis and the upregulation of rates of protein breakdown.
Denervation downregulates mTOR complexes thus decreasing capacity for protein synthesis
[129]. Moreover, denervation is associated with upregulated atrogenes (Atrogin1 and MuRF1),
which are heavily involved in proteasome mediated muscle wasting [130]. Also autophagy genes
are upregulated in response to denervation [60]. To my knowledge denervation has never been
examined in cancer-cachexia; therefore, it is worthwhile for future research to examine this
considering its role in inducing numerous factors regulating protein turnover.
Cancer-Cachexia: The Role of Mitochondria in Muscle Wasting
It is clear that mechanisms related to muscle wasting may also be related to muscle
metabolism since glycolytic muscle fibers have greater wasting susceptibility with several
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Figure 1-3: Schematic of mitochondrial damage leading to skeletal muscle atrophy.
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diseases [70, 131, 132]. In fact, mitochondrial induced mechanisms of skeletal muscle atrophy
are a common feature across numerous models of skeletal muscle atrophy [133]. Mitochondrial
degeneration may instigate skeletal muscle atrophy through mechanisms such as reduced protein
synthesis, increased autophagy, an upregulation of skeletal muscle atrogenes, produce
inflammation and alter myogenesis all of which are altered in cancer-cachexia [134-140] (Figure
3). This may be due to reduced energy production and/or excess mitochondrial ROS production
[137-140]. In cancer, there are dysregulations in mitochondrial quality control mechanisms
which may instigate mitochondrial degeneration [9, 141]. These quality control mechanisms
include mitochondrial biogenesis, mitochondrial dynamics and mitochondrial specific autophagy
[142]. Because of this, the mitochondria may be a potential therapeutic target to treat cancercachexia.
In order to prevent mitochondrial degeneration, several regulatory processes must be
implemented to ensure that the mitochondria are able to perform oxidative metabolism. These
processes include the biogenesis of new mitochondrial components, fusion and fission of new
and damaged mitochondrial regions with the network (dynamics), and the selective degradation
of damaged mitochondrial regions through the process of autophagy (mitophagy) [142]. These
mitochondrial regulatory processes aid in the maintenance of the mitochondrial network that and
ensures that the mitochondria does not emit excess toxic substances such as reactive oxygen
species. In cancer-cachexia, many of these mitochondrial regulatory processes appear to be
disrupted, which may induce mitochondrial degeneration [9, 141, 38]. Mitochondrial
degeneration quickly leads to a loss of mitochondrial function, which is commonly associated
with skeletal muscle atrophy [143]. Disrupted mitochondrial function leads to an upregulation of
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cellular catabolic affects such as reduced protein synthesis, increased autophagy and increased
proteasome induced atrophy [144, 140].
A. Mitochondrial Biogenesis and Dynamics
PGC-1α is a transcriptional co-activator that coordinates the transcription factors critical
for the addition of mitochondrial components [145]; therefore, PGC-1α is critical for optimal
metabolic function [146, 147]. In fact, PGC-1α may even regulate protein turnover processes
[148]. PGC-1α can actually inhibit FOXO3 and thereby reduce the expression of both Atrogin1
and MuRF1 [148]. Cancer-cachexia seems to dysregulate the expression of PGC-1α [147, 38].
This altered expression of PGC-1α will likely have drastic affects in cellular oxidative
metabolism, which if PGC-1α signaling becomes disrupted, may instigate a loss of mitochondrial
function which induces catabolic effects [149].
PGC-1α appears to perform an important role in promoting mitochondrial quality through
other mitochondrial regulatory factors such as mitochondrial dynamics and mitophagy [150, 142]
(Figure 4). Non-
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Figure 1-4: Schematic of regulators of the mitochondrial network.
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exacerbates mitochondrial dysfunction [142]. Mitochondrial dynamics is the process in which
the mitochondrial network is enzymatically divided (fission) or merged (fusion) [142].
Mitochondrial division is mediated by a single dynamin-related protein, DRP1, whereas fusion
requires two families of dynamin-like proteins, Mitofusin 1/2 (MFN1/MFN2) and OPA1.
Evidence suggests that Dynamin Related Protein 1 (DRP1) divides mitochondria by forming
helical structures that wrap around mitochondria [151-154]. The process of mitochondrial
dynamics is highly regulated. Proteins such as FIS1 or Mitochondria Fission Factor (MFF) are
involved in coordinating the recruitment of fission factors to the mitochondrial membranes
[155]. Moreover, kinase activity will promote interaction of fission factors to fission regulators
[155]. It is clear regulators of mitochondrial dynamics are involved in mitochondrial function.
Specifically, MFN2 regulates critical co-factors for oxidative metabolism [156].
Dysregulation in mitochondrial dynamics may instigate skeletal muscle atrophy [157, 158].
Dysregulation in mitochondrial dynamics favoring an upregulation of mitochondrial fission
proteins and a downregulation of mitochondrial fusion proteins will promote atrophic stimuli
[159]. Recent evidence suggests an increase in mitochondrial fission is a required signal that
promotes AMPK-FOXO3 signaling promoting increased expression of Atrogin-1 and MuRF
[158]. In cancer-cachexia, like other (patho)physiological stimuli, there is a dysregulation in
mitochondrial dynamics [9].
B. Mitochondrial Specific Autophagy
Mitochondrial specific autophagy (mitophagy) is another mitochondria quality control
process that when disrupted appears to exacerbate (patho) physiological conditions such as aging
and diabetes [160, 161]. Mitophagy is the selective engulfment of mitochondria by
autophagosomes and their subsequent catabolism by lysosomes [162]. Mitophagy is highly
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selective in nature [160]. This selectivity initially was found associated with a loss in
mitochondrial membrane potential at the inner membrane [163]; however, recently other factors
such as Uth1p and Cyclophilin D seem to be involved [164, 165]. This process of mitophagy is
crucial for the maintenance of a healthy mitochondrial network [166].
Mitophagy regulation appears to be multifaceted. The PINK-Parkin pathway appears to be a
key regulator of mitophagy [162]. Parkin is a cytosolic E3 ligase that translocates to the
mitochondria upon depolarization [167, 168]. Parkin will then ubiquitinate mitochondrial outer
membrane proteins in order to initiate the process of mitophagy [169]. Intriguingly, Parkin also
inhibits mitochondrial fusion by triggering the degradation of MFN 1/2 [170]. Furthermore
PINK-1 can act as a molecular sensor for damaged mitochondria which will then aid in the
recruitment of Parkin to the mitochondrial membrane [171]. It appears PINK-1 will directly
phosphorylate Parkin in order to aid in the recruitment to the mitochondria [172]. BNIP3 is
another protein involved in the process of regulating the accumulation of PINK-1 to the outer
membrane of the mitochondria [173]. BNIP3 is a stress-induced molecular adaptor that directly
interacts with the mitochondria and LC3 to promote the process of mitophagy [174].
Cancer-cachexia appears to increase susceptibility for mitophagy in skeletal muscle [175,
14]. In cachectic human patients, markers for autophagasome formation are elevated along with
elevated p62 protein content [14]. Considering p62 is a cargo protein that becomes degraded
once autophagy occurs, this data suggests that there may be impaired autophagy clearance in
individuals with cancer-cachexia. Protein contents of both BNIP3 and Nix/BNIP3L tend to
increase in human cachectic patients [14]. There are mixed results in the expression of PINK-1
mRNA in cachectic cancer patients [14]. Taken together, this data suggests that the process of
mitophagy appears to be upregulated in cancer-cachexia; however, autophagosome clearance
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may be impaired. This failure for autophagosome clearance may result in excess damaged
mitochondria in the cytosol of the cell.
It is clear that cancer-cachexia induces dysregulation of mitochondrial quality control
processes which most likely results in degeneration of the mitochondrial network. It is well
established that cancer cells utilize a glycolytic metabolism; however, due to impairments in
muscle oxidative metabolism associated with cancer glycolytic metabolism may also be utilized
in muscle [176]. This is termed the Warburg effect [176]. Mechanisms for the induction of the
Warburg effect in skeletal muscle are not understood.
C. Mitochondrial Super Complex
The electron transport chain is a multi-protein system organized into 4 respiratory chain
complexes (complex 1-4) used to create a chemiosmotic gradient from reducing NADH and
FADH2. Complex 5 then uses this chemiosmotic gradient to generate ATP. The structure of
these electron transport complexes will change from freely moving along the inner membrane of
the mitochondria to a multi-protein oligomerization called the supercomplex [177]. Briefly,
subunits of complex 1 in the mitochondrial electron transport chain contribute to the
oligomerization of complex 1, complex 3 and complex 4 [178]. Also, COX7C and COX7A
subunits of complex 4 attach to complex 3 and complex 1 [178]. This supercomplex formation
has been theorized to be critical for the transport of electrons through the electron transport chain
[178]. Mitochondrial supercomplex formation has been shown to reduce the diffusion distance
required for the transfer of electrons [179, 180]. This increases the efficiency of electron transfer
between complexes and limits the opportunity for ROS production [179, 180].
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Recently exercise was shown to be a key contributor to mitochondrial supercomplex
formation [181]. Increased mitochondrial supercomplex formation likely increases energy
production efficiency, which is needed during exercise [181]. The importance of supercomplex
formation has recently become clinically relevant. Disease states such as aging [182, 183] and
diabetes [184] have impaired mitochondrial supercomplex formation in skeletal muscle.
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Figure 1-5: Schematic of Mechanisms to neutralize ROS.
Mitochondrial ROS in Cancer-Cachexia
Multiple lines of evidence suggest that cancer-cachexia may lead to mitochondrial
degeneration [141, 9]. Mitochondrial degeneration leads to a robust decrease in mitochondrial
oxygen consumption and diminished ATP production from metabolic substrates [185].
Furthermore, mitochondrial degeneration leads to excess mitochondrial ROS production which
disrupts cellular health [186, 187]. Because of this, mitochondrial ROS may induce cancercachexia.
Mitochondrial ROS is neutralized in a two-step process starting with SOD 2/3 in the
conversion of superoxide molecules to H2O2 [188] followed by catalase converting H2O2 into
H2O [186]. H2O2 is problematic for cellular responses as it can freely pass through the
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mitochondrial membrane; while other forms of ROS that are more reactive per se (superoxide)
typically need a channel to cross the mitochondrial membrane [188]. Superoxide will likely
exacerbate normal mitochondrial processes.
A. ROS Signaling
It is clear that in many cases ROS and RNS can play a double role in organisms [189]. At
elevated levels free radicals induce oxidative damage and tissue dysfunction; however, free
radicals may also elicit a stress response beneficial to the cell [189]. It is currently accepted that
all cellular sources of ROS provide significant contribution to processes that damage tissues.
Cells assure their survival, through mechanisms such as autophagy and apoptosis [189]. Elevated
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Atrogin1 and
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Reduced
Protein
Synthesis

DNA
Fragmentation
and Apoptosis

Muscle Mass
Figure 1-6: Mechanisms in which ROS induces atrophy.
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ROS is widely studied in a variety of (patho)physiological conditions, and is associated with
impaired skeletal muscle function [190]. Excess ROS is associated with elevated skeletal muscle
inflammation as well as apoptotic signaling, promoting skeletal muscle atrophy [191-194]. The
first reported incident of oxidative stress inducing skeletal muscle atrophy was identified
approximately 2 decades ago in a hindlimb unloading model [195]. Since this early observation,
numerous animal studies have confirmed that prolonged skeletal muscle inactivity promotes
oxidative stress and a growing number of studies reveal that “select” antioxidants can delay
disuse muscle atrophy [191, 192]. ROS significantly decreases the content of proteins associated
with muscle health and function, including myosin, alpha-actinin, desmin, talin, and troponin I
[193]. The mechanisms in which ROS impairs skeletal muscle health are through apoptotic
signaling, promoting increased protein breakdown, reducing protein synthesis and oxidizing
cellular proteins [194].
B. ROS and Apoptosis
Apoptotic signaling is involved in the induction of skeletal muscle atrophy by inducing
nuclear and myofilament degradation [196]. ROS activates both caspase 3 and calpain which is
responsible for nuclear and myofilament degradation [196]. Futhermore, ROS may be
responsible for the loss of myonuclei which has been observed in many atrophic conditions [197,
198]. This loss of myonuclei decreases the skeletal muscle myonuclear domain [197]. It has been
shown that the number of nuclei in skeletal muscle is relatively stable; which implies that loss of
nuclei may not be involved in the induction of skeletal muscle atrophy [197]. This myonuclear
loss leads to a decrease in the amount of skeletal muscle tissue that muscle cells can support
[198]. This myonuclear loss may be the result of satellite cell apoptosis which prevents the
addition of additional myonuclei [199]. ROS has been shown to induce apoptosis of satellite
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cells, which may reduce satellite cell pool and prevent the addition of new myonuclei [200].
Apoptotic signaling is the only thing that can degrade actinomyosin complexes which makes it a
clear mechanism for the induction of skeletal muscle atrophy [196].
C. ROS and Protein Turnover
Apoptosis is not the only mechanism of muscle atrophy that ROS induces. Exposing
skeletal muscle myotubes to ROS activates proteases leading to protein degradation [201].
Specifically H2O2 upregulates expression of specific E3 and E2 proteins that are thought to
regulate muscle catabolism, including atrogin1, MuRF1, and E214k [201]. Furthermore, ROS
can impede cell signaling pathways that promote skeletal muscle protein synthesis [202, 203].
Specifically ROS disrupts the assembly of the mTOR complex [203] and reduces
phosphorylation of 4EBP1 [202]. Furthermore, ROS increases the expression of Calpain1.
Calpain1, a calcium activated protease, seems to be required for muscle atrophy as displayed in
C2C12 cells and evidenced by the use of small interfering RNA’s against Calpain1 [193].
Calpain1 is involved in the regulation of numerous protein turnover pathways including
the ubiquitin proteasome pathway and anabolic processes mediated by Akt-mTOR-p70S6K and
ERK-MAPK [204].Taken together, excess ROS imbalances protein turnover towards protein
degradation.
ROS may potentially be a key instigator of cancer-cachexia; however, it has not been
directly measured in cancer-cachexia. Some researchers have implicated excess oxidative stress
as a potential mechanism for inducing cancer-cachexia and have successfully attenuated
cachexia progression with antioxidant treatments such as quercetin [205]. Utilizing antioxidants
to specifically treat cancer-cachexia is challenging because antioxidants may influence tumor
growth as well [206]. ROS exerts a dual role within the tumor itself, as it either promotes
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proliferation and vascularization of the tumor or induces senescence and apoptosis [206].
Currently it is postulated that antioxidants may only be helpful for individuals with a
compromised antioxidant defense status due to the inability to specifically target skeletal muscle
ROS production [206].
Models to Study Cancer-Cachexia
Cachexia is a wasting disease that is associated with the course of multiple underlying
disease processes, including cancer, chronic kidney disease, chronic heart failure, AIDS and
other chronic diseases [207]; therefore, animal models to successfully study cachexia are crucial
to gain a greater understanding of the condition. Intriguingly, each of these disease states
produces clinical symptoms of cachexia that are strikingly similar such as increased energy
expenditure, loss of lean body mass and fat mass and a loss of appetite [208]. Of utmost
importance is identifying models to study cancer-cachexia given that cachexia affects up to 80%
of individuals with certain types of cancer [209]. Despite the gravity of cachexia, there have only
been a few clinical trials to attempt to treat the condition; therefore, a reliable animal model to
study cachexia is critical to provide insight to potential therapies that could be utilized to treat
cachexia [210].
Patients with cancer-cachexia, like other diseases/disorders that induce muscle wasting,
are exposed to a high inflammatory environment. This high inflammatory environment may be
the root cause behind the hypophagia seen in many cachectic individuals [210]. In order to
mimic inflammatory responses induced by cancer animals can be injected with cytokines such as
TNFα, IL-1β or IL-6 [211, 212]. These inflammatory cytokines are often injected directly into
skeletal muscle to induce a quick response to inflammation [213]. This method for inducing
cachexia has its draw backs. While it is easy to isolate specific cytokines to examine direct
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signaling responses elicited by them, there are many other tumor properties that are not going to
be examined.
Animal models that simulate human cancer-cachexia most commonly use implanted
tumor cell lines such as Lewis Lung Carcinoma (LLC) and C26 model, colorectal tumors,
syngeneic sarcomas and other types of stable, cachectogenic neoplasms [214-217]. Other models
for the study of cancer-cachexia include methylcholanthrene-induced sarcomas [218], prostate
tumors [219], Yoshida AH-130 hepatoma (rats only) [220], EHS chondrosarcomas (mice only)
[6], MAC16 colon adenocarcinoma [221], and Walker 256 carcinosarcomas [222]. In
implantation models, the rate in which cancer-cachexia occurs is largely dependent on the
amount of tumor cells injected into the mouse and the location of the injection of tumor cells. If
1X107 tumor cells are implanted into the hind flank of a mouse than cachexia occurs around 30
days after implantation [217, 24].
LLC is considered the most commonly used and best characterized model of cancer
cachexia [223, 210]. These cell lines are implanted subcutaneously into experimental animals
and are allowed to grow to a particular burden at which point they cause symptoms of cachexia.
The implanted cell lines do not metastasize significantly, a key difference from cachexia-causing
neoplasms in humans, but implanted tumors have been demonstrated to be similar in many other
ways to human cancer [210]. The commonly used tumor lines induce cachexia through release of
cachexia-inducing factors and stimulation of host-tumor interactions [210]. Many of these
implanted tumor cells express or induce inflammatory cytokines or prostaglandins, which is
similar to human cancer [210]. Moreover, implanted tumors have been reported to result in key
features of cachexia, including anorexia, weight loss and increased energy expenditure which is
similar to human cancer [224]. A key advantage of the LLC model to study cancer-cachexia is
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the ease of monitoring tumor growth and proliferation and knowing the exact time frame in
which the animal has cancer.
Genetic models such as the APC/Min+ mouse are also commonly used in order to study
cachexia. The APC/Min+ mouse will sporatically have a mutation that will lead to colorectal
cancer. The APC/Min+ model of cancer-cachexia has been shown to be largely IL-6 dependent
[225]. The rate in which muscle loss occurs in APC/Min+ may vary. Typically this model will
exhibit mild cancer-cachexia by 16 weeks of age and will continue to a severe form of cancercachexia after that [7]. These mice typically do not live much longer than 20 weeks of age. These
mice have a distinct advantage of not being hypophagic, so cachexia can be attributed to factors
secreted by cancer or cancer proliferation. However, most human cancer patients are
hypophagic; therefore, the APC/Min+ mouse may not accurately reflect human cancer. Another
disadvantage is the inability to pinpoint when the mouse is cancerous.
Different models used for the analysis of cancer-cachexia often have vastly different
results. For example, rates of protein synthesis are different based on the model and the number
of tumor cells injected. Because of this, it is of utmost importance to specify details of the
specific model used to induce cachexia. The tumor microenvironment may be dramatically
different for each line of tumor and therefore, may contribute to the differences observed with
each cell line. Future research should use an omics approach to compare muscle wasting of
different models of cancer-cachexia order to identify differences between models of cancercachexia.
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Gaps in Cancer-Cachexia Literature
Considerable progress has been made behind mechanisms of cancer-cachexia; however,
the process of cancer-cachexia is not fully understood. Specifically, progression of cancercachexia has not been well examined and ROS as a potential mechanism for the onset of cancercachexia has not been studied.
First, studies do not examine the progression of cancer-cachexia. In cancer-cachexia
literature, studies tend to only examine end point cachexia [9, 27, 24]. This can provide valuable
information about the atrophic pathways that are elevated when the muscle is cachectic;
however, it does not address signaling that instigated cancer-cachexia. Recent literature calls for
research investigating modalities that could be used to prevent cancer-cachexia [226].
Understanding signaling that leads to the induction of cancer-cachexia will provide valuable
information that could be used to develop therapies to prevent cancer-cachexia. Using a time
course experiment will provide this information.
Second, ROS has been implicated as a possible mechanism leading to cancer-cachexia;
however, it has yet to be measured in cancer-cachexia. Moreover, antioxidant therapies have
been utilized with mixed results because they fail to specifically target skeletal muscle. In fact,
antioxidants may progress tumor proliferation leading to a worsened prognosis. Utilizing muscle
specific ROS neutralizing agents may prove to be a valuable treatment for cancer-cachexia.
A few other gaps in literature include the study of cancer-cachexia in aged animals and
chemotherapy mediated muscle wasting. In the clinic, cancer normally occurs in older
individuals; therefore, studies should focus on the progression of cancer-cachexia in aged
animals. It is possible that pre-existing sarcopenia may speed up the onset of cancer-cachexia.
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Also, chemotherapy agents may induce muscle wasting. Therefore, it is important to study
cancer-cachexia in conjunction with chemotherapy treatment.
Summary of Literature Review.
Cancer is one of the leading causes of death worldwide with over half of the people
affected by cancer dying as a result of the condition [1, 2]. Cancer-cachexia is a wasting
syndrome that occurs in approximately 80% of cancer patients [4, 5]. In fact, cancer-cachexia is
the primary cause of death for 22%-30% of all individuals with cancer [4, 5]. Cancer-cachexia is
multifactorial and cannot be fully reversed by nutritional support with a combination of reduced
food intake and abnormal metabolism, seemingly induced by tumor- and host-derived factors [4].
Cancer-cachexia is associated with reduced muscle protein synthesis and increased
muscle protein breakdown [7, 8], which leads to a loss of skeletal muscle mass [10]. There are
many factors that influence this dysregulation of protein turnover including reduced protein
synthesis, elevated autophagy, elevated proteasome activity and impaired myogenesis. Cancercachexia is likely metabolically induced; therefore, mitochondrial degeneration may prompt
cancer-cachexia. Mitochondrial degeneration results in inefficient ATP production and excess
mitochondrial reactive oxygen species (ROS) production. Mitochondrial degeneration results in
reduced protein synthesis and the upregulation of atrophic signaling. Furthermore, mitochondrial
degeneration results in excess mitochondrial ROS production. Elevated levels of ROS reduces
protein synthesis and promotes protein breakdown. Furthermore, ROS upregulates apoptosis in
skeletal muscle.
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Mitochondrial degeneration may be behind the induction of signaling contributing to
cancer-cachexia. Future cancer-cachexia experiments should focus on mechanisms that lead to
the onset of cancer-cachexia in order develop adequate therapies.
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Chapter 2
Doctoral Dissertation Proposal
Cancer is one of the leading causes of death worldwide with over half of the people
affected by cancer dying as a result of the condition [2, 3]. Cancer-cachexia is a wasting
syndrome that occurs in approximately 80% of cancer patients [4-6]. In fact, cancer-cachexia is
the primary cause of death for 22%-30% of all individuals with cancer [4-6]. Cancer-cachexia is
defined as a multifactorial syndrome which displays an ongoing loss of skeletal muscle mass
(with or without loss of fat mass) that cannot be fully reversed by conventional nutritional
support and leads to progressive functional impairment [4, 6]. Underlying mechanisms of cancercachexia are not fully understood.
Cancer-cachexia is associated with reduced muscle protein synthesis and increased
muscle protein breakdown [7, 8], which leads to a loss of skeletal muscle mass [9]. The
progression of signaling which induces cancer-cachexia is not understood. Cancer-cachexia is
likely metabolically induced; therefore, mitochondrial degeneration may prompt cancercachexia. Mitochondrial degeneration results in inefficient ATP production and excess
mitochondrial reactive oxygen species (ROS) production. Therefore, the central hypothesis of
this proposal is mitochondrial
Cancer-cachexia

degeneration occurs before the onset of
measurable cancer-cachexia and aiding
cellular capacity to neutralize
mitochondrial ROS prevents cancer

Figure 2-1. Schematic of the central hypothesis.

induced muscle wasting (Fig. 1).
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Specific Aim 1: Analyzed degeneration of the mitochondrial network throughout the
progression of cancer-cachexia. Phosphate Buffered Saline (PBS) or Lewis Lung Carcinoma
was implanted to the hind flank of C57Bl/6J mice at 8 weeks of age. The tumor was allowed to
develop for 1, 2, 3 or 4 weeks. Reporter gene Mitotimer was utilized to directly assess
mitochondrial quality. Mitotimer shifts from a green to a red fluorescent spectra when the
mitochondrial network is damaged. Mitotimer was electroporated into C57Bl/6J mice at 6 weeks
of age (2 weeks prior to tumor implantation). A 30% increase in mitotimer’s red/green
fluorescent ratio was considered severe mitochondrial degeneration in accordance to previous
literature [10]. Mitochondrial degeneration can lead to a loss of mitochondrial function and
excess mitochondrial ROS production; therefore, mitochondrial respiration and reactive oxygen
species production were measured throughout the progression of cancer-cachexia. Succinate
Dehydrogenase staining was used to assess the amount of oxidative and non-oxidative muscle
fibers. Immunoblot was utilized to analyze regulators of the mitochondrial network and
antioxidant enzymes.
Specific Aim 2: Utilized a time course of the progression of Cancer-cachexia to analyze
dysregulation in protein turnover signaling. Muscle atrophy was assessed by muscle wet
weights and cross sectional area (CSA). Groups with 10% decrease in muscle wet weights and/or
a mean decrease of 30% in the CSA of the Tibialis Anterior muscle when compared to PBS
control injection was considered cachectic in accordance to previous literature [11-14] . 24-hour
protein synthesis was measured using deuterium oxide labelling followed by GC-MS based
assessment. Immunoblot and RT-PCR was used to measure the expression and signaling of key
enzymes in muscle wasting pathways (denervation, myogenesis, protein synthesis, autophagy,
E3 ligase/proteasome). TUNEL assay was utilized to assess apoptotic nuclei.
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Specific Aim 3: Determined enhanced mitochondrial ROS scavenging is sufficient to
attenuate cancer-cachexia In-Vitro and examine the role of MAPK in the onset of cancercachexia In-Vitro. Myotubes were treated with either control (Con, Low serum media: 25%
volume of 10% fetal bovine serum growth media diluted in serum free media) or LLC
conditioned media (LCM, 25% volume of LLC conditioned 10% fetal bovine serum diluted in
serum free media). Mito-TEMPO (MitoT, a mitochondrial specific antioxidant) was given to a
subset of myotubes in each group. Myotube diameter was assessed in all experimental
conditions. Inhibitors specific to p38 and ERK 1/2 MAPK were used in Con and LCM
conditions were used to assess the role of MAPK in the loss of myotube diameter. Immunoblot
and RT-PCR were used to measure dependent variables specific to protein breakdown.
These experiments gave insight to mechanisms behind cancer-cachexia and will open doors
to new therapeutic treatments to combat cancer-cachexia.
Research Strategy
A.Significance
A1. Cancer-cachexia is a major health care problem. While skeletal muscle atrophy is
common to many chronic disease conditions [15-17], it is especially problematic in cancer [6, 4].
Cancer-cachexia is defined as a multifactorial syndrome which displays an ongoing loss of
skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by
conventional nutritional support and leads to progressive functional impairment [4, 6]. Cancercachexia has been linked to increase mortality during hospital visits [18] and increases likelihood
of death [15]. In fact, cancer-cachexia is the primary cause of death for 22%-30% of all
individuals with cancer [4, 5]. Moreover, cancer-cachexia is costly to treat [19]. Current
therapies to prevent muscle wasting are not fully efficacious; therefore, a critical need
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Figure 2-2. Two weeks prior to LLC implantation the fluorescent reporter pMitoTimer[1] was
transfected into contralateral flexor digitorum brevis muscles. MitoTimer is a mitochondrially
targeted variant of DsRed, validated by Laker et al.[1] to emit green fluorescence when
mitochondria are “healthy” and shift to red when mitochondria are “damaged”. Construct
quantified by calculation of the ratio of red:green fluorescence whereby a greater red:green
ratio signifies degenerated mitochondria. Locations of pure red puncta colocalize with LC3
and appear to represent completely degenerated mitochondria targeted for autophagy[1].
remains to identify mechanisms and potential therapeutic targets to prevent muscle
atrophy in disease states.
Cancer-cachexia is a result of an imbalance of protein turnover favoring protein
degradation; however, underlying mechanisms are not clear. In cancer-cachexia, it is apparent
muscle atrophy is metabolically induced [20-22]. Energy stress instigated from tumor derived
factors induces increased protein breakdown and a reduction in protein synthesis [7, 8]. The
mitochondria is responsible for the majority of cellular energy production. A potential
mechanism behind the cellular energy stress induced by tumor burden is mitochondrial
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Figure 2-3. Mitochondrial dysfunction in Cancer-Cachexia. Respiratory control ratio
measured in plantaris muscle of C57BL/6J mice 4 weeks following implantation of 1X106
Lewis Lung Carcinoma cells in the hind flank. Mitochondrial function in permeabilized
plantaris muscle.
degeneration. Mitochondrial degeneration results in inefficient ATP production and excess
mitochondrial ROS production.
A2. Mitochondrial degeneration is apparent in cancer-cachexia. Development of
mitochondrial dysfunction and derangements in response to tumor burden may instigate skeletal
muscle atrophy. Mitochondrial degeneration leads to skeletal muscle atrophy through a number
of different mechanisms including impaired ATP production and excess mitochondrial ROS
excretion which reduces protein synthesis and promotes protein breakdown [23]. Due to the
mitochondria’s central role in cellular metabolism, mitochondrial degeneration may instigate
cancer-cachexia [24, 22, 25]. Furthermore, we have more recently acquired preliminary evidence
of mitochondrial degeneration utilizing Mitotimer (a mitochondrially targeted plasmid which
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shifts from green to red fluorescence upon mitochondrial damage [1], Fig 2). This suggests that
tumor burden elicits mitochondrial degeneration, which may induce cancer-cachexia.
Experiments will identify if mitochondrial degeneration precedes cancer-cachexia.
Mitochondrial degeneration inevitably leads to a loss of mitochondrial function which results in
reduced ATP production leading to skeletal muscle wasting. I have preliminary evidence that
suggests mitochondrial function is impaired 4 wks following tumor implantation (Fig 3).
A3.

Cancer-cachexia is associated with impaired regulation of the mitochondrial

network. In order to effectively perform oxidative metabolism, several regulatory processes
must be implemented to ensure mitochondrial health. These processes include the biogenesis of
new mitochondrial components, fusion and fission of new and damaged mitochondrial regions
with the network (dynamics), and the selective degradation of damaged mitochondrial regions
through the process of autophagy (mitophagy) [26]. Cancer-cachexia appears to be associated
with dysregulation of mitochondrial quality controllers according to our data (Fig 4). Intriguingly
it appears dysregulation of mitochondrial biogenesis and dynamics occurs prior to severe
cachexia (Fig 4). Therefore, evidence exists that mitochondrial degeneration precedes cancercachexia and may be the instigation event.
A4. Aiding in mitochondrial ROS neutralization may attenuate cancer-cachexia.
Mitochondrial degeneration is prevalent in many atrophic conditions; however, whether
alleviating atrophy by neutralizing mitochondrial ROS is less certain. Additionally,
mitochondrial degeneration is associated with excess ROS leak from the mitochondria which
may provide the primary mechanism of muscle atrophy via ROS-induced damage to other
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Figure 2-4: Mitochondrial quality control regulators are disrupted prior to wasting in a
colorectal cancer model to study cancer-cachexia.
cellular mechanisms (i.e., protein accretion)[25]. Recent studies suggest: genetic enhancement
of mitochondrial antioxidant defense through transgenic overexpression of mitochondrial
catalase (MCAT) improves muscle function in aging [27] and inhibition of the ROS producer
NADPH Oxidase may attenuate Duchenne Muscular Dystrophy [28].; therefore, aiding in the
capacity to neutralize mitochondrial ROS may prevent cancer-cachexia. Mitotimer is a reporter
gene that shifts from green to red fluorescence upon oxidation of a handful of amino acids [10]
;therefore, preliminary evidence suggests that ROS is elevated due to tumor burden (Fig 2).
However, these data do not elucidate if mitochondrial ROS scavenging protects against muscle
atrophy. Therefore, it is likely that promoting mitochondrial quality by mitochondrial
antioxidant defense mechanisms may prevent cancer-cachexia.
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A5. MAPK involvement in cancer-mediated muscle wasting. In models to study
cancer-cachexia, it appears that p38 MAPK expression is induced in response to tumor burden
[29], and experimental evidence suggests inhibition of both p38 and ERK 1/2 MAPK may
attenuate cancer-induced muscle loss [30]. Other literature indicates this may be mediated
through the ubiquitin proteasome system [31, 30, 32]. Furthermore, ROS is a mediator for the
induction of p38 MAPK and inhibition of p38 MAPK partially prevents loss of myotube
diameter In-Vitro [33]. Therefore, p38 and ERK 1/2 MAPK may be potential therapeutic targets
to treat cancer-cachexia.
The central hypothesis of this proposal was mitochondrial degeneration occurs
before the onset of measurable cancer-cachexia and aiding cellular capacity to neutralize
mitochondrial ROS prevents cancer induced muscle wasting (Fig. 1).
B. Innovation
The proposed study was innovative in observing atrophic signaling during the
progression of the development of cancer-cachexia and used innovative methodologies to target
the primary research questions. The approach of assessing the timecourse of cancer-cachexia to
identify and compare the onset of muscle mitochondrial derangements and atrophy mechanisms
was novel and provided greater understanding of the pathogenesis of cancer-cachexia. We
utilized multiple approaches to identify mechanisms of muscle atrophy as well as mitochondrial
degeneration. This represented a first of its kind encompassing approach to understand the
progression of cancer-cachexia. While prior evidence suggests that oxidative stress may be
involved in the onset of cancer-cachexia, no study has attempted to prevent cancer-cachexia by
specifically neutralizing ROS in skeletal muscle. Therefore, the study was innovative in the
proposed hypothesis for underlying mechanisms for cancer-cachexia. Additionally, we used
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Figure 2-5: Schematic of Experimental Design for Aim 1 and 2.
innovative methodologies to examine multiple modalities of muscle atrophy and determine the
role of mitochondrial degeneration in atrophy. This study was the first to use Mitotimer to
measure mitochondrial degeneration in cancer-cachexia. Moreover, mitochondrial function and
mitochondrial ROS production were not examined in cancer-cachexia.
C. Approach
Overall approach. In order to test the central hypothesis, I perfomed a series of
experiments designed to reveal if mitochondrial degeneration precedes cancer-cachexia and
uncover if ROS is involved in the onset of cancer-cachexia. I performed timecourse assessments
of muscle atrophy and mitochondrial quality throughout the progression of cancer-cachexia
using the Lewis Lung Carcinoma (LLC) tumor implantation model in order to determine
atrophic signaling that leads to cancer-cachexia and examine mitochondrial degeneration
throughout the progression of cancer-cachexia. These experiments gave valuable insight into
metabolic aspects which induce cancer-cachexia. We utilized MitoT to ameliorate cancercachexia in-vitro by increasing cellular capacity to neutralize mitochondrial ROS production, a
negative by-product of damaged mitochondria. These experiments provided novel information
for mechanisms which will induce cancer-cachexia and provided novel therapeutic targets for the
treatment of cancer-cachexia.
Specific Aim 1.Determined if mitochondrial network degeneration preceded cancercachexia. Hypothesis and Rationale. We hypothesized mitochondrial derangements precede
the development of cancer-cachexia and may instigate muscle wasting. Preliminary data
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Figure 2-6. Mean CSA and a histogram of values in PBS and 4 wk LLC animals. There is a
dramatic decrease in mean CSA and an increase in the number of small muscle fibers in the
4wk LLC group.
suggested dysregulation of proteins which aid in the maintenance of the mitochondrial network
(Fig 4). These mitochondrial impairments may present before cancer-cachexia . To test this
hypothesis, we proposed to examine mitochondrial quality and function throughout the
development of cancer-cachexia.
Culturing of LLC Cells: LLC cells were cultured in 10% Fetal Bovine Serum Growth
Media with 1% Penicillin and Streptomycin added. Once confluent, cells will be trypsinized,
counted and diluted in PBS for implantation.
Induction of muscle atrophy by cancer-cachexia. For tumor implantation we performed
LLC implantation. Briefly, LLC was implanted to the hind flank of anesthetized mice at 1X106
cells in a 100 µL suspension in sterile PBS. Atrophy was allowed to develop for up to 4 wks,
similar to prior reports, and cohorts harvested weekly.
Model confirmation. To confirm atrophy and validate models we examined hindlimb
muscle wet weights and cross-sectional area (CSA) of TA myofibers. Groups with 10% decrease
in muscle wet weights and/or a mean decrease of 30% in the CSA of the Tibialis Anterior muscle
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when compared to PBS control injection was considered cachectic (Fig 6). These numbers were
consistent with previous literature [11, 12, 34].
Fluorescent reporter. MitoTimer was delivered by electric pulse-mediated gene transfer
to flexor digitorum brevis muscles 2 wks prior to tumor implantation. To assure data quality
MitoTimer fluorescence was assessed day of tissue harvest and microscopy acquisition
parameters were carefully controlled using the Nikon TiS fluorescent microscope. We measured
the ratio of red:green fluorescence and number of pure red puncta (completely degenerated
mitochondria) (Fig 2).
Mitochondrial respiration and ROS emission: Small strips, ~10 mg, of muscle were
teased to near-single fibers and permeabilized with saponin to open small pores in the
membrane. Mitochondrial oxygen consumption (VO2) of a permeabilized fiber bundle was
measured as described. Mitochondria were primed with malate and glutamate. Maximal
respiration (ADP-stimulated, state 3) and state 4 respiration were measured. The respiratory
control ratio (RCR) was calculated by dividing state 3 by state 4. The dry weight of the
permeabilized mitochondria was used to normalize the results. ROS emission was measured
using amplex red hydrogen peroxide detection kit. In the presence of horse radish peroxidase, the
Amplex Red reagent reacts with H2O2 in a 1:1 stoichiometry to produce the red-fluorescent
oxidation product, resorufin.
Succinate Dehydrogenase Staining: Tibialis Anterior (TA) muscles were embedded in
optimal cutting temperature (OCT) compound and frozen in liquid nitrogen cooled isopentane.
Sections were cut at 10 µm using a cryostat and stained for Succinate Dehydrogenase (SDH).
Sections were placed in incubation solution (50 mM Soduim succinate, 50 mM phosphate buffer,
0.12M KH2PO4 & 0.88M Na2HPO4), 0.5 mg/ml Nitroblue tetrazolium for 40 min in a 37o C
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water bath. Slides were washed 3 min with dH2O and imaged. Images were collected with Nikon
Sight DS-Vi1 camera mounted on an Olympus CKX41 inverted microscope. SDH+ (purple) and
SDH– fibers were counted, cross-validated by two independent and blinded investigators, and
circled for cross sectional area analysis using Nikon Basic Research Imaging Software.
Analysis of Mitochondrial Regulatory Proteins: Immunoblot and RT-PCR were
performed in order to measure the protein content of key proteins involved in mitochondrial
regulatory processes. Immunoblot targets included are PGC-1α, COX IV, CYT C, TFAM,
PPARα/γ, NRF2, MFN 1/2, DRP1, FIS1, OPA1 and BNIP3.
Statistics and Sample Size Determination. To determine differences among conditions, a
One-way ANOVA with a factor of tumor progression between groups was used for the global
analysis. To delineate differences among means, the Student Newman Keuls post hoc test was
used. I estimated that 8 animals/group were needed to achieve statistical significance at α = 0.05
and β = 0.20 (power = 0.80).
Anticipated Results and Interpretation of Findings. We expected mitochondrial
degeneration to precede cancer-cachexia suggesting mitochondrial degeneration may instigate
cancer-cachexia. The use of directly measuring mitochondrial quality by Mitotimer as well as
functional measurements and ROS assays provided significant insight into mechanisms of
mitochondrial dysfunction. Multiple modes of muscle wasting are present in cancer-cachexia,
and mitochondrial degeneration may be behind the induction of all modes of muscle wasting in
cancer based on our data.
Potential Problems and Contingency Plans. While preliminary evidence is clear that
mitochondrial degeneration takes place in cancer-cachexia, we were not sure if it preceded
muscle wasting and instead occured concomitantly. Loss of mitochondrial function in a muscle
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wasting state will not only induce skeletal muscle atrophy, but it will make it difficult to recover
from atrophy; therefore, mitochondrial degeneration may still play a significate role in cancercachexia. Furthermore, I collaborated with Dr. Michael P. Wiggs in order to successfully
complete these assays.
Specific Aim 2.Utilized a time course of the progression of Cancer-cachexia to
analyze dysregulation in of protein turnover. Hypothesis and Rationale. We hypothesized
cancer-cachexia will occur 4 weeks following tumor implantation demonstrated by a loss of
muscle mass and fiber size. Furthermore, we hypothesized that skeletal muscle wasting will be
brought on by increased protein breakdown and reduced protein synthesis. Our time frame for
inducing cancer-cachexia was based off of prior research from our laboratory and other
laboratories [11](Fig.6). To test this hypothesis we proposed to examine muscle atrophy over the
course of cancer-cachexia progression (Fig 5).
Culturing LLC cells. Was performed as in Aim 1.
Induction of Muscle Atrophy by Cancer-Cachexia and conformation of model. Was
performed as in Aim 1.
Measurement of Protein Synthesis: A bolus of deuterium oxide was injected
intraperitoneally in the mouse approximately 24 hours before tissue collection. Each mouse was
then given 4% deuterated drinking water in order to maintain the levels of deuterium oxide in the
blood [35-37]. The deuterium is transferred to amino acids inside the cell before the amino acid
is incorporated in the protein chain. GC-MS was used to detect the deuterium levels in the
skeletal muscle to measure 24 hour protein synthesis via the amount of deuterium taken up by
the muscle[35-37]. Myofibrillar fraction of muscle was used in order to assess protein synthesis.
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This method has been validated in mouse models to give an accurate measurement of protein
synthesis [35, 36].
Analysis of Protein Turnover Signaling: Immunoblot and RT-PCR were used to
understand alterations in the expression in proteolytic signaling of various pathways. Targets
included to AKT, 4EBP1, p70S6K, FOXO 1/3, p62, LC3 A/B, Ubiquitin, Atrogin-1, MuRF and
Caspace 3. Post translational modifications such as phosphorylation of targets were measured as
necessary to delineate activation of pathways.
TUNEL Assay to measure apoptotic nuclei: 10 µm sections were fixed in 4%
paraformaldehyde. Roche Diagnostics (Indianapolis, IN) In Situ cell death detection Fluorescein
(11684795910) was used to detect damaged DNA. Manufacturer’s protocols were used. Slides
were mounted with DAPI mounting media. Nikon Ti-S inverted epiflourescent microscope with
LED-based light source was used to image total nuclei (DAPI) and TUNEL + nuclei (FITC).
Total nuclei and TUNEL + nuclei were then counted using Nikon Basic Research Imaging
Software.
Statistics and Sample Size Determination. To determine differences among conditions, a
One-way ANOVA with a factor of tumor progression between groups was used for the global
analysis. To delineate differences among means, the Student Newman Keuls post hoc test was
used. I estimated that 8 animals/group were needed to achieve statistical significance at α = 0.05
and β = 0.20 (power = 0.80).
Anticipated Results and Interpretation of Findings. We anticipated that LLC implantation
induced cancer-cachexia after 4 wks tumor growth based off of a reduction of mean CSA and a
decrease in muscle wet weight. Furthermore, we anticipated that protein turnover signaling
favored catabolic pathways. We hypothesized protein synthesis was decreased by 4 wk LLC.
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These data provided novel evidence for mechanisms of cancer-cachexia as well as a time frame
in which atrophic pathways are enhanced.
Potential Problems and Contingency. With the tumor implantation model it was possible
that not all animals will be able to reach the 4 wk timepoint. To account for this, twice as many
animals were utilized than what would be needed to account for premature animal death due to
tumor burden. In order to ensure I was able to successfully measure protein synthesis I worked
with Dr. Michael Wiggs, an expert on this technique to measure protein synthesis.
Specific Aim 3.Demonstrated that improving ROS scavenging attenuated cancercachexia In-Vitro. Hypothesis and Rationale. I hypothesized promoting cellular capacity to
neutralize mitochondrial ROS by using MitoT was sufficient to attenuate loss of myotube
diameter in cells treated with LLC conditioned media. Cancer is associated with an increase in
bloodborne factors likely secreted from tumor cells including inflammatory cytokines that induce
excess ROS production in skeletal muscle. Damaged mitochondria, are the greatest cellular ROS
emitter [38], thereby removal of mitochondrial ROS (MitoT) was likely to prevent such ROSinduced cell damage. This experiment provided evidence for mechanisms of mitochondrial
degeneration in cancer-cachexia and demonstrated efficacy of ameliorating cancer-cachexia
through promotion of mitochondrial ROS scavenging.
LLC conditioned media. LLC cells were grown to 100% confluence. Media was then
filtered and diluted to 25% total volume in serum free media. For the Control group, 10% fetal
bovine serum growth media was diluted to 25% total volume with serum free media.
LLC conditioned media decreases myotube diameter. Myotube diameter was assessed
~24 hours after treating C2C12 cells with either Control or LLC conditioned media. Myotube
diameter decreased by ~40%.
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Drug Treatments. 2 µM of MitoT suspended in DMSO was given to a subset of cell
culture wells in both Con and LCM. The DMSO vehicle was administered to cell culture wells in
equal volume as the MitoT treatment. SB202190 (p38 MAPK inhibitor) was given to both Con
and LCM cells at a concentration of 20 µM. PD098059 (MEK inhibitor upstream of ERK 1/2
MAPK) was administered to both Con and LCM treated cells at a concentration of 20 µM.
Analysis of Protein Breakdown. Immunoblot and RT-PCR were used to understand
alterations in the expression in proteolytic signaling of various pathways. Targets included
FOXO 1/3, Ubiquitin, Atrogin-1 and MuRF. Post translational modifications such as
phosphorylation of targets were measured when it was necessary to delineate activation of
pathways.
Statistics and Sample Size Determination. To determine differences among conditions, a
two-way ANOVA with factors of tumor (Control Media vs. LLC Conditioned Media) and
treatment (Vehicle vs. MitoT) were used for the global analysis. To delineate differences among
means, the Student Newman Kuels post hoc test was used. I estimated that an n of 6 in each
group was needed to achieve statistical significance at α = 0.05 and β = 0.20 (power = 0.80).
Anticipated Results and Interpretation of Findings. I anticipated that aiding in the
scavenging of mitochondrial ROS with MitoT attenuated loss of myotube diameter. I have
shown that mitochondrial degeneration is present in cancer-cachexia. Excess mitochondrial ROS
production is associated with degeneration, induced skeletal muscle atrophy by a variety of
mechanisms. These findings provided valuable insight to mechanisms that promote cancercachexia.
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Potential Problems and Contingency. While our laboratory had vast experience with cell
culture experiments, we had only utilized MitoT for a brief period of time. In order to
compensate for our inexperience with MitoT, we allotted additional time to troubleshoot cell
culture protocols. It was possible that MitoT could have had no effect on myotube diameter;
however, this information was still valuable and gave insight to therapies to treat cancercachexia.
Timeline. Animal work for Aims 1 and 2 was completed December 2016. Analysis of
dependent variables for aims 1 and 2 were completed by December 2017. Writing Aims 1 and 2
was complete by January 2018. Dependent variable analysis for aim 3 was complete by January
2018. Writing for Aim 3 and dissertation overview was complete by February 2018. My
dissertation defense was completed by March 2018. By following this plan I was able to graduate
with my dissertation by May 2018.
Summary. Cancer is one of the leading causes of death worldwide with over half of the
people affected by cancer dying as a result of the condition [2, 3]. Cancer-cachexia is a wasting
syndrome that occurs in approximately 80% of cancer patients causing the death of 20-30% of
the cancer patients [4, 5]. Cancer-cachexia is multifactorial and cannot be fully reversed by
nutritional support [4]; therefore, understanding underlying mechanisms of cancer-cachexia
is critical to the development of adequate therapies.
These experiments provided novel insight towards mechanisms behind cancer-cachexia.
Moreover, this was the first study which focuses on the progression of cancer-cachexia. Utilizing
MitoT in order to aid in cellular capacity handle ROS gave mechanistic insight towards the role
of mitochondrial ROS in cancer-cachexia. The data from these experiments could lead to novel
therapies to treat cancer-cachexia.
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Abstract
Background: Cancer-cachexia is largely irreversible, at least via nutritional means, and
responsible for 20-40% of cancer-related deaths. Therefore, preventive measures are of primary
importance, however little is known about muscle perturbations prior to onset of cachexia.
Cancer-cachexia is associated with mitochondrial degeneration; yet, it remains to be determined
if mitochondrial degeneration precedes muscle wasting in cancer-cachexia. Therefore, our
purpose was to determine if mitochondrial degeneration precedes cancer-induced muscle atrophy
wasting in tumor bearing mice.
Methods: First, weight stable (MinStable) and cachectic (MinCC) ApcMin/+ mice were compared
to C57Bl6/J controls for mRNA contents of mitochondrial quality regulators in quadriceps
muscle. Next, Lewis Lung Carcinoma cells (LLC) or PBS (control) were injected into the hindflank of C57Bl6/J mice at 8 wks age, and tumor allowed to develop for 1, 2, 3 or 4 wks to
examine timecourse of cachectic development. SDH stain was used to measure oxidative
phenotype in TA muscle. Mitochondrial quality and function were assessed using the reporter
MitoTimer by transfection to flexor digitorum brevis and mitochondrial function/ROS emission
in permeabilized adult myofibers from plantaris. RT-qPCR and Immunoblot measured the
expression of mitochondrial quality control and antioxidant proteins. Data were analyzed by oneway ANOVA with Student-Newman Kuels post hoc test.
Results: MinStable mice displayed ~50% lower Pgc-1α, Pparα, and Mfn2 compared to C57Bl6/J
controls; whereas MinCC exhibited 10-fold greater Bnip3 content compared to C57Bl6/J
controls. In LLC, cachectic muscle loss was evident only at 4 wks post-tumor implantation.
Oxidative capacity and mitochondrial content decreased by ~40% 4 wks post-tumor
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implantation. Mitochondrial function decreased by ~25% by 3wks after tumor implantation.
Mitochondrial degeneration was evident by 2 weeks LLC compared to PBS control, indicated by
Mitotimer Red/Green ratio and number of pure red puncta. Mitochondrial ROS production was
elevated by ~50% to ~100% when compared to PBS at 1-3 wks post-tumor implantation.
Mitochondrial quality control was dysregulated throughout the progression of cancer-cachexia in
tumor-bearing mice. In contrast, antioxidant proteins were not altered in cachectic muscle
wasting.
Conclusions: Functional mitochondrial degeneration is evident in LLC tumor-bearing mice prior
to muscle atrophy. Contents of mitochondrial quality regulators across ApcMin/+ and LLC mice
suggest impaired mitochondrial quality control as a commonality among pre-clinical models of
cancer-cachexia. Our data provide novel evidence for impaired mitochondrial health prior to
cachectic muscle loss and provides a potential therapeutic target to prevent cancer-cachexia.
Key Words
Cancer, Cachexia, MitoTimer, ROS, muscle wasting, mitochondrial quality
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Introduction
Cancer is one of the leading causes of death worldwide [1, 2]. Moreover, therapies to
prevent mortality from cancer are inadequate [3]. Cancer-cachexia is a wasting syndrome which
occurs in up to 80% of cancer cases and is directly attributable for up to 40% of cancer-related
deaths [4-6]. Cancer-cachexia is primarily defined by an ongoing loss of skeletal muscle mass
and function, which nutritional therapies currently lack sufficient efficacy to reverse [4, 6].
Therefore, prevention remains a substantial goal of cachexia research, and recent literature calls
for a focus on therapies to prevent cachexia [7]. Prior evidence suggests skeletal muscle oxidative
capacity may influence atrophy in cancer-cachexia and other forms of muscle wasting [8-11].
Mitochondria are organelles critical for muscle oxidative metabolism. In fact, mitochondrial
quality may be critical to the maintenance of skeletal muscle mass [12]. We recently acquired
evidence in ApcMin/+ mice, a genetic model of colorectal cancer, suggesting impaired
mitochondrial quality control in quadriceps muscle of weight stable (not yet cachectic) mice (Fig
1). These data suggest impaired mitochondrial quality may precede development of cachexia and
thus be a critical step in development of this condition, which has recently been discussed in
detail [13]. Therefore, to better define such impacts, we have sought to investigate development
of mitochondrial impairments across a time course of cachectic development in tumor-bearing
mice.
Mitochondrial quality can be defined as the general health and function of the
mitochondrial network [14]. When the mitochondrial network is impaired, degeneration of the
network structure occurs leading to a loss of mitochondrial function (impaired ATP production)
[15] and excess mitochondrial reactive oxygen species (ROS) production, disrupting cellular
health [16, 17]. These related but distinct events result in impaired mitochondrial health and may
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initiate skeletal muscle atrophy [18-24]. Cancer appears to impair the mitochondrial network in
skeletal muscle [25], which may lead to cancer-cachexia. In addition to mitochondrial
degeneration in cancer-cachexia, a decreased content of ROS eliminating enzymes has been
reported [26]. Antioxidants may attenuate the progression of cancer-cachexia by aiding in the
elimination of cellular ROS [27], suggesting ROS as an instigator for cancer-cachexia.
Considering these points, there is a clear need to understand if mitochondrial degeneration,
associated with mitochondrial ROS production and impaired energy production, may be the
initiating event behind the onset of cancer-cachexia.
Skeletal muscle has a series of processes involved in mitochondrial quality control to aid
in the maintenance of the mitochondrial network [28, 14]. These processes are the biogenesis of
new mitochondrial components, fusion and fission of new and damaged mitochondrial regions
within the network (dynamics), and the selective degradation of damaged mitochondrial regions
through the process of autophagy (mitophagy) [28]. Mitochondrial biogenesis is primarily
regulated by PGC-1α, a transcriptional co-activator that coordinates the transcription factors
critical for the addition of mitochondrial components [29]. Mitochondrial dynamics is a highly
regulated process in which components of the mitochondrial network are enzymatically divided
(fission) or merged (fusion) [28]. Mitophagy is a highly selective engulfment of mitochondria by
autophagosomes and their subsequent catabolism by lysosomes [30, 31]. Many of these
mitochondrial regulatory processes are impaired in cancer-cachectic muscle [32, 25, 13], which
may directly promote skeletal muscle atrophy [33-35]; however, current literature predominantly
only measures mitochondrial quality control regulators at late stage cancer-cachexia. It is
possible this mitochondrial degeneration occurs only after development of cancer-induced
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muscle wasting; however, currently it is not known if such mitochondrial degeneration may
precede and potentially instigate the muscle wasting in cancer-cachexia.
To our knowledge, mitochondrial degeneration during the progression of cancer-cachexia
has not been examined over a time course protocol; therefore, the purpose of this study was to
examine mitochondrial quality throughout the progression of cancer-cachexia in tumor-bearing
mice. We hypothesized that impaired mitochondrial quality would be evident prior to the onset
of cachexia. To test this hypothesis, we measured multiple functional (ROS emission, respiratory
function, degeneration via pMitoTimer reporter gene) and signaling aspects of the mitochondria
across time course progression of cancer-cachexia in tumor bearing mice. Utilizing direct and
functional measurements of the mitochondrial network over time course progression, we now
highlight a potential mechanism behind the onset of cancer-cachexia. We additionally provide
evidence that signaling for mitochondrial quality control is impaired in pre-cachectic mice from
each of two pre-clinical models of cancer-cachexia. Our study provides a novel insight into
mitochondrial perturbations prior to development of the cachectic phenotype.
Methods
Animals and Interventions. Animal experiments were performed at two major
institutions. All procedures were approved by the Institutional Animal Care and Use Committees
of the University of Arkansas, Fayetteville (LLC experiments) and University of South Carolina
(ApcMin/+ experiments). A subset of the mice used for the LLC experiment have previously been
reported on [36].
In the current study we have utilized two pre-clinical models of cancer-cachexia – the
ApcMin/+ mouse, a genetic model of colorectal cancer, and LLC implantation. Initial observations
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were made at the level of mRNA contents in the ApcMin/+ and followed by functional assessments
of mitochondrial quality through time course of tumor development using the LLC implantation
model. As pre-clinical models of cancer-cachexia often exhibit inherent differences the
utilization of two models additionally was utilized to add surety that observations were not
unique to any one model.
ApcMin/+ mice. ApcMin/+ mice used in this study were on a C57BL/6 (B6) background and
were originally purchased from Jackson Laboratories. All mice used in the present study were
obtained from the investigator’s breeding colony (JAC) within the Center for Colon Cancer
Research Mouse Core at the University of South Carolina. Experimental mice were group
housed, kept on a 12:12-h light-dark cycle, and had access to standard rodent chow (no. 8604
Rodent Diet; Harlan Teklad, Madison, WI) and water ad libitum. Male ApcMin/+ and B6 mice
were aged to 18-20 wks of age, and stratified based on cachexia severity at sacrifice as
previously described [25]. Experimental Groups included (B6 [control]), weight stable ApcMin/+
mice (MinStable; no weight loss) and cachectic ApcMin/+ mice (MinCC; 11.3% body weight loss).
Phenotypic description of ApcMin/+ mice in Table 1.
LLC Growth and Tumor Implantation. Lewis Lung Carcinoma (LLC) cells (ATCC CRL1642) were plated in 250 mL culture flasks in DMEM supplemented with 10% Fetal Bovine
Serum plus 1% Penicillin and Streptomycin. Once confluent, cells were trypsinized, counted and
diluted in PBS for implantation. LLC cells were plated at passage 2.
Male C57BL/6J (Stock 000664) mice were purchased from Jackson Laboratories. The
mice were kept on a 12:12-h light-dark cycle with ad libitum access to normal rodent chow and
water. At 6 wks of age, MitoTimer [15] (a reporter gene that directly measures mitochondrial
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quality) was delivered by electric pulse-mediated gene transfer to the flexor digitorum brevis
(FDB) muscle on one foot of each mouse (described below). 1X106 LLC cells suspended in 100
µL sterile PBS were implanted to the hind flank of mice at 8 wks of age as described [37, 36].
The tumor was allowed to develop for 1, 2, 3 or 4 wks in separate cohorts of animals. For sham
control one group of mice received a bolus injection of 100 µL sterile PBS. PBS controls were
age-matched to the most cachectic group (4 wk post-implantation, 12 weeks of age at tissue
collection). Animal tissues were quickly collected under isoflurane anesthesia prior to
euthanasia. Tissues were weighed and snap-frozen in liquid nitrogen for further processing and
stored at -80°C. Body weights between the PBS and 4 wk group were not different; however, the
4 wk group lost a significant amount of muscle mass. According to Fearon et al., loss of skeletal
muscle mass is an effective diagnostic criteria for cancer-cachexia [6]. Phenotypic description of
LLC tumor-bearing mice in Table 2.
Plasmid DNA Amplification and Electroporation. DH5-α Escherichia coli containing
pMitoTimer plasmid [15] were amplified and plasmid DNA isolated using PureLink HiPure
Plasmid Filter Maxiprep kit (Life Technologies, K210017). Plasmid transfection to FDB muscle
was performed as described by Laker et al. [15]. Briefly, 10 µL of 0.36 mg/mL hyaluronidase (in
saline) was injected with insulin syringe with a 30 gauge needle subcutaneously above the FDB
muscle prior to plasmid DNA injection. One hour after hyaluronidase injection, 20 µg of DNA
was injected into the FDB muscle. 10 minutes following DNA injection, the mice were
anesthetized, and an electrical field was delivered through gold-plated acupuncture needles
placed at the heel of the foot and at the base of the toes. 10 pulses were delivered at 20 ms
duration/pulse and 1 Hz at 75V using an S88 Stimulator (Grass Telefactor).
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Mitochondrial Function and ROS production. This methodology was adapted from Kisuk
Min et al. 2015 [38]. Briefly, small strips of plantaris muscle, ~10 mg, of muscle were teased to
near-single fibers and permeabilized with saponin to open small pores in the membrane.
Mitochondrial oxygen consumption (VO2) of a permeabilized fiber bundle was measured.
Briefly, mitochondria were primed with malate and glutamate. Maximal respiration (ADPstimulated, state 3) and state 4 respiration (ADP depleted respiration) was measured. The
respiratory control ratio (RCR) was calculated by dividing state 3 by state 4 respiration. The dry
weight of the permeabilized mitochondria was used to normalize the results.
Mitochondrial ROS was measured in permeabilized plantaris fibers. All forms of ROS
were converted to hydrogen peroxide by the addition of Superoxide Dismutase 1. ROS emission
was measured using amplex red hydrogen peroxide detection kit. In the presence of peroxidase,
the Amplex Red reagent reacts with H2O2 in a 1:1 stoichiometry to produce the red-fluorescent
oxidation product, resorufin. Plantaris muscle was utilized for mitochondrial respiration and
ROS analyses because it is a mixed fiber type and as a smaller muscle more easily teased apart
into near single fiber bundles, which is required for the assay.
Fluorescence microscopy for MitoTimer. For MitoTimer, freshly harvested FDB muscles
were fixed for 20 min in 4% PFA at room temperature and washed 5 min in PBS. Muscles were
then whole mounted on gelatin-coated glass slides using 50% glycerol in PBS as mounting
media and cover slipped. MitoTimer images were acquired at 100X magnification using the
FITC (green, excitation/emission 488/518 nm) and TRITC (red, excitation/emission 543/572 nm)
channels on a Nikon Ti-S inverted epiflourescent microscope (Melville, NY) with LED-based
light source with controlled acquisition parameters as described by Laker et al. [15]. All slides
were imaged the day of tissue harvest. Acquisition parameters were set using a pilot study of
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cachectic and control animals and maintained consistent throughout all experiments. A specially
written MATLAB program was a generous gift from Dr. Z. Yan (U. Virginia) and was used to
analyze MitoTimer red: green ratio and pure red puncta as described by Laker et al. [15]. The
assay is best performed on freshly dissected muscles as time ex vivo impacts the fluorescent
indicator of MitoTimer. Therefore we transfected and utilized the FDB which can be dissected,
whole mounted to microscope slide and imaged within 30 min of the initial dissection.
Cryosectioning. Tibialis Anterior (TA) muscles were embedded in optimal cutting
temperature (OCT) compound and frozen in liquid nitrogen cooled isopentane. Sections were cut
at 10 µm using a Leica CM1859 cryostat (Leica Biosystems, Buffalo Grove, IL) and stained for
Succinate Dehydrogenase (SDH). Sections were placed in incubation solution (50 mM Soduim
succinate, 50 mM phosphate buffer, 0.12M KH2PO4 & 0.88M Na2HPO4), 0.5 mg/ml Nitroblue
tetrazolium for 40 min in a 37o C water bath. Slides were washed 3 min with dH2O and imaged.
Images were collected with Nikon Sight DS-Vi1 camera mounted on an Olympus CKX41
inverted microscope. SDH+ (purple) and SDH– fibers were counted, cross-validated by two
independent and blinded investigators, and circled for cross sectional area analysis using Nikon
Basic Research Imaging Software (Melville, NY). There was no difference between the
measurements across two blinded researchers. TA muscle was utilized because it is a bigger
muscle, which minimizes freezer damage to fibers to centrally located muscle fibers. Other
muscles suitable for cryosectioning such as the gastrocnemius were utilized for other analyses.
RNA isolation, cDNA synthesis and quantitative real-time PCR. RNA isolation, cDNA
synthesis and quantitative real-time PCR were performed as we have previously described [3941, 14]. Taqman probes or SYBR primers specific to Pgc-1α1, Cox4, Pparα, Mfn2, Opa1, Drp1,
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MFF, Fis1, Bnip3 and Beclin1. Taqman probes and SYBR primers have previously been
reported in Greene et al. [14].
Immunoblotting. Immunoblotting performed as we have previously described [41, 14, 42,
40, 43]. Membranes were probed overnight for primary antibodies. Protein targets were selected
based upon prior literature to encompass key components of each of the mitochondrial quality
control systems [28, 14] and ROS protection [44, 26] as previously described. Primary antibodies
were specific to mitochondrial content and biogenesis proteins: COX-IV (Cell Signaling 4844S),
VDAC (Cell Signaling 4866S), PGC-1α (Santa Cruz sc-13067), PPARα (Santa Cruz sc-9000),
PPARδ (Santa Cruz sc-7197), TFAM (Cell Signaling 7495). Mitochondrial dynamics proteins:
MFN1 (Santa Cruz sc-50330), MFN2 (Santa Cruz sc-50331), OPA1 (Santa Cruz sc-367890),
DRP1 (Cell Signaling 14647), Fis1 (Novus NB100-56646). Mitophagy proteins: BNIP3 (Cell
Signaling 3769), PINK 1 (Santa Cruz sc-33796), p-PARKIN (Ser65, Abcam ab154995),
PARKIN (Cell Signaling 42115). Antioxidant proteins: SOD1 (Genetex GTX100554), SOD2
(Cell Signaling 131945), SOD3 (R and D Systems AF4817), GPx7 (Genetex GTX117516),
GPx3 (Genetex GTX89142) and Catalase (Cell Signaling 140975). Primary antibodies were
isolated from rabbit, mouse and goat. Antibodies were diluted in TBST with 5% milk.
Membranes were imaged on Protein Simple FluorChem (Minneapolis, MN) and analyzed using
Alpha View software. All bands were normalized to the 45 kDa Actin band of Ponceau S stain as
a loading control. There was no difference detected between the 45 kDa Actin band of Ponceau S
stain across experimental groups. Powdered gastrocnemius muscle (mixed fiber type) was
utilized to represent both type I and II fibers for immunoblot analysis.
Statistical Analysis. For ApcMin/+ independent variables were B6 control, weight stable
ApcMin/+ mice (MinStable) and cachectic ApcMin/+ mice (MinCC). For LLC, independent
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variables were PBS and number of weeks tumor progressed. A One-way ANOVA was employed
as the global analysis for each dependent variable in both experiments. Differences among means
were determined by Student Newman-Keuls post hoc test. For all experiments, the comparisonwise error rate, α, was set at 0.05 for all statistical tests. All data were analyzed using the
Statistical Analysis System (SAS, version 9.3, Cary, NC, USA), figures were compiled using
GraphPad Prism (La Jolla, CA, USA) and data expressed as mean ± standard error of the mean
(SEM).
Results
Mitochondrial quality control is dysregulated before severe cancer-cachexia in ApcMin/+
mice. ApcMin/+ mice were stratified into experimental groups based on % total body weight loss
from peak body weight as an estimate of cachectic development as previously described [25].
Cachectic mice (MinCC) lost on average 11.3% body weight by time of tissue harvest, while no
loss was seen in B6 or weight stable (MinStable) controls (Table 1). Loss of body weight
coincided with reduction in quadriceps muscle mass. While no significant differences in muscle
mass were observed between B6 (118 ± 4.6) and MinStable (103 ± 3.6), MinCC (67 ± 5.5)
quadriceps mass was reduced compared to both B6 and MinStable (Table 1). Intriguingly, the
process of mitochondrial biogenesis was dysregulated in MinStable mice indicated by a ~50%
decrease in mRNA content of both Pgc-1α and Pparα (Figure 1 a). Furthermore, a ~50%
decrease in Mfn2 mRNA in weight stable ApcMin/+ mice indicated alterations in mitochondrial
fusion before cancer-cachexia occurred (Figure 1 b). Bnip3 mRNA was increased by 10-fold in
MinCC only, which indicates an upregulation of mitophagy in mice with cancer-cachexia
(Figure 1 c).
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Characterization of the progression of LLC-induced cancer-cachexia. Body weights
(Body weight with tumor weight subtracted) of the C57Bl/6J mice were not different between
groups throughout the 4 wk progression of cancer-cachexia; however, muscle wet weights of
TA, gastrocnemius, plantaris, quadriceps and soleus were ~15-20% lower 4 wks following tumor
implantation compared to PBS, with no significant differences in muscle weights between PBS,
1, 2, and 3 wk animals (Table 2). Furthermore, epididymal fat decreased by ~35% in mice with 4
wks tumor growth compared to PBS. Spleen weight, a surrogate marker for inflammatory state,
was 270% and 450% greater 3 and 4 wks, respectively, following tumor implantation when
compared to PBS control (Table 2).
Oxidative phenotype is diminished 4 wks following tumor implantation. The percentage
of SDH+ fibers in the Tibialis Anterior muscle was ~20% lower in mice 4 wks following tumor
implantation (Figure 2 a/b), indicating a loss of muscle oxidative phenotype. Furthermore, there
was a greater number of small muscle fibers that are SDH- 4 wks following tumor implantation
compared to PBS control while little difference was observed in SDH+ suggesting specific
atrophy of non-oxidative muscle fibers (Figure 2 c/d). There was a lower mitochondrial content 4
wks following tumor implantation compared to PBS indicated by a ~50% decrease in both COXIV and VDAC protein contents (Figure 2 e-g). No significant changes in SDH or mitochondrial
content (COX-IV/VDAC) were observed prior to 4 wk tumor development.
Mitochondrial degeneration occurs before cancer-cachexia. Mitochondrial network
degeneration is evident 2 wks following tumor implantation. Examining the MitoTimer
fluorescence spectra we observed a ~50% and 4 fold greater MitoTimer Red:Green ratio and
number of pure red puncta, respectively (Figure 3 a-c). These measures were previously
validated by Laker et al. [15] to directly indicate impaired mitochondrial quality. Furthermore,
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mitochondrial function (indicated by the RCR, the ratio of State 3: State 4 respiration) was ~25%
and 45% lower 3 and 4 wks following tumor implantation compared to PBS (Figure 3 d).
Moreover, mitochondrial ROS production, indicated by H2O2 emission, was two-fold greater 1
wk following tumor implantation and remained elevated through 3 wks post tumor implantation
compared to PBS (Figure 3 e).
LLC impairs mitochondrial quality control before development of cancer-cachexia. LLC
implantation did not affect the mitochondrial biogenesis proteins PGC-1α, PPARα or TFAM;
however, one week following tumor implantation, PPARδ protein content was ~40% lower
compared to PBS, but not significantly different from control in other experimental groups (2-4
wks post tumor implantation) (Figure 4 a/b). Mitochondrial dynamics was dysregulated as soon
as 1 wk following tumor implantation. Opa1 (a protein critical for mitochondrial inner membrane
fusion) content was ~45% lower than PBS control in all LLC tumor-bearing groups (Figure 4
c/d). Intriguingly, mitochondrial fission proteins Drp1 and Fis1 were differentially expressed
throughout the progression of cancer-cachexia. Drp1 protein content was ~ 45% lower 4 wks
following tumor implantation compared to PBS, an apparent lower Drp1 content in 1-3 wk tumor
groups did not reach significance (Figure 4 c/d). In contrast, Fis1 protein content was elevated
~80% in 4 week cachectic animals compared to PBS only (Figure 4 c/d). Mitophagy regulator
BNIP3 protein content was ~2-fold greater in 3 wks following tumor implantation compared to
PBS (Figure 4 e/f). In contrast, PINK1, p-PARKIN and PARKIN protein content were not
significantly different among groups (Figure 4 e/f).
Antioxidant enzymes are unchanged despite increased mitochondrial ROS production.
Protein contents of SOD1, SOD2, SOD3, GPx3, GPx7 and Catalase were not different among
experimental groups (Figure 5).
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Discussion
Current literature is clear that mitochondria are dysregulated in cachectic skeletal muscle
[32, 25, 45]. However, our findings are the first to demonstrate mitochondrial network
deterioration and dysfunction occurs before the onset of cancer-induced loss of muscle mass in
tumor-bearing mice. Recently, mitochondria have been implicated as critical controllers of
skeletal muscle mass [46]; therefore, mitochondrial degeneration may be a key promotor of
cancer-cachexia. Initial observations presented here and by White et al. [25], compared
mitochondrial quality control regulators across degrees of cachexia in ApcMin/+ mice suggesting
impaired mitochondrial quality precedes cachectic phenotype which have herein been built upon
via time course and functional assessments in LLC tumor-bearing mice. The current study
demonstrates increased mitochondrial oxidative stress within the muscle one week post tumor
implantation, followed by mitochondrial network degeneration and lost mitochondrial function 2
and 3 weeks post tumor implantation, respectively. Moreover, mitochondrial quality control
regulators are altered throughout the progression of cancer-cachexia in both ApcMin/+ and Lewis
Lung Carcinoma pre-clinical models suggesting early mitochondrial degenerations are a
common alteration in development of muscle wasting in cancer-cachexia across pre-clinical
models. Our findings clearly present functional mitochondrial degeneration as an early event
preceding muscle wasting in the development of cancer-cachexia in both LLC tumor-bearing and
ApcMin/+ mice. Furthermore, to our knowledge we are the first to examine progression of cancercachexia by time course design. The data presented herein demonstrate the imperative nature to
elucidate intramyofibrillar alterations prior to the onset of the cachectic phenotype.
Cancer-cachexia alters mitochondrial quality control signaling in ApcMin/+ mice. In our
examination of the ApcMin/+ mouse we note that mRNA contents of regulators of mitochondrial
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biogenesis (Pgc-1α and Pparα) and fusion (Mfn2) occur in the MinStable condition, that is in
tumor bearing mice who do not present signs of the cachectic phenotype. In contrast, the mRNA
content of mitophagy marker Bnip3 was elevated only in cachectic mice. These signaling data
are similar to White et al. [25] and suggested that mitochondrial quality control is impaired prior
to signs of cachexia beginning with downregulations of biogenic and fusion regulators and
progressing to elevated markers of mitophagy in cachectic mice. Considering these data, we next
elected to tease the mitochondrial degenerations in progression of cancer-cachexia induced
muscle wasting using a tumor implantation model (LLC) to allow time course assessments of the
functional mitochondrial alterations in development of this condition.
Cancer-cachexia impairs oxidative phenotype and mitochondrial content in skeletal
muscle in LLC tumor bearing mice. Using this model (1X106 LLC cells implanted into the hind
flank) of LLC-induced cancer cachexia it takes 4 weeks for the cachectic phenotype (muscle
wasting) to develop [36, 37, 47]. While, our mice did not lose total body weight after 4 weeks
following tumor implantation, significant muscle and fat mass was lost along with an increased
spleen mass indicative of an inflammatory state [48], which is an effective diagnostic criteria [6].
Loss of oxidative phenotype in late stage cancer-cachexia has commonly been observed in the
literature [25, 13, 49]; however, oxidative phenotype throughout the progression of cancercachexia is understudied. Our data indicates loss of oxidative phenotype (SDH stain) and
mitochondrial content (COX-IV/VDAC) occur concomitantly with cancer-induced muscle loss.
Furthermore, when cancer-cachexia develops, our data indicates oxidative muscle fibers may be
resistant to atrophy during the initial stages of wasting (CSA distribution by SDH stain). Based
on our data and prior reports cancer-cachexia preferentially impacts glycolytic muscle fibers;
however, oxidative fibers have superior antioxidant defenses when compared to glycolytic fibers
84

[50, 51], which may slow cancer-cachexia. This is commonly observed in cancer-cachexia
literature [49], and indicates that oxidative metabolism is an important factor for the maintenance
of muscle size. Therefore, muscle mitochondria may be a primary target of the cancer
environment, and may be a contributor to cancer-induced muscle wasting [13].
Mitochondrial degeneration occurs prior to the onset of cancer-induced muscle loss. To
determine functional mitochondrial degeneration we examined multiple functional parameters
including respiratory function, ROS emission and fluorescence-based measures of network
degeneration. We measured a 2-fold increase in ROS production 1-wk post tumor implantation.
Chronically elevated ROS may be an instigating factor for the muscle wasting observed in
tumor-bearing mice as it has been shown to promote protein catabolic functions [16, 17]. We do
note that mitochondrial ROS production appeared to normalize at 4 wk post tumor implantation,
however these data are normalized to tissue mass and it must also be noted that at this timepoint
mitochondrial density is ~50% reduced by COX-IV and VDAC markers. Next, utilizing the
reporter pMitotimer [15], we observed signs of network degeneration 2 wks following tumor
implantation along with the sudden and dramatic appearance of pure red puncta which by prior
reports appear to be completely degenerated mitochondria tagged for autophagic degradation
[15]. Degeneration of the mitochondrial network then leads to impaired mitochondrial
respiratory function, which we observed 3 wks following tumor implantation. These combined
findings suggest early and progressive derangements in mitochondrial health during the
development of cancer-cachexia in tumor-bearing mice (Figure 6).
The mitochondrial aberrations described herein may induce LLC mediated cancercachexia considering damaged mitochondria have been shown to directly promote atrophic
signaling in skeletal muscle in other models [21-24]. Furthermore, cellular energy stress induced
85

by mitochondrial dysfunction leads to skeletal muscle wasting [52]. Our data demonstrates clear
evidence that mitochondrial degeneration occurs before the development of cancer-induced
muscle wasting in tumor-bearing mice. Critically, these aberrations are most likely due to
influences of the tumor microenvironment as mitochondrial disruptions are observed only one
week following tumor implant when the animal presents as otherwise healthy.
To provide insight to how these mitochondrial derangements occur we next examined
mechanisms of the mitochondrial quality control system in the LLC mice as mitochondrial
degeneration observed in cancer-induced muscle wasting may be attributed to disruptions to
these processes. While not all measured markers of mitochondrial quality control were altered
we note that when impacts were observed in mitochondrial biogenic (PPARδ) and fusion (Opa1)
proteins these alterations were via downregulation and occurred shortly after tumor implantation
(1 wk). Intriguingly, ApcMin/+ mice exhibit a significant reduction in Pgc-1α mRNA content in
MinStable mice, while PGC-1α protein content is not altered throughout the progression of
cancer-cachexia in the LLC pre-clinical model. This may be explained by differences in the
tumor microenvironment between the pre-clinical models. Moreover, Pgc-1α mRNA content is
not different between MinCC and B6 control. At this time we are unable to be certain as the
reason behind reduced Pgc-1α mRNA in MinStable mice, however, differences in the
inflammatory environment between the MinStable and MinCC group may explain this [53],
however this is only speculative. Similar to ApcMin/+ mice, in LLC mice the mitochondrial fission
regulator Fis1 and mitophagy protein BNIP3 were both met with induced expression and both
only impacted later in cachectic development. These observations in mitochondrial quality
control are similar to those presented here in the ApcMin/+ mouse, and congruent with prior
literature in cancer-cachexia [32], whereby early downregulations in biogenic and fusion
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regulators followed by strong induction of Bnip3 mRNA content is observed. These combined
data suggest early stage mitochondrial degeneration as a commonality in two otherwise distinct
pre-clinical models of cancer-cachexia.
These observations may directly tie to the development of cachectic wasting. First, Opa1
has recently been identified as a key controller of muscle size [54]. Second, the induction of Fis1
suggests an upregulation in the amount of fragmented mitochondria, which are typically
inefficient at generating ATP [55] leading to cellular energy stress and loss of muscle mass.
Furthermore, a decrease in content of these controllers of mitochondrial dynamics may indicate
alterations in the balance of fusion and fission of the mitochondria [56]. Finally, mitophagy is
regulated by two distinct processes: BNIP3-mediated mitophagy and PINK1-PARKIN-mediated
mitophagy [57, 58]. While we have observed induction of BNIP3, such an impact on PINK1PARKIN expression was not seen. This suggests differential regulation of BNIP3 compared to
PINK1-PARKIN whereby alterations present in cancer-cachexia selectively induce BNIP3mediated mitophagy.
Considering the 2-fold increase of mitochondrial ROS production and the shift in
MitoTimer fluorescence spectra, we next examined how cellular anti-oxidant defense
mechanisms might be impacted in development of cancer-cachexia. Multiple lines of evidence
suggest excess ROS induces skeletal muscle atrophy [59-64]. Intriguingly, we examined protein
contents of 6 anti-oxidant components all of which are unchanged despite an increase in
mitochondrial ROS production, suggesting a failure of the system to adequately respond to
mitochondrial oxidative stress which may exacerbate free radical-induced proteolysis during
cancer-cachexia. Unfortunately, we were unable to perform functional enzyme activity assays of
anti-oxidant proteins to further elucidate the cellular response to oxidative stress due to lack of
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tissue. Further experiments should be performed to test these enzymatic activities to determine
any alterations in function of anti-oxidant proteins.
Relationship between mitochondrial degeneration and cancer-cachexia. Mitochondrial
degeneration is a common feature across numerous models of skeletal muscle atrophy [12, 65,
66], including cancer-cachexia. In fact, mitochondrial degeneration may instigate skeletal muscle
atrophy through mechanisms including reduced protein synthesis, increased autophagic and
ubiquitin-proteasome mediated protein catabolism, inflammation and altered myogenesis all of
which are perturbed in cancer-cachexia [18-24]. In this study, we have clearly shown aberrations
in the mitochondrial network, beginning with increased ROS production and leading to loss of
mitochondrial function in cancer-cachexia (Figure 6). Intriguingly, these alterations occur before
cancer-induced loss of muscle mass occurs (Figure 6) and while animals would otherwise appear
healthy suggesting mitochondrial degeneration in cancer-cachexia is largely resultant of the
tumor microenvironment. Functional data presented herein across time course with LLC-induced
muscle wasting coupled with signaling data presented from the ApcMin/+ and LLC experiments
suggest that early onset mitochondrial degeneration is likely a common factor in development of
cancer-induced muscle loss across pre-clinical models which otherwise display distinct
mechanistic traits.
Conclusions and future direction. In summary, this is the first experiment to investigate
mitochondrial degeneration and dysfunction throughout a time course development of cancercachexia in tumor-bearing mice. While altered signaling of mitochondrial regulatory processes
(biogenesis, dynamics and mitophagy) provides important insight into potential mechanisms
behind mitochondrial degeneration, the current study directly measures mitochondrial quality
(MitoTimer), mitochondrial ROS emission and respiratory function (RCR) in order to fully
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assess mitochondrial aberrations that occur throughout the progression of cancer-cachexia in a
pre-clinical model. Intriguingly, mitochondrial aberrations such as increased ROS production
occur as soon as 1 wk after tumor implantation (Figure 6), which is likely instigated by the tumor
microenvironment however at this time we cannot rule out denervation, hypoxia and/or
apoptosis. Data from the current study implicate the importance of early cancer detection as well
as preventive measures for cancer-cachexia. However, cancer-cachexia is often not treated
before stage IV of cancer is reached [67]. These data suggest targeting of mitochondrial quality
may be vital for the treatment and prevention of cancer-cachexia whether pharmacologically or
through exercise [28, 15]. Though future studies will need to validate promotion of
mitochondrial quality as an efficacious modality. To accomplish this, future experiments should
be performed to determine if promoting maintenance of mitochondrial quality may prevent
cancer-induced muscle wasting. We now see a clear need for further study of the early-stage
progression of cancer-cachexia as well as early-stage impacts of the tumor microenvironment.
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Tables
Table 1
Variable

B6

MinStable

MinCC

Peak BW (g)

27.4±0.4

25.34±0.7

25.5±0.9

Sac BW (g)

27.4±0.4 a

25.34±0.7 a

22.7±0.8 b

BW Loss (g)

0±0 a

0±0 a

11.3±1.1 b

Quadriceps
(mg)

111.7±4.7 a

103.5±3.1 a

67±5.5 b

Tibia (mm)

17.5±0.1

17.06±0.1

17.2±0.1

Table 1: Body and tissue weights in B6 and ApcMin/+ mice . Tibia length was measured as an
estimate of total body size which did not differ between experimental groups, therefore all tissue
weights are presented as non-normalized wet weights. Lettering denotes statistical significance at
an alpha set at p<0.05.
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Table 2
Variable
(LLC)
Body
Weight (g)
Tumor
Weight (g)
BW Tumor (g)
TA (mg)
Gastroc
(mg)
Plantaris
(mg)
EDL (mg)
Soleus (mg)
Spleen (mg)

PBS (n=24)
24.9±0.3 a

1 Week
(n=16)
23.9±0.3 a

2 Week
(n=16)
23.8±0.6 a

3 Week
(n=12)
24.4±0.8 a

4 Week
(n=14)
27.0±0.6 b

N/A

0.03±0.007 a

0.2±0.03 a

0.8±0.1 b

3.5±0.4 c

24.9±0.3

23.9±0.3

23.7±0.6

23.6±0.7

23.5±0.6

45.1±0.9 a
134.6±2.1 a

43.8±1.2 a
129.5±2.5 a

44.5±1.2 a
130.0±4.1 a

18.3±0.4 a

18.3±0.3 a

18.1±0.6 a

42.9±1.6 a
125.2±3.5
a,b
17.7±0.7 a

38.3±1.3 b
118.4±4.1
b
15.9±0.6 b

9.9±0.4
8.7±0.2 a
81.1±3.2 a

9.4±0.3
8.2±0.2 a,b
81.9±2.8 a

9.9±0.3
8.1±0.2 a,b
85.7±2.6 a

151.2±6.8
367.5±12.9 a

173.0±8.9
332.5±22.6 a

152.3±6.7

149.2±5.7

161.7±3.9
348.2±12.8
a
147.8±8.8

9.6±0.4
8.1±0.3 a,b
222.8±31.1
b
173.2±8.9
316.7±33.6
a
148.5±7.6

8.6±0.5
7.7±0.2 b
366.5±31.8
c
156.8±10.0
240.4±19.2
b
127.1±7.2

Lungs (mg)
EpiFat
(mg)
Quadriceps
(mg)
Tibia (mm)

17.4±0.1

17.4±0.1

17.3±0.1

17.4±0.1

17.3±0.1

Table 2: Body and tissue weights at the time of harvest in LLC tumor-bearing mice. N of 1224/group as indicated on table was utilized. Tibia length was measured as an estimate of total
body size which did not differ between experimental groups, therefore all tissue weights are
presented as non-normalized wet weights. Lettering denotes statistical significance at an alpha
set at p<0.05.
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Figure 1. mRNA content of mitochondrial quality controllers in quadriceps muscle of B6 and
APC/Min+ mice. A: mRNA content of mitochondrial biogenesis controllers. B: mRNA content
of mitochondrial dynamics controllers. C: mRNA content of mitophagy regulators. N of 5-6 was
utilized for each group. Lettering denotes statistical significance at an alpha set at p<0.05.
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Figure 2. Oxidative muscle fibers and mitochondrial content across a time course progression of
cancer-cachexia in LLC tumor-bearing mice. A-D: SDH staining performed in TA muscle. A:
Representative images for SDH stain across the different experimental groups. Scale bar is 50
µM long. B: % SDH+ fibers throughout the progression of cancer-cachexia. C: Cross Sectional
Area distribution of SDH+ fibers. D: Cross Sectional Area distribution of SDH- fibers. E-G:
Immunoblotting in gastrocnemius muscle. E and F: Immunoblot quantification of mitochondrial
content markers COX-IV (E) and VDAC (F). G: Representative immunoblot images. N of 10 for
each group was used for SDH analysis and N of 8 for each group was utilized for immunoblot
analysis. Lettering denotes statistical significance at an alpha set at p<0.05.
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Figure 3. Mitochondrial degeneration precedes muscle wasting in cancer-cachexia in LLC
tumor-bearing mice. MitoTimer is a mitochondrially targeted variant of DsRed validated by
Laker et al., 2014 [15] to emit green fluorescence when mitochondria are healthy and shift to red
when mitochondria are damaged. A-C: MitoTimer in FDB muscle. A: Representative
MitoTimer images taken at 100X magnification. Scale bar is 20 µM in length. B: Quantification
of MitoTimer Red: Green ratio. C: Quantification of pure red puncta in MitoTimer. Locations of
pure red puncta co-localize with LC3 and appear to represent completely degenerated
mitochondria targeted for autophagy [15]. D-E mitochondrial function and ROS emission in
plantaris muscle. D: Respiratory control ratio (Ratio of State 3: State 4 respiration) of
permeabilized plantaris muscle. E: Mitochondrial H2O2 production in permeabilized plantaris
muscle. N of 12-24 per group was utilized for MitoTimer, while n of 12/group was utilized for
respiration and ROS production analysis. Lettering denotes statistical significance at an alpha set
at p<0.05.
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Figure 4. Immunoblot analysis of mitochondrial quality control regulators during progression of
cancer-cachexia in gastrocnemius muscle of LLC tumor-bearing mice. A and B: Immunoblot
quantification (A) and representative immunoblots (B) of mitochondrial biogenesis regulators
PGC-1α, PPARα, PPARδ and TFAM. c and d: Immunoblot quantification (C) and representative
immunoblots (D) of mitochondrial dynamics regulators MFN1, MFN2, OPA1, DRP1 and Fis1. E
and F: Immunoblot quantification (E) and representative immunoblots (F) of mitophagy
regulators BNIP3, PINK1, p-PARKIN and PARKIN. N of 7-8 per group was utilized for
immunoblot analysis. Lettering denotes statistical significance at an alpha set at p<0.05.
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Figure 5. Content of antioxidant enzymes during progression of cancer-cachexia in
gastrocnemius muscle of LLC tumor-bearing mice. A: Representative images of antioxidant
enzymes. No statistically significant findings were found. N of 7-8 per group was utilized for
immunoblot analysis.
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Figure 6

Figure 6. Summary of functional mitochondrial derangements preceding cachectic muscle
wasting in tumor-bearing mice.
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Abstract
Cancer cachexia occurs in approximately 80 percent of cancer patients and is a key
contributor to cancer-related death. The mechanisms controlling development of tumor-induced
muscle wasting are not fully elucidated. Specifically, the progression of cancer-cachexia is
underexplored. Therefore, we examined skeletal muscle mass throughout the progression of
cancer-cachexia. Lewis Lung Carcinoma (LLC) was injected into the hind-flank of C57BL6/J
mice at 8 wks age with tumor allowed to develop for 1, 2, 3, or 4 wks and compared to PBS
injected control. Tumor-induced muscle wasting was evident at 4 wks following LLCimplantation. Muscle cross sectional area decreased ~40% and collagen deposition increased 3fold 4 wks following tumor implantation. Myogenic signaling was altered in tumor-bearing mice
when compared to control animals. Protein synthesis did not change throughout the progression
of cancer-cachexia. FOXO1/3 mediated ubiquitin proteasome system was induced 4 wks
following tumor implantation. Moreover, there was an increase in autophagy machinery after 4
wks of tumor growth. Apoptosis mediated DNA damage did not change throughout the
progression of cancer-cachexia. Finally, MAPK signaling was altered in cachectic muscle. These
data show dysregulation of controllers of skeletal muscle mass throughout a time-course progress
of cancer-cachexia and give insight to potential therapeutic mechanisms.

Key Words: protein synthesis, LLC, ubiquitin, MAPK, ERK, p38
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Introduction
Cancer is one of the leading causes of death worldwide with over half of the people
affected by cancer dying as a result of the condition [1, 2]. Cancer-cachexia is a wasting
syndrome that occurs in approximately 80% of cancer patients [3-5]. In fact, cancer-cachexia is
the primary cause of death for 20%-40% of cancer deaths [3-5]. Cancer-cachexia is defined as a
multifactorial syndrome which displays an ongoing loss of skeletal muscle mass (with or without
loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to
progressive functional impairment [3, 5]. As efforts to reverse cancer-cachexia have been largely
unsuccessful, recent suggestions in the literature have emphasized needs to focus on prevention
of the condition [6]. However, few efforts have been placed toward understanding the early stage
development of cancer-cachexia. We recently demonstrated that muscle mitochondrial health is
impaired well before onset of measurable muscle wasting in cancer-cachexia in Lewis Lung
Carcinoma (LLC) tumor-bearing mice using a time course model [7]. Those data suggest early
onset derangements in muscle health. Therefore, it may become critical to define the early
alterations that may trigger the onset of the cachectic phenotype to best define mechanisms of
cancer-induced muscle wasting. However, skeletal muscle atrophy occurs primarily by an
imbalance of protein turnover favoring protein degradation over protein synthesis [8, 9]; yet, the
underlying mechanisms of muscle loss in the development of cancer-cachexia have not been
fully elucidated. Therefore, a critical need remains to define alteration of muscle protein turnover
processes in the development of cancer-cachexia induced muscle wasting.
From prior literature, it is clear cancer-cachexia is associated with decreased rates of
muscle protein synthesis, and increased rates of protein degradation [10-13]. We also know that
protein turnover is regulated by a series of anabolic processes including myogenesis and protein
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synthesis [14-16] [17, 18] [19, 20] [21, 22] [10-13], and catabolic processes including the
ubiquitin proteasome system, autophagy, and apoptosis [23] [24] [13] [8, 25] [26-28]. Each of
these processes may present significant dysregulation during cancer-cachexia; however, the
nature by which this negative protein balance develops in cancer-cachexia remains largely
unknown. The initial development of cancer- induced muscle wasting is understudied in
scientific literature despite the need to consider measures to prevent the condition. Therefore, the
purpose of this study was to examine regulation of protein turnover in skeletal muscle throughout
a time course progression of cancer-cachexia in tumor-bearing mice. By examining a
comprehensive measurement of protein turnover regulation throughout the progression of
cancer-cachexia we provide key information about the pathogenesis of this condition.
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Methods
Animals and Interventions
Animal experiments were performed at the University of Arkansas, Fayetteville. All
procedures were approved by the Institutional Animal Care and Use Committee of the University
of Arkansas. We have previously reported on several aspects of these animals regarding body
and tissue masses and mitochondrial health [7].
Tumor Implantation and Tissue Collection. Male C57BL/6J mice were purchased from
Jackson Laboratories. The mice were kept on a 12:12-h light-dark cycle with ad libitum access to
normal rodent chow and water. 1X106 LLC cells suspended in sterile PBS were implanted to the
hind flank of mice at 8 weeks of age [7]. The tumor was allowed to develop for 1, 2, 3 or 4
weeks as previously described [7]. To allow measure of protein synthesis, a bolus of deuterium
oxide (~20 µL/g body weight) was injected intraperitoneally in the mouse approximately 24
hours before tissue collection. Drinking water was thereafter supplemented with 4% deuterium
oxide in order to maintain the plasma pool of deuterium oxide [29-31]. Animal tissues were
quickly collected under isoflurane anesthesia prior to euthanasia. Tissues were quickly weighed
and snap-frozen in liquid nitrogen for further processing and stored at -80°C.
Histology
Tibialis Anterior (TA) muscles were imbedded in optimal cutting temperature (OCT)
compound and frozen for sectioning. Sections were cut at 10 µm using a Leica CM1859 cryostat
(Leica Biosystems, Buffalo Grove, IL) and stained with Hematoxylin & Eosin (H & E) for cross
sectional area analysis. Muscle fibers were circled using Nikon Basic Research Imaging
Software (Melville, NY). Roche Diagnostics (Indianapolis, IN) In Situ cell death detection
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Fluorescein (11684795910) was used to detect damaged DNA. Manufacturer’s protocols were
used. Slides were mounted with DAPI mounting media. Nikon Ti-S inverted epiflourescent
microscope with LED-based light source was used to image total nuclei (DAPI) and TUNEL +
nuclei (FITC). Total nuclei and TUNEL + nuclei were then counted using Nikon Basic Research
Imaging Software.
24-Hour Protein Synthesis In-Vivo
A detailed description of this method for measuring protein synthesis has previously been
published [32]. 15 mg and 35 mg of gastrocnemius muscle were powdered and homogenized in a
10% TCA solution for mixed and myofibrillar FSR, respectively. In order to isolate the
myofibrillar fraction, homogenate was centrifuged at 600 G for 15 minutes. The supernatant
containing cytosolic proteins was then discarded. Mixed and myofibrillar fractions were then
washed 3 times with 10% TCA solution by centrifugation to eliminate cytosolic amino acids and
subsequently placed in 6 M HCL. The solution was then heated at 100˚C for 24 hours in order to
break down proteins into their amino acid building blocks. An aliquot of the hydrolysate was
dried down and derivatized with a 3:2:1 solution of methyl-8, methanol, and acetonitrile to
determine 2H-labeling of alanine on its methyl-8 derivative. The solution was then placed in a
GC-MS capillary column (Agilent 7890A GC HP-5 ms capillary column) and positioned in the
GC-MS. 1 µL of solution was ran on the Agilent GC-MS at an 80:1 split. GC-MS settings have
previously been described [32, 30]. A ratio of deuterated alanine over alanine was employed to
assess protein synthesis. In order to normalize results based on the precursory pool of 2H2O,
plasma was reacted with 10 M NaOH and a 5% solution of acetone in acetonitrile for 24 h in
order to conjugate the free 2H2O to acetone. The solution was extracted by adding Na2SO4 and
chloroform, and placed in capillary columns to be analyzed on the GC-MS to detect acetone at
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an 80:1 split. FSR of mixed and myofibrillar proteins were calculated using the equation EA ×
[EBW × 3.7 × t (h)]−1 × 100, where EA represents amount of protein-bound [2H]alanine
(mole% excess), EBW is the quantity of 2H2O in body water (mole% excess), 3.7 represents the
exchange of 2H between body water and alanine (3.7 of 4 carbon-bound hydrogens of alanine
exchange with water) and t(h) represents the time the label was present in hours.
RNA isolation, cDNA synthesis, and quantitative real-time PCR
Adult gastrocnemius muscles were collected and frozen in liquid nitrogen at time of
harvest. 20-30 µg of powdered gastrocnemius muscle was homogenized into a 1 mL TRIZOL
solution, and RNA was isolated using a commercially available kit (Ambion, Life Technologies).
Isolated RNA purity and concentration was confirmed using Bio-Tek (Winooski, VT) Power
Wave XS plate reader with Take3 microvolume plate and Gen5 software. After which, 1 μg of
RNA was reverse transcribed into cDNA using previously described methods and Vilo
SuperScript (11755050, Invitrogen, Carlsbad, CA) reagents cDNA was diluted to 1:100 (10
ng/μL) and Ct values analyzed using TaqMan reagents and commercial Step-One real-time RTPCR instrumentation (Applied BioSystems, Foster City, CA). Assessment of 18s
(Mm03928990_g1), Pax7 (Mm01354484_m1), MyoD (Mm00440387_m1), MyoG
(Mm00446194_m1) and Igf1 (Mm00439561_m1) were performed using TaqMan probes (Life
Technologies) and corresponding TaqMan reagents. No differences were seen in 18s among
experimental conditions for experiments presented. Final quantification of gene expression was
calculated using the ΔΔCT method. Relative quantification was calculated as 2−ΔΔCT.
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Immunoblotting
Gastrocnemius muscle was homogenized in a buffer containing 0.23 M Tris-HCL, pH
6.8, 4.5% w/v SDS, 45% glycerol, 0.04% w/v Bromophenol Blue, 80 mM dithiothreitol,
0.57mM 2-mercaptoethanol, complete, mini protease inhibitor cocktail (Roche, Indianapolis,
IN), and phosphatase inhibitor cocktails (Sigma-Aldrich) and denatured at 95°C. Concentrations
were determined using the RC/DC assay (500-0119, BioRad, Hercules, CA) and 40 μg total
protein was resolved by SDS-PAGE, transferred to a PVDF membrane and blocked in 3% w/v
Bovine Serum Albumin in Tris-buffered saline with 0.2% Tween 20 (TBST). Membranes were
probed overnight for primary antibodies specific to p-AKT (Cell Signaling 9271), AKT (Cell
Signaling 9272), p-4EBP1 (Cell Signaling 9644), 4EBP1 (Cell Signaling 9452), p-p70s6k (Cell
Signaling 9205), p70s6k (Cell Signaling 9202), p-FOXO1 (Cell Signaling 9464), FOXO1 (Cell
Signaling 2880), p-FOXO3 (Cell Signaling 9464), FOXO3 (Cell Signaling 2497), p-FOXO4
(Cell Signaling 9471), FOXO4 (Cell Signaling 9472), Beclin1 (Cell Signaling 3738), p62 (Sigma
p0067) and LC3 (Cell Signaling 4108) isolated from rabbit and mouse. Antibodies were diluted
in TBST with 5% milk. Licor secondary antibodies conjugated with HRP (animal experiments)
or Infared (IR) Dye (cell culture experiments) were used according to manufacturers protocols.
For animal experiments, membranes were imaged on Protein Simple FluorChem (Minneapolis,
MN) with Licor WesternSure Premium Chemiluminescent substrate (926-95000) and analyzed
using Alpha View software. For cell culture experiments membranes were imaged on Licor
Odyssey FC using IR detection. All bands were normalized to the 45 kDa Actin band of Ponceau
S stain as a loading control.
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Statistical Analysis
For animal experiments, independent factors were PBS and number of weeks tumor
progressed. A One-Way ANOVA was employed as the global analysis for each dependent
variable. Where significant F-ratios were found, differences among means were determined by
Student Newman-Keuls post hoc test. For all experiments, the comparison-wise error rate, α, was
set at 0.05 for all statistical tests. All data were analyzed using the Statistical Analysis System
(SAS, version 9.3, Cary, NC, USA), figures were compiled using GraphPad Prism (La Jolla, CA,
USA) and data expressed as mean ± SEM.
Results
Characterization of the progression of LLC-induced cancer-cachexia. Phenotypic
characteristics of these mice including body and tissue masses have previously been reported [7].
Most importantly, muscle wet weights were ~15-20% lower 4 wks following tumor implantation
when compared to PBS control mice [7]. Here, we report that mean CSA of TA muscle fibers
were ~15% smaller 3 wks following tumor implantation and ~40% smaller by 4 wks of tumor
growth compared to PBS control mice (Figure 1B). Furthermore, there were a larger number of
small fibers (200µM2-600µM2 area) and a smaller number of large fibers (>1400 µM2) when
comparing 4 wks of tumor burden to PBS control mice (Figure 1C). Finally, we assessed mRNA
content of putative markers of muscle denervation. We observed that while mRNA of
Acetylcholine Receptor (AchR) α, Gad45A, RUNX1 and MusA were not significantly altered
(Figure S1). AchR δ and AchR ε were downregulated by ~35% and 45% 2 wks and 3 wks
following tumor implantation, respectively (Figure S1).
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Myogenic signaling is impaired 1 wk following tumor implantation. To determine the
impacts of the tumor-bearing state on anabolic functions in the muscle we assessed aspects of
myogenesis and protein synthesis. Briefly, myogenesis is the formation of muscular tissue which
is necessary for repair of injured muscle. Satellite cells are labeled with Pax7 [33]. Upon
activation, satellite cells express MyoD and subsequently Myogenin which is responsible for
proliferation and differentiation of satellite cells, respectively [21, 22]. From these assessments
we observed that Pax7 mRNA content was ~35% lower 1 wk following tumor implantation
when compared to PBS control mice, and did not recover throughout the progression of cancercachexia (Figure 2A). MyoD mRNA content was ~50% lower in both 1 wk and 2 wk tumorbearing groups when compared to PBS control mice (Figure 2B). mRNA content of MyoD
recovered 3 wks following tumor implantation. In tumor-bearing mice, CyclinD1 mRNA content
was ~45% lower than PBS control mice in all tumor-bearing groups (Figure 2C). Myogenin
mRNA was ~50% lower than PBS control mice 1 wk following tumor implantation, but
recovered by 3 and 4 wks following tumor implantation (Figure 2D).
Mixed protein synthetic rate is lower in cachectic muscle. Next, in our assessment of
anabolic function we determined 24-h FSR and assessed mTOR signaling components. Mixed
muscle FSR was ~40% lower than the PBS control group 4 wks following tumor implantation
with no other significant differences among experimental conditions (Figure 3A). In contrast,
there was no significant change in myofibillar FSR during the progression of cancer-cachexia
(Figure 3B); however, there was a mean decrease in the 3 and 4 wk groups when compared to
PBS. To examine mTOR related signaling we assessed the upstream marker Akt, mTOR
Complex component and negative regulator of mTOR – Deptor, and downstream mTOR targets
p70S6K1 and 4EBP-1 [34] [17, 18]. We observed that content and phosphorylation of Akt,
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p70s6k and 4EBP1 did not change throughout the progression of cancer-cachexia (Figure 3
C,E,F). However, Deptor protein content was ~40% greater 3 wks following tumor implantation
when compared to other experimental groups (Figure 3D).
Protein breakdown is upregulated in cachectic muscle. To investigate the contributions
of putative catabolic processes we assessed markers of the ubiquitin-proteasome system,
autophagy and apoptosis. With regards to the ubiquitin-proteasome system, FOXO1 and FOXO3
signaling are important regulators of the atrogenes: Atrogin1 and MuRF1 [23]. These are
important E3 ligases known to promote skeletal muscle wasting [23]. We observed that total
FOXO1 protein content was ~50% greater than PBS control mice 4 wks following tumor
implantation (Figure 4A). Phosphorylation of FOXO1T24 and FOXO4T28 did not change as tumor
growth progressed; however, there was a non-significant ~50% mean increase in FOXO3T32
phosphorylation relative to total protein content 4 wks following tumor implantation when
compared to other experimental groups (Figure 4B). Furthermore, Atrogin1 mRNA content was
3 fold greater than PBS control mice 4 wks after tumor implantation (Figure 4C), while MuRF1
mRNA content was 2 and 4 fold greater than PBS control mice at 3 and 4 wks following tumor
implantation (Figure 4D), respectively. Muscle protein ubiquitination was ~50% higher than
PBS control mice 4 wks following tumor implantation (Figure 4E).
To provide insight into the potential contributions of autophagy, a process involved in the
formation of an autophagosome in order to facilitate lysosomal clearance of proteins and
organelles [26-28], we examined upstream regulator Beclin1, as well as LC3 (involved in the
closing of the autophagosome) and p62 (a linker protein between the autophagosome and cargo
that is degraded by the lysosome upon completion of autophagy). Beclin1 protein content was
~80% greater than PBS control mice 4 wks post tumor implantation (Figure 4F). Furthermore,
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total LC3 protein content was ~60% higher than PBS control mice after 4 wks of tumor growth
(Figure 4G). By contrast, there was no change in the LC3 II:I ratio (an indicator of autophagy
initiation) throughout the progression of cancer-cachexia (Figure 4H) nor in protein content of
p62 (marker of autophagy resolution, Figure 4I).
Apoptosis is not altered in progression of LLC-induced cancer-cachexia. To examine
apoptosis in cachectic muscle, we used TUNEL staining, and Caspase 3 protein content. Loss of
myonuclei may limit the muscles’ ability to increase in size. There was no significant difference
in the number of TUNEL positive nuclei throughout the progression of cancer-cachexia (Figure
5A). Moreover, total Caspase 3 was not different between the PBS, 1 wk, 2 wk, 3 wk and 4wk
groups (Figure 5B). Cleaved Caspase 3 was not detectable by immunoblot.
MAPK phosphorylation is induced in tumor-bearing mice. MAPKs are key controllers of
both anabolic and catabolic signaling within skeletal muscle [35, 36], therefore in order to assess
MAPKs in cachectic muscle we examined p38 and ERK phosphorylation status. ERKT202/Y204
and p38T180/Y182 MAPK phosphorylations relative to respective total protein contents were 4 fold
and 3 fold greater than PBS control mice 4 wks following tumor implantation, respectively
(Figure 6A/B).
Discussion
Loss of muscle mass occurs largely from an imbalance of protein turnover favoring
protein degradation [37], which is commonly observed in late stage cancer-cachexia [11, 10,
38]; however, we are the first to measure modalities of protein turnover throughout a time course
development of LLC-induced cancer-cachexia. We recently demonstrated that impaired
mitochondrial health develops well prior to onset of muscle wasting [7]. Those data suggest
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impaired myocellular health prior to measurable muscle wasting. Here, we have shown
alterations in cellular programing necessary for the maintenance of muscle mass as soon as 1 wk
following tumor implantation with impaired signaling for satellite cell proliferation and
myogenesis. Interestingly, through additional assessments of muscle protein synthesis and
degradative pathways including autophagy, ubiquitin-proteasome system and apoptosis, it
appears primary decrements contributing to the negative protein balance occur via activation of
the ubiquitin-proteasome system and reduced mixed muscle protein synthesis which develop
concurrent to the onset of phenotypic muscle wasting. The data presented in this study provides a
comprehensive overview of machinery responsible for the maintenance of muscle mass
throughout the progression of cancer-cachexia in tumor-bearing mice.
Cross Sectional Area is altered in tumor-bearing mice. In the current study cachectic
muscle mass loss developed at 4 wks post tumor implantation, which is commonly observed in
this model [39, 16, 40, 7]. These mice display a degree of muscle mass loss (~15% smaller
muscle wet weights [7], and a ~40% decrease in mean CSA) that would be considered a negative
prognosis clinically and greatly increase mortality among cancer patients. However, the
reductions in total muscle mass are smaller than many prior reports and without significant loss
in tumor free body mass suggesting that 4 wk tumor-bearing mice displayed mild/moderate
cachexia. We have demonstrated that AchR δ and ε are downregulated in cachectic muscle;
however, at this point we cannot conclude that functional denervation is occurring. In fact,
AChR density is often higher than needed for efficient capture of the acetylcholine released [41];
therefore, functional denervation is not likely occurring at this stage in the development of
cancer-cachexia.
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Satellite Cells and Myogenic Signaling. In cancer-cachexia, the sarcolemma becomes
damaged due to factors secreted by the tumor, which elicits a repair response [19]. Our data
indicates Pax7 mRNA, a satellite cell marker, content decreased as soon as 1 wk following
tumor implantation, implying the satellite cell pool may be diminished thus impairing
regenerative capacity shortly after the onset of the tumor-bearing state [42]. Intriguingly, these
results appear to contradict findings from He et al. [20] in which an increase in Pax7 protein
content was noted in response to tumor burden in both C26 and LLC models of cancer-cachexia.
These contradictions may be due to methodology differences to measure Pax7 expression. It is
possible that reduced Pax7 mRNA here coupled with increased Pax7 protein previously reported
[20] indicates altered turnover of Pax7 and accumulation of dysfunctional satellite cells, at
current though this speculation requires further testing to resolve. Moreover, our data shows that
both MyoD (important for satellite cell proliferation [22]), MyoG (important for satellite cell
differentiation [22]) and Cyclin D1 mRNAs content are decreased 1 wk following tumor
implantation. Dysregulation of MyoD and MyoG mRNA expression corroborates recent findings
outlining impaired myogenesis in response to tumor burden in mice [20]. Taken together the
aberrant myogenic signaling we observe suggests a potential limit on muscle regrowth potential
post cancer treatment suggesting a need to determine means impairing myogenic potential in
early tumor-bearing states to prevent this effect.
Mixed muscle protein synthesis is reduced concurrent to muscle wasting in tumorbearing mice. In cancer cachexia literature, there is an ongoing debate as to whether a decrease
in protein synthesis, upregulated protein degradation or both play a bigger role in the onset of
cancer-induced muscle wasting [43]. There appears to be discrepancies based on both the type of
model used and the methodology for measuring protein synthesis [43, 44, 38, 16, 45]. Our
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protein synthesis data showed a decrease in the mixed muscle fraction with no change in the
myofibrillar fraction (despite a ~25% mean decrease in FSR) measured over a 24 hour time
period. These results corroborate studies such as Toledo et al. [44] which describes a ~50%
reduction in protein synthesis in the gastrocnemius muscle in LLC tumor bearing mice. We are
the first to measure protein synthesis in LLC tumor-bearing mice utilizing deuterium oxide for a
24 hour time period, a validated measurement of protein synthesis [29], in LLC tumor-bearing
mice. This approach, may provide a specific advantage in the ability to assess protein synthetic
function over the course of a full light/dark cycle and thus a potentially more accurate reflection
of basal protein synthetic rates. In regards to myofibrillar protein synthesis, we should note that
most reports measuring muscle protein synthesis in a cachectic phenotype have more severe
wasting with greater losses in muscle masses and losses in total body mass than this study [16,
44, 46, 47]. It is likely that development of a more severe phenotype would alter protein
synthetic signaling and induce a more severe loss of myofibrillar FSR comparable to other
studies. These data suggest that decrements in mixed-muscle protein synthesis is a significant
contributor to muscle wasting in LLC tumor-bearing mice.
Induction of skeletal muscle protein degradation systems in tumor-bearing mice. Our data
indicates that there is increased protein breakdown 4 wks after tumor implantation which in the
absence of impairments in protein synthesis likely explains muscle mass losses at this stage of
cachectic development. We note upregulation of E3 ligases Atrogin1 and MuRF1 4 wks
following tumor implantation with concomitantly increased protein ubiquitination. This increase
in the ubiquitin-proteasome system likely occurs through enhanced FOXO1 content and a mean
increase FOXO3 phosphorylation 4 wks following tumor-implantation.
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Autophagy is another key controller of protein breakdown [26-28]. Our data indicates an
increase in Beclin1 and LC3 protein content 4 wks following tumor-implantation. Based on
current data it appears that rates of autophagy are not significantly enhanced in the cachectic
state; however, autophagy machinery (Beclin1 and LC3) appears to be upregulated suggesting
greater capacity for protein degradation through this system in cachectic muscle. Finally, we
observed no significant induction of apoptosis in the muscle of cachectic mice, suggesting that at
this stage of mild/moderate cachectic wasting apoptosis is not a primary contributor to muscle
protein degradation.
Therefore, in our assessments of muscle anabolic and catabolic functions in tumorbearing mice we observe early onset decrements to myogenic signaling, followed by reduced
mixed muscle protein synthesis, increased ubiquitin-proteasome function, increased atrogene
expression and an upregulation of autophagy machinery. Loss of protein synthesis and the
promotion of protein breakdown occur concomitantly with cancer-mediated muscle loss.
MAPK signaling is altered in tumor-bearing mice. To identify potential mechanisms
leading to impaired protein anabolism and enhanced protein ubitination we next examined
MAPK signaling in tumor-bearing mice. Our data shows that both ERK and p38 MAPK
phosphorylation’s increase by 4 fold and 3 fold, respectively 4 wks following tumor
implantation. Prior literature shows an increased phosphorylation of these MAPKs can lead to
both impaired muscle regeneration and increased protein breakdown [48, 35, 36, 49-52]. The
next chapter in this dissertation further explores MAPKs role in the promotion of cancermediated muscle loss.
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Summary and conclusions. In this study, we have analyzed muscle size, myogenesis,
protein turnover and apoptosis throughout the progression of cancer-cachexia. Based on our data,
loss of mixed protein synthetic rates along with increased protein breakdown via the ubiquitinproteasome system are likely the major contributors for the onset of cancer-cachexia in LLC
tumor-bearing mice. Furthermore, there appears to be early alterations in myogenic signaling
potentially contributing to the irreversibility of cancer-cachexia. Future research should continue
to examine MAPKs role in cancer-induced muscle wasting. These data will provide novel
information for the development of therapies to prevent and treat cancer-cachexia.
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Figures

Figure 1. Cross sectional area throughout the progression of cancer-cachexia. A: Hematoxylin
and Eosin staining sample images (scale 50 µM). B. Mean CSA of TA muscle fibers throughout
the progression of cancer-cachexia. C. Histogram of fiber sizes throughout the progression of
cancer-cachexia. N of 7-8 was utilized for each group. Lettering denotes statistical significance
at an alpha set at p<0.05.
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Figure 2. Myogenic signaling throughout the progression of cancer-cachexia. A. Pax7 mRNA content

throughout the progression of cancer-cachexia. B. MyoD mRNA content throughout the
progression of cancer-cachexia. C. CyclinD1 content throughout the progression of cancercachexia. D. MyoG content throughout the progression of cancer-cachexia. N of 7-8 was utilized
for each group. Lettering denotes statistical significance at an alpha set at p<0.05.
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Figure 3. Protein synthesis throughout the progression of cancer-cachexia. A. Mixed FSR
throughout the progression of cancer-cachexia. B. Myofibrilar FSR throughout the progression
of cancer-cachexia. C. AKT phosphorylation relative to total protein. D. Deptor protein content
throughout the progression or cancer-cachexia. E. 4EBP1 phosphorylation relative to total
protein content. F. p70s6k phosphorylation relative to total protein content. G. Sample images
for immunoblot analysis. N of 7-8 was utilized for each group. Lettering denotes statistical
significance at an alpha set at p<0.05.
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Figure 4. Protein breakdown throughout the progression of cancer-cachexia. A. FOXO1 protein
content throughout the progression of cancer-cachexia. B. Phosphorylation of FOXO3 relative to
total protein content throughout the progression of cancer-cachexia. C. Atrogin1 mRNA content
throughout the progression of cancer-cachexia. D. MuRF1 mRNA content throughout the
progression of cancer-cachexia. E. Ubiquitinated proteins throughout the progression of cancercachexia. F. Beclin1 protein content throughout the progression of cancer-cachexia. G. Total
LC3 protein content throughout the progression of cancer-cachexia. H. LC3 II/I ratio throughout
the progression of cancer-cachexia. Immunoblot sample image of ubiquitin. I. p62 protein
content throughout the progression of cancer-cachexia. J. Representative immunoblot images. N
of 7-8 was utilized for each group. Lettering denotes statistical significance at an alpha set at
p<0.05.
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Figure 5. Apoptosis throughout the progression of cancer-cachexia. A. Percent TUNEL + nuclei
throughout the progression of cancer-cachexia. B. Total caspase 3 protein content throughout the
progression of cancer-cachexia. D. Sample images for the TUNEL assay including a positive
control image. E. Representative immunoblot images. N of 7-8 per group was utilized. Lettering
denotes statistical significance at an alpha set at p<0.05.
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Figure 6. MAPK signaling throughout the progression of cancer-cachexia. A. ERK MAPK
phosphorylation relative to total protein content. B. p38 MAPK phosphorylation relative to total
protein content. C. Representative immunoblot images. N of 7-8 per group was utilized.
Lettering denotes statistical significance at an alpha set at p<0.05.
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Figure S1. Denervation markers throughout the progression of cancer-cachexia. A. AchR α
mRNA content throughout the progression of cancer-cachexia. B. AchR δ mRNA content
throughout the progression of cancer-cachexia. C. AchR ε mRNA content throughout the
progression of cancer-cachexia. D. Gad45A mRNA content throughout the progression of
cancer-cachexia. E. Runx1 mRNA content throughout the progression of cancer-cachexia. F.
Mus A mRNA content throughout the progression of cancer-cachexia. N of 7-8 was utilized for
each group. Lettering denotes statistical significance at an alpha set at p<0.05.
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Abstract
Cancer-cachexia contributes to as much as 40% of cancer related deaths. The underlying
mechanisms behind tumor-induced muscle wasting are not fully elucidated. In this dissertation I
have shown that oxidative stress and enhanced MAPK phosphorylation is present in cachectic
muscle; therefore, I have elected to use Lewis Lung Carcionoma conditioned media (LCM) to
mimic cancer-cachexia in an in-vitro system to examine the roles of oxidative stress, p38 MAPK
and ERK 1/2 MAPK in muscle atrophy in vitro. To do so, myotubes were treated with either
Control or LCM concurrently with either MitoTEMPO (MitoT, a mitochondrial specific
antioxidant), SB202190 (inhibitor of p38 MAP kinase) or PD98059 (MEK1/2 inhibitor
preventing ERK 1/2 activity). MitoT and inhibition of p38 MAPK, but not ERK-MAPK,
ameliorated LCM-induced loss of myotube diameter by ~30 and 20% respectively. Inhibition of
p38 MAPK protected against LCM-mediated upregulation of total ubiquitin, and p38 MAPK
inhibition downregulated the mRNA content of Atrogin-1 and MuRF-1 by ~40 and 50%,
respectively. Also, LCM reduced puromycin incorporation by ~50%, while long term (18 hour)
inhibition of both p38 and ERK MAPK increased puromycin incorporation by ~75% despite no
change in protein synthetic signaling. These data indicate oxidative stress and p38 MAPK
signaling may be key promoters of cancer-induced muscle loss.

Key Words: MAPK, p38 ERK, mitotempo, LLC, cancer, cachexia, conditioned, media
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Introduction
Cancer-cachexia is a co-morbidity of cancer that is defined as an ongoing loss of skeletal
muscle mass and function that cannot be fully reversed by conventional nutritional support [1, 2].
Cancer-cachexia occurs in approximately 80% of cancer patients and is the primary cause of
death for 20%-40%, depending on type of cancer, of the estimated 8.2 million cancer related
deaths globally [3, 1, 4, 2]. Furthermore, loss of muscle mass increases chemotherapy toxicity
leading to increased suffering for cancer patients [5-7]. Cancer-cachexia is a major global health
care problem that is often overlooked and underestimated; therefore, more effort is needed to
understand underlying mechanisms of cancer-mediated muscle loss in efforts to then develop
efficacious treatment modalities.
Skeletal muscle wasting is primarily caused by an imbalance of protein turnover favoring
protein degradation over protein synthesis; however, mechanisms behind this imbalance of
protein turnover vary depending on the (patho)physiological circumstance [8, 9]. Cancercachexia is a complex wasting syndrome which is not fully understood; however, we recently
demonstrated that oxidative stress in skeletal muscle occurs well before cancer-induced muscle
wasting [10]. Therefore, oxidative stress may be a key contributor of cancer-cachexia [11],
however more research is needed to further validate this observation.
Reactive oxygen and nitrogen species (ROS/RNS) exhibit pleotropic effects on skeletal
muscle [12] meaning ROS is often beneficial to skeletal muscle when produced at manageable
levels; however, when ROS production is elevated for extended periods of time (oxidative stress)
ROS have a wide array of cytotoxic effects [12]. Oxidative stress can lead to increased rates of
protein breakdown through the ubiquitin proteasome system [13], as well as decreased rates of
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skeletal muscle protein synthesis [14, 15]. Considering the early onset of mitochondrial oxidative
stress I have recently observed in tumor-bearing mice [10], and its likely role in generating a
negative protein balance [13] [14, 15], targeting ROS may be a potentially efficacious
therapeutic strategy to treat cancer-cachexia; however, antioxidant administration may increase
tumor size [16].
Additionally, MAPKs are known to mediate multiple cellular events including the
induction of catabolic functions, and MAPK activation and signaling are dysregulated during
oxidative stress [17]. Specifically, both p38 MAPK and ERK MAPK are major regulators of
proteostasis [18-21]. Inhibition of p38 MAPK signaling can attenuate ROS mediated
upregulation of the ubiquitin proteasome system as well as autophagy related genes [17]. In
chapter four of this dissertation I observed that phosphorylation of both p38 and ERK MAPK
were elevated in cachectic muscle when compared to muscle from control mice, this event
developed concurrently to the onset of muscle wasting in tumor-bearing mice. This cancercachexia mediated induction of MAPK signaling may therefore directly contribute to muscle
loss. In fact, pharmacological inhibition of both p38 and ERK 1/2 MAPK attenuated cancerinduced muscle loss [22]. However, more research is needed to fully understand the utility of
targeting MAPKs in the prevention and treatment of cancer-cachexia.
Currently, it is postulated that antioxidants may only be helpful for individuals with a
compromised antioxidant defense status due to the inability to specifically target skeletal muscle
ROS production [16]. Therefore, it is critical to understand the role of oxidative stress mediated
muscle loss in cancer-cachexia in a controlled in-vitro environment. Using Lewis Lung
Carcinoma conditioned media (LCM) to mimic tumor derived bloodborne factors is a wellestablished in-vitro model to study cancer-cachexia [23, 24]. Utilizing this model, I hypothesize
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that LCM induces loss of myotube diameter which will be attenuated by antioxidant treatment,
and that LCM-mediated loss of myotube diameter is dependent on MAPK signaling. This
research will open new doors for development of targeted therapies to treat cancer-cachexia and
provide mechanistic insight into pathological cellular processes behind cancer-induced muscle
wasting.
Materials and Methods
Tissue Culture
C2C12 myoblasts were plated at 50,000 cells per well of a 6 well cell culture plate with
2mL DMEM (11965092, Life Technologies, Carlsbad, CA) supplemented with 20% Fetal
Bovine Serum (26140079, Life Technologies) and 1% pen/strep (15140122, Life Technologies).
Cell proliferation and differentiation were performed as previously described [25, 26]. Myoblasts
were plated for experiments at passage 6.
LLC Conditioned Media Treatment
In order to collect LLC conditioned media (LCM), LLC cells were grown to 100%
confluence as previously described [10, 27]. LLC cells were then incubated in DMEM
supplemented with 10% Fetal Bovine Serum and 1% pen/strep for ~18 hours. The media was then
collected and filtered to remove cell particulates. LLC conditioned media was then diluted to 25%
total volume in serum free media. For the Control group, 25% total volume of 10% fetal bovine
serum growth media was diluted in serum free media. C2C12 myotubes were then treated with
either control or LCM for 24 hours. This method was adapted from Puppa et al. [28] and Guohua
et al. [24].
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Drug Treatments
To determine if neutralizing mitochondria-derived ROS may protect against LCM
induced myotube atrophy MitoTEMPO (MitoT, a mitochondrial targeted antioxidant) was
administered to C2C12 cells incubating in either control or LCM at a concentration of 2 µM.
MitoT has a wide range of concentrations used in literature (1nM [29]-25 µM[30])
To examine the roles of p38 MAPK and ERK 1/2 MAPK in the loss of myotube diameter
on myotubes treated with Control or LCM, differentiated C2C12 myotubes were treated with
either PD98059 (20 µM; PHZ1164, Life Technologies) (MEK1/2 inhibitor preventing ERK 1/2
activity) or SB202190 (20 µM; S7067, Sigma Aldrich) (inhibitor of p38 MAP kinase). These
concentrations of inhibitors have been previously published by Brown et al. [26].
Myotube Diameter Analysis
Myotube diameter analysis was performed as previously published [26, 25]. Briefly,
C2C12 myoblasts proliferated until 80-100% confluency. The myoblasts were differentiated for
120 hours. Myotubes were then placed in control or LCM and appropriate drug treatments were
added. Myotubes were imaged with 40X objective with a phase contrast filter using Nikon TiS
(Nikon, somewhere, someplace). 5 lines were drawn across the diameter of each myotube
representing sections across the full length of the tube in order to measure the average diameter
of the myotube. This was performed on every myotube imaged in the experimental conditions.
Researcher was blinded from experimental conditions for this analysis. All cell culture
experiments were conducted in triplicate and repeated in order to ensure data accuracy.
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MitoSox Analysis
After 18 hours incubation in control or LCM with either vehicle or MitoT treatment, 5μM
MitoSOX Red (M36008, Invitrogen) in PBS was added to differentiated C2C12 cells for 10
minutes, rinsed, and cells were visualized at 510/580nm (ex/em) on Nikon TiS epifluorescent
microscope (Melville, NY) to assess mitochondrial superoxide production.
RNA isolation, cDNA synthesis, and quantitative real-time PCR
RNA was isolated from cells as previously described [25, 26]. Isolated RNA purity and
concentration was confirmed using Bio-Tek (Winooski, VT) Synergy HTX plate reader with
Take3 microvolume plate and Gen5 software. After which, 1 μg of RNA was reverse transcribed
into cDNA using previously described methods [31, 32]. cDNA was diluted to 1:100 (10 ng/μL)
and Ct values analyzed using TaqMan reagents and commercial Step-One real-time RT-PCR
instrumentation (Applied BioSystems, Foster City, CA). Assessment of 18s (Mm03928990_g1),
Atrogin-1 and MuRF-1 were performed using TaqMan probes (Life Technologies) and
corresponding TaqMan reagents. No differences were observed in 18s among experimental
conditions for experiments presented. Final quantification of gene expression was calculated
using the ΔΔCT method. Relative quantification was calculated as 2−ΔΔCT.
Immunoblotting
C2C12 cells were homogenized in a buffer containing 0.23 M Tris-HCL, pH 6.8, 4.5%
w/v SDS, 45% glycerol, 0.04% w/v Bromophenol Blue, 80 mM dithiothreitol, 0.57mM 2mercaptoethanol, complete, mini protease inhibitor cocktail (Roche, Indianapolis, IN), and
phosphatase inhibitor cocktails (Sigma-Aldrich) and denatured at 95°C as previously described
[25]. Concentrations were determined using the RC/DC assay (500-0119, BioRad, Hercules, CA)
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and 20μg total protein was resolved by SDS-PAGE, transferred to a PVDF membrane and
blocked in 5% Milk in Tris-buffered saline. Membranes were probed overnight for primary
antibodies specific to ERK 1/2 MAPK (Cell Signaling 4695), phosphorylated ERK 1/2 MAPK
(Cell Signaling 4370, T 202/ Y204), p38 MAPK (Cell Signaling 9212), phosphorylated p38
MAPK (Cell Signaling 4511, Y 180/182), ), p-4EBP1 (Cell Signaling 9644), 4EBP1 (Cell
Signaling 9452), p-FOXO1 (Cell Signaling 9464), FOXO1 (Cell Signaling 2880), p-FOXO3
(Cell Signaling 9464), FOXO3 (Cell Signaling 2497), Ubiquitin (Cell Signaling 3933) and
Deptor (EMDMillipore, ABS222) all isolated from rabbit. Antibodies were diluted in 50% LiCor
Blocking Buffer and 50% TBS. Membranes were imaged on LiCor Odyssey Fc (Lincoln, NE)
and analyzed using Image Studio software (LiCor). All bands were normalized to the 45 kDa
Actin band of Ponceau S stain as a loading control.
SuNSET Protein Synthesis
Protein synthesis was measured using the SuNSET protocol [33, 34] as we have
previously published [25]. Briefly, 1μM puromycin dihydrochloride (Calbiochem, Darmstadt,
Germany) was added to cell culture media and incubated 30 minutes prior to protein extraction.
Immunoblotting protocols were followed as described above using 1:20,000 dilution of mouse
anti-puromycin IgG 2a antibody (EMD Millipore, Darmstadt, Germany) followed by 1:20,000
dilution of HRP conjugated anti-mouse IgG fragment specific 2a antibody (Jackson
ImmunoResearch Labs, West Grove, PA). The entire lane was assessed for optical density and
this was normalized to optical density of the entire lane of Ponceau S stain. This was used as a
relative measure of the amount of actively translated proteins in the polysome prior to harvest of
cells.

143

Statistical analysis
Independent factors included media (con or LCM) and drug treatment (Vehicle or
MitoT/SB/PD as appropriate to experiment) Control (Con) Vehicle, LCM Vehicle, Con MitoT,
LCM MitoT, Con MAPK inhibitors (includes PD098059 and SB202190 all administered during
separate experiments) and LCM MAPK inhibitors. These independent factors were divided into
three separate cell culture experiments hereafter referred to as LCM MitoT, LCM p38 inhibitor
and LCM ERK 1/2 inhibitor. Data in each separate cell culture experiments were analyzed by
two-way ANOVA with factors of media (Con vs LCM) and pharmacological inhibition (Vehicle
vs MitoT, SB or PD). Here significant F ratios were found a Student Newman Kuels Post Hoc
test was used to delineate differences among means. For all experiments, the comparison-wise
error rate, α, was set at 0.05 for all statistical tests. All data were analyzed and graphed using
using GraphPad Prism (La Jolla, CA, USA) and data expressed as mean ± SEM.
LSD post hoc anal ysis was used to dis tinguis h differenc es

Results
MitoT Protects Against LCM-Mediated Loss of Myotube diameter. Myotube diameter of
C2C12 myotubes treated with LCM were ~40% smaller than groups treated with control media,
however, myotube diameter of cells treated with LCM+MitoT were not significantly different
from myotubes treated with control media (Figure 1A). MitoSox fluorescence from C2C12
myotubes treated with LCM exhibited a ~20% greater mean red intensity from MitoSox when
compared to cells treated with control media. MitoSox fluorescence of myotubes treated with
MitoT was ~20% lower when compared to cells treated with vehicle (Figure 1B). LCM
treatment resulted in 50% less puromycin incorporation when compared to myotubes treated
with control media with no effect of MitoT (Figure 1C). Ubiquitin protein content was not
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different between groups (Figure 1D); however, there was a ~40% mean increase in LCM
vehicle when compared to other groups (p=0.08).
MitoTempo rescues LCM-mediated loss of myotube diameter through FOXO signaling.
Neither LCM nor MitoT treatment altered the relative phosphorylations of p38 MAPK, ERK
MAPK, 4EBP1or FOXO3; however, LCM+Vehicle treatment increased relative FOXO1
phosphorylation by ~50% (Figure 2A). Atrogin-1 mRNA content was not different between
experimental groups; however, MuRF-1 mRNA was ~40% greater in LCM+MitoT when
compared to Control+Vehicle (Figure 2B).
Inhibition of p38 MAPK partially protects against LCM-Mediated Loss of Myotube
Diameter. Myotube diameter of cells treated with LCM+Vehicle was ~40% smaller than cells
treated with Control Media, while myotube diameter of cells treated with LCM+SB202190 was
~25% smaller than myotubes treated with control media and ~20% greater when compared to
myotube diameter of cells treated with LCM+Vehicle (Figure 3A). Relative phosphorylation of
MAPK APK was ~40 and 50% in Control+ SB202190 and LCM+ SB202190 when compared to
control vehicle, respectively (Figure 3B). Puromycin incorporation was ~2 fold greater in
myotubes treated with SB202190 when compared to myotubes treated with vehicle, additionally
a ~50% lower mean puromycin incorporation in LCM cells compared to control media did not
reach statistical significance (p=0.058) (Figure 3C). Protein ubiquitination was ~2 fold greater in
LCM+Vehicle when compared to all other groups, and not different between control media and
LCM+SB202190 (Figure 3D). Neither LCM nor SB202190 treatment altered the protein content
or relative phosphorylations of 4EBP1, Deptor and FOXO3; however, LCM+Vehicle treatment
increased relative FOXO1 phosphorylation by ~2.5 fold (Figure 3E). Atrogin-1 mRNA content
was ~50% higher in LCM+Vehicle when compared to control media groups, and 50% lower
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than control media groups with LCM+SB202190 (Figure 3F). MuRF-1 mRNA content was
~60% lower in groups containing SB202190 when compared to the vehicle counterparts (Figure
3F).
ERK 1/2 MAPK inhibition does not protect against LCM-mediated loss of myotube
diameter despite promoting protein synthesis. Diameter of myotubes treated with LCM was
~35% lower than the myotube diameter of myotubes treated with Control media, regardless of
ERK MAPK inhibition (Figure 4A). Phosphorylated ERK relative to total ERK was ~50% lower
in groups containing PD98059 when compared to the Control Media+Vehicle group.
LCM+Vehicle was ~30% lower than Control+Vehicle (Figure 4B). Puromycin incorporation
was 3-fold and 2-fold greater in Control+PD98059 and LCM+PD98059, respectively when
compared to Control+Vehicle (Figure 4C). Ubiquitin protein content was ~50% greater with
LCM+PD98059 treatment when compared to control+vehicle treatment (Figure 4D). Protein
content or relative phosphorylations of 4EBP1, Deptor, FOXO3 and FOXO1 was not different
between groups. Both Atrogin-1 and MuRF-1 mRNA was decreased by ~30 and 40% with
LCM+Vehicle treatment when compared to control+vehicle treatment, respectively.
Discussion
In this study, I have demonstrated treatment with both the mitochondrial ROS scavenager
MitoT and p38 MAPK inhibitor SB202190 can attenuate LCM-mediated loss of myotube
diameter in vitro. Both MitoT and SB202190 protected against the promotion of ubiquitinmediated catabolism from LCM treatment, while p38 MAPK inhibition additionally upregulated
protein synthesis in myotubes. In contrast, inhibition of ERK MAPK did not protect against
LCM-mediated loss of myotube diameter. These data suggest that oxidative stress and
subsequent p38 MAPK activation in the tumor-bearing state may be key developments in the
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development of cachectic muscle loss. These findings help to elucidate potential mechanisms
behind tumor-induced loss of myotube diameter and may provide insight to further therapeutic
strategies via targeting of oxidative stress and p38 MAPK.
The use of LCM to mimic cancer-cachexia in-vitro is a well-established model [23, 24];
however, there are distinct differences between this model and LLC implantation in-vivo.
Specifically, in Chapter 3 of this dissertation I established that mitochondrial ROS production
doubles in-vivo [10]. LCM treatment of myotubes only increases mitochondrial ROS production
by ~20-30% in-vitro. Moreover, in Chapter 4, I showed MAPK phosphorylation to be enhanced
in cachectic muscle, while in-vitro LCM treatment had no effect on MAPK signaling. Other
studies have demonstrated that LCM treatment promotes phosphorylation of both p38 and ERK
MAPK; however, this may be attributed to differences in the LCM treatment protocol [23]. Gao
et al. [23] used a protocol which utilized 3 days of likely less concentrated LCM media, while in
this dissertation I used a more concentrated LCM for a shorter time frame. These differences
among others need to be further explored in order to effectively mimic cancer-cachexia in-vitro.
LCM-mediated loss of myotube diameter is rescued by increased mitochondrial ROS
scavenging. The loss of myotube diameter in response to LCM (~30-40% loss across
experiments) mimics the cachectic phenotype observed in-vivo (~40% loss of cross sectional
area of adult muscle). In this study, MitoT treatment ameliorated LCM-mediated loss of myotube
diameter, which suggests oxidative stress will induce cancer-mediated muscle loss. In chapter 3
of this dissertation, oxidative stress increased dramatically shortly after tumor implantation.
Unfortunately at this time MitoT exact mechanism of protection against LCM-mediated muscle
loss is not fully understood. Also, future studies should analyze if increasing ROS scavenging invivo protects against cancer-cachexia. In fact, there is much controversy on this topic as
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antioxidant administration may exacerbate tumor growth [16]. However, my data suggests
specifically targeting mitochondrial ROS in the muscle may be an effective strategy to treat
cancer-cachexia if targeted to skeletal muscle; therefore, future studies should be developed to
examine potential means by which to specifically target mitochondrial ROS.
LCM-mediated loss of myotube diameter is rescued with p38 inhibition. In Chapter 4, p38
MAPK phosphorylation increased by 3-fold in cachectic muscle; however, LCM treatment did
not alter p38 MAPK phosphorylation status. Despite this, long term p38 MAPK inhibition (~18
hours) ameliorated LCM-induced loss of myotube diameter. The mechanism behind this appears
to be through a combination of inhibiting catabolic signaling (decreased protein ubiquitination as
well as decreased Atrogin-1 and MuRF-1 mRNA content) and the promotion of protein
synthesis. These data are consistent with previous literature regarding p38 MAPK’s role in
catabolic signaling [17]. At this point, p38 MAPK’s role in the regulation of protein synthesis is
not clear.
Inhibition of ERK-MAPK does not protect against LCM mediated loss of myotube
diameter despite promoting protein synthesis. ERK MAPK inhibition in cancer-cachexia
literature has been shown to protect stretch-induced protein synthetic response in-vitro [35]
which is consistent with these findings. ERK-MAPK has pleiotropic roles in modulating
proteostasis. In an acute manner, ERK-MAPK has been seen to promote protein synthesis
following acute resistance exercise [36].However, I have previously shown that IL-6 induced
chronic phosphorylation of ERK-MAPK inhibits anabolic signaling [26]. In conjunction with
that previous work, these current findings suggest that longer term ERK MAPK activity may in
fact repress anabolic functions and thus alleviating this ERK MAPK activity may be necessary to
promote muscle protein anabolism. However, considering these discrepancies in the literature,
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more research is needed to further elucidate the role of ERK-MAPK with the regulation of
protein synthesis as well as the onset of cancer-cachexia.
Based on these data, the compounds which ameliorated LCM-mediated loss of myotube
diameter (MitoT and p38 MAPK inhibitor) appeared down-regulate the ubiquitin proteasome
system response. Inhibition of ERK MAPK promoted protein synthesis, but did not alter
ubiquitin proteasome mediated catabolism. Taken together, this suggests the ubiquitin
proteasome system is largely responsible for cancer-induced muscle wasting.
The current study uncovers potential mechanisms for tumor mediated loss of muscle size,
and a new role of MAPK signaling in the regulation of protein synthesis, which will lead to new
novel studies. Increased mitochondrial ROS scavenging and p38 MAPK inhibition ameliorated
LCM-mediated loss of myotube diameter. Considering ROS induces p38 MAPK
phosphorylation [17], the protective effect of MitoT and p38 inhibition against tumor derived
factors may be acting through similar mechanisms. In chapters 3 and 4 of this dissertation ROS
emission and p38 phosphorylation are both elevated, which suggests oxidative stress mediated
p38 phosphorylation may be a potential mechanism for cancer-induced muscle wasting. These
data may lead to the development of therapies to treat cachexia, and broadens the understanding
of skeletal muscle plasticity.
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Figures
Figure 1

Figure 1. MitoT Protects Against LCM-Mediated Loss of Myotube diameter. A: Myotube
diameter analysis of control media+vehicle, control media+MitoT, LCM+vehicle and
LCM+MitoT. B. Mitosox analysis of control media+vehicle, control media+MitoT,
LCM+vehicle and LCM+MitoT. C: Puromycin incorporated for groups control media+vehicle,
control media+MitoT, LCM+vehicle and LCM+MitoT after 30 minutes puromycin treatment
following 18 hours of treatments. D: Protein content of ubiquitin following 18 hours of control
media+vehicle, control media+MitoT, LCM+vehicle or LCM+MitoT treatment. All measured in
C2C12 myotubes and normalized to and Ponceau S. * P < 0.05 between indicated groups. Data
are mean ± SEM. E: Representative immunoblot images for each protein of interest taken in
order from same membrane.
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Figure 2
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Figure 2. MitoTempo rescues LCM-mediated loss of myotube diameter through FOXO
signaling. A: Protein content of p-p38 relative to total p38, p-ERK relative to total ERK, p4EBP1 relative to total 4EBP1, p-FOXO3 relative to total FOXO3 and p-FOXO1 content relative
to total FOXO1 following 18 hours of control media+vehicle, control media+MitoT,
LCM+vehicle or LCM+MitoT treatment. B: Atrogin-1 and MuRF-1 mRNA content following 18
hours of control media+vehicle, control media+MitoT, LCM+vehicle or LCM+MitoT treatment.
All measured in C2C12 myotubes and normalized to and Ponceau S. * P < 0.05 between
indicated groups. Data are mean ± SEM. C: Representative immunoblot images for each protein
of interest taken in order from same membrane.
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Figure 3
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Figure 3. Inhibition of p38 MAPK partially protects against LCM-Mediated Loss of Myotube
Diameter. A: Myotube diameter analysis of control media+vehicle, control media+SB202190,
LCM+vehicle and LCM+SB202190. B. Protein content of relative MAPK APK phosphorylation
following 18 hours of treatments. C: Puromycin incorporated for groups control media+vehicle,
control media+SB202190, LCM+vehicle and LCM+SB202190 after 30 minutes puromycin
treatment following 18 hours of treatments. D: Protein content of ubiquitin following 18 hours of
control media+vehicle, control media+SB202190, LCM+vehicle or LCM+SB202190 treatment.
E. Protein content of p-4EBP1 relative to total 4EBP1, Deptor, p-FOXO3 relative to total
FOXO3 and p-FOXO1 content relative to total FOXO1 following 18 hours of control
media+vehicle, control media+SB202190, LCM+vehicle or LCM+SB202190 treatment. F.
Atrogin-1 and MuRF-1 mRNA content following 18 hours of control media+vehicle, control
media+SB202190, LCM+vehicle or LCM+SB202190 treatment. All measured in C2C12
myotubes and normalized to and Ponceau S. * P < 0.05 between indicated groups. Data are mean
± SEM. G: Representative immunoblot images for each protein of interest taken in order from
same membrane.
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Figure 4
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Figure 4. Inhibition of ERK-MAPK does not protect against LCM mediated loss of myotube
diameter despite promoting protein synthesis. A: Myotube diameter analysis of control
media+vehicle, control media+PD98059, LCM+vehicle and LCM+PD98059. B. Protein content
of p-ERK relative to total ERK following 18 hours of control media+vehicle, control
media+PD98059, LCM+vehicle and LCM+PD98059 treatment. C: Puromycin incorporated for
groups control media+vehicle, control media+PD98059, LCM+vehicle and LCM+PD98059 after
30 minutes puromycin treatment following 18 hours of treatments. D: Protein content of
ubiquitin following 18 hours of control media+vehicle, control media+PD98059, LCM+vehicle
and LCM+PD98059 treatment. E. Protein content of p-4EBP1 relative to total 4EBP1, Deptor, pFOXO3 relative to total FOXO3 and p-FOXO1 content relative to total FOXO1 following 18
hours of control media+vehicle, control media+PD98059, LCM+vehicle and LCM+PD98059
treatment. F. Atrogin-1 and MuRF-1 mRNA content following 18 hours of control
media+vehicle, control media+PD98059, LCM+vehicle and LCM+PD98059 treatment. All
measured in C2C12 myotubes and normalized to and Ponceau S. * P < 0.05 between indicated
groups. Data are mean ± SEM. G: Representative immunoblot images for each protein of interest
taken in order from same membrane.
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Chapter 6
Overall Conclusions
This dissertation examines a novel time course progression of cancer-cachexia. These
data indicate that pathological changes in muscle metabolism occur very shortly after tumor
implantation into the mouse host. From a clinical standpoint, these data suggest that preventative
measures to cancer-cachexia should be taken immediately upon diagnosis, at least if the cancer
type is associated with cachexia. Furthermore, I have shown increased oxidative stress and
aberrant MAPK signaling in skeletal muscle is at least partially responsible for the onset of
cancer-cachexia through in vitro studies. Future studies following this dissertation should focus
on the efficacy of antioxidant therapy and MAPK inhibition in-vivo as potential therapies for
cancer-cachexia. Additionally, as characteristics of cancer-cachexia often vary across models, in
order to ensure data is consistent across cancer types, these experiments should be repeated in
other clinical models of cancer-cachexia.
Mitochondrial Degeneration Occurs Prior to Cancer-Induced Muscle Wasting (Chapter 3).
This was the first experiment to investigate mitochondrial degeneration and dysfunction
throughout a time course development of cancer-cachexia in tumor-bearing mice. This aim
provided insight into causes of skeletal muscle metabolic dysfunction beyond mitochondrial
quality control (biogenesis, dynamics and mitophagy), and directly measured mitochondrial
quality (MitoTimer), mitochondrial ROS emission and respiratory function (RCR). Intriguingly,
mitochondrial ROS production doubled as soon as 1 wk following tumor implantation, which I
hypothesize was likely instigated by tumor-derived circulating factors. These data implicated the
importance of early cancer detection, as well as preventive measures for cancer-cachexia,
especially since cancer-cachexia is often not treated before stage IV of cancer is reached [1].
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Cancer-Induced Muscle Wasting Occurs Through a Combination of Reduced Protein
Synthesis and Increased Protein Breakdown (Chapter 4).
In this study we analyzed muscle size, myogenesis, protein turnover and apoptosis
throughout the development of cancer-cachexia. Based on our data, loss of mixed protein
synthetic rates along with increased protein breakdown occur concurrently with muscle wasting.
Furthermore, there appeared to be early alterations in myogenic signaling potentially
contributing to the irreversibility of cancer-cachexia. In conjunction with my observations in
chapter 3, inefficient mitochondria and oxidative stress may cause the dysregulated protein
turnover we observed in this study; however, at this point we cannot definitively state the
mechanism behind cancer-cachexia. We also observed elevated p38 and ERK MAPK signaling
in cachectic muscle; therefore, we hypothesized pathological MAPK signaling may also be a
major contributing factor in the onset of LLC-induced cancer-cachexia.
Oxidative Stress and Dysregulated MAPK Signaling Lead to Loss of Myotube Diameter InVitro (Chapter 5).
In this study I used LLC Conditioned Media (LCM) to mimic cancer-cachexia in-vitro.
LCM induced a ~40% loss of myotube diameter when compared to control media, which was
similar to the loss of muscle cross sectional area I observed in-vivo (Chapter 4). Based on
findings of early mitochondrial oxidative stress (Chapter 3) and aberrant MAPK signaling
(Chapter 4) in the development of cancer-cachexia in-vivo, I performed in vitro experiments to
target these aspects to determine potential efficacy of antioxidants or MAPK inhibition in
preventing cancer-induced muscle loss. Using a mitochondrial targeted antioxidant (MitoTempo,
herein referred to as MitoT), I was able to partially rescue tumor-derived loss of myotube
diameter. Moreover, I examined the role of MAPKs in the promotion of cancer-cachexia. In
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Chapter 4 of this dissertation, ERK and p38 MAPK phosphorylation were elevated 2 fold in
cachectic muscle when compared to control muscle. By using inhibitors for both ERK and p38
MAPK, I demonstrated that p38 inhibition partially rescued LCM-dependent loss of myotube
diameter, while ERK inhibition appeared to have no effect.
Underlying mechanisms in which MitoT and p38 MAPK inhibition rescue myotube
diameter are still not fully understood; however, it appears both MitoT and p38 MAPK inhibition
prevent an upregulation of catabolic programing. Long term MAPK inhibition (~18 hours) also
appeared to promote protein synthesis. Mechanisms behind MAPK involvement in protein
synthesis are not fully understood. This aim uncovered potential mechanisms for tumor
mediated loss of muscle size, and a new role of MAPK signaling in the regulation of protein
synthesis, which may lead to potential for development of new and efficacious therapeutic
strategies.
Concluding Statements
These studies give a clear overview of the changes in skeletal muscle physiology
throughout a timecourse progression of cancer-cachexia. These data provide new insight into
potential underlying aberrations into the root cause of cancer-cachexia, and may lead to the
development of new therapeutic strategies.
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Limitations and Delimitations
This dissertation has a few limitations and delimitations which should be taken into
consideration. For the timecourse studies (Chapters 3 and 4), there was not an age matched
control for the 1 wk, 2 wks or 3 wks tumor growth groups. It is possible that differences in age
may influence dependent variable analysis; however, age differences did not appear to affect
skeletal muscle size. Also, it is common that the development of cancer-cachexia occurs with
hypophagia, unfortunately I was unable to collect appropriate food intake data to determine if
this may have aided in the onset of cachectic muscle loss in this study.
In previous literature LCM treatment commonly occurs over 72 hour to mimic a
cachectic phenotype in cells [2, 3] ; however, I obtained a significant loss of myotube diameter
after only 18 hours of LCM treatment. Because of this I elected to use an 18 hour LCM treatment
for my in-vitro studies in Chapter 5 instead of the commonly used 72 hour treatment. One
difference between my methodology and prior literature may have been the confluence of LLC
cells upon harvest of LCM. LLC cells were ~90% confluent before the 10% FBS growth media
incubated on those cells for another 24 hours. Because of this, it is likely my LCM was more
concentrated than prior studies.
For my experiments in Chapter 5 of this dissertation, I was unable to test MitoTempo
treatment and MAPK inhibition in-vivo in order to make sure my findings are translatable to
mammals. This is a worthwhile goal for future studies.
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MitoTimer Methodology
FDB Electroporation:
-Prepare plasmids at 2μg/μl in sterile saline and need 20μl for one FDB muscle. If co-injecting
an over-expression vector with a reporter gene (i.e. pMitoTimer or pGFP3), make a ratio of 3:1
(over-expression vector:reference reporter gene).
-Prepare a solution of .36mg/ml hyaluronidase in sterile saline (Store at -20 degrees C)
1. Using an anesthetizing box, deeply anesthetize a mouse using 4% isoflurane in O2 with an
anesthetic instrument. Monitor the anesthetic depth by toe pinch reflex
2. Under observation of a dissection microscope, inject 10 µL of the hyaluronidase solution
under the footpads of one foot of the mouse using a 1” long insulin needle. Penetrate the skin at a
point close to the heel of the foot and advance the needle subcutaneously towards the base of the
toe for ¼”
3. Repeat with other foot if needed
4. Disconnect the anesthesia and place mouse in cage. Allow animal to fully recover from
anesthesia
5. After 1HOUR, anesthetize the animal again. Following the same procedure described for the
hyaluronidase solution, inject a total of 20 µg of the plasmid DNA. The total injection volume
should be less than 20 µL/foot. Note: when 15-20 µL is needed it is advisable to close the skin at
the needle entry point with tissue-glue
6. Disconnect the anesthesia and place the mouse in a cage. Allow it to fully recover from
anesthesia, wait for 10-15 min
170

7. Anesthetize the animal for a third time, place it on a heating pad
8. Select one foot of the animal. Place one gold-platted acupuncture needle under the skin at heel
and a second one at the base of the toes. Electrodes are oriented parallel to each other and
perpendicular to the long axis of the foot.
9. Connect the head of the needles (electrodes) to the electrical stimulator using micro-clip
connectors. Electro orate the muscles by applying 10 pulses, 20ms in duration/each, at 1Hz.
Depending on the spacing of the electrodes, the pulsing voltage amplitude is adjusted (by
monitoring with an oscilloscope) to yield an electric field of about 75V/cm. Note: no
contractions in response to the stimuli should be observed if the level of anesthesia is adequate.
10. If needed, repeat with other foot
11. Return animal to cage, observe to make sure animal is okay, allow recovery for 10-15 days

FDB Harvest and Mounting
1. Harvest FDB. If both confocal microscopy and protein analysis is required, carefully slice the
muscle in half longitudinally. Immediately homogenize half of the muscle in protein buffer and
incubate the other half with 1 mL 4% PFA for 20 minutes (at room temperature) and then
transfer to 1 mL PBS and incubate for 5 min. Try not to expose to tissue to bright light in order
to preserve the fluorescence of the reporter if you use pMitoTimer.
2. Carefully remove the tendon running the length of the muscle. Place the tissue on a gelatin
coated slide. Use tweezers to orientate the tissue and flatten it on the slide. Make sure there are
no air bubbles under the tissue.
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3. Allow the tissue to adhere to the slide. This typically takes 5-10 min, but it can vary on the
thickness and type of tissue.
4. On one side of the slide pipette 50:50 PBS:Glycerol and place a coverslip over the slide. You
want the coverslip to be as close to the slide as possible. This is easy for thin tissues, and you can
push the coverslip and slide together if the tissue is deformable (press and wiggle, Be very
careful with this).
5. Remove any excess 50:50 that has come out from under the coverslip with blotting paper.
6. Seal the coverslip by painting the edges with nail polish. This will prevent the 50:50 from
evaporating over time.
7. Image immediately
MitoTimer Imaging
Parameters for imaging Mito-Timer on ConFocal Microscope
-Use FITC (green) and TRITC (red) channels.
-Aspect ratio: 800x800
-Green HV: 565
-Red HV: 685
-Gain: 1
-Offset: 10%
-Lazer intensity: 15%
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-2 pixels/sec
-0.5 um slice
-check sequential imaging (line)
-Take at least 10 images at 100X magnification

Parameters for imaging Mito-Timer on epiflourescent microscope.
-Aspect Ratio: 800X600
-Set equal exposure times for both FITC and TRITC channels (100 ms is a good place to start).
Make sure this is the same for all images taken for all groups.
-Analog Gain: 2X
-Image FITC and TRITC Channels and Merge Images.
-Save images as ND2 files.
MitoTimer Analysis.
Make a matlab folder for each sample. Inside the matlab folder make three more folders and
label them 10X, 40X and 100X for the different objectives images were taken at. For your saved
ND2 images, separate the channels and save each image separately as 1_Green or 1_Red
depending on the filter for the image. Save as jpeg. Make sure LUTs is normalized across all
images for the entire study before you save the individual images. For the next images for the
sample you would save them as 2_Green or 2_Red. Save them to the appropriate folder based on
the objective the images were taken at. Open the cell profiler software and make the output
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folder the same folder that the images are saved in. Hit analyze in the bottom left and corner.
Once the cell profiler is finished, open up the matlab code and change the destination in three
different spots to the folder the images are saved in. Run the matlab program and then copy the
data to an excel spreadsheet.

Protein Synthesis Methodology
Dueterium Dosages
All injections or consumption of 2H20 should begin 24 hours before tissue harvest. For rats or
mice use 20ul of 99.8% 2H20 per gram body weight (20ul · g bw-1). Animals should have access
to 4% 2H20 ad libitum at all times after injection. Using this calculation, our lab has consistently
obtained 2.5 – 3.0 atom percent excess of 2H-labeling of body water, which is adequate for
determining FSR. It is possible to use a higher or lower dose in order to increase or decrease
enrichment, but not necessary.
Mice
Mice weigh anywhere from 20 – 35 g, so you would inject 0.4 - 0.7ml respectively of 99.8%
2

H20.

Animal Injections
All injections should be delivered via intraperitoneal (I.P.) injection.
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Plasma Collection and Analysis
This assay requires 20ul of plasma to measure the concentration of 2H20 in the blood. It is
recommended to draw at least 500ul of whole blood in order to have more than enough plasma
for multiple attempts getting the plasma concentration.
Mice Blood Samples
Blood taken from animals should drawn from either from a cardiac puncture (if non-survival to
obtain the maximal amount of blood), lateral saphenous vein, or the tail vein and placed in
microcentrifuge tube. Store on ice in until plasma is separated by centrifugation. Mice have a
total blood volume of approximately 1.5ml, therefore the only way to get a large enough blood
volume is cardiac puncture.
Obtaining plasma from whole blood
1. Centrifuge whole blood samples at 3,800 rpm at 4ºC for 20 min.
2. Extract plasma (liquid supernatant) with 1.0 ml pipette or transfer pipette and place into 1.5
ml microcentrifuge tubes, freeze at -80ºC until analysis.
Preparation of Plasma Samples for Analysis:
1. Remove samples from -80ºC and allow thawing for analysis.
2. Place 20ul of plasma into 2.0 ml microcentrifuge tubes.
3. Add 2.0 µl of 10N NaOH to samples.
4. Add 4.0 µl of a 5% (vol/vol) acetone (CH3Cl3) in acetonitrile (CH3CN), cap and allow
settling for a minimum of 24 h.
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We have found that you should do a quick spin in the centrifuge to ensure that all of the
products in the reaction are in the bottom of the microcentrifuge tube.
5. Add ~0.5 g sodium sulfate (Na2SO4) to samples.
0.5 g is not an exact measurement, but it should be relatively close. Sodium sulfate acts as
a drying agent in this process
6. Add 0.6 ml of chloroform (CH3Cl3) to each sample, cap and vortex vigorously.
- Chloroform stops the reaction of 2H transferring from deuterium to acetone
7. Extract 100ul from the centrifuge tube and add to a GC-MS vial containing the insert.
*The reason we use inserts in the vials is to cut down on costs. The glass vials cost ~$1 a
piece, while the inserts cost only $0.25. Please do not label on or throw away the glass vials.
Instead label on the screw caps and throw away both the insert and screw cap.
2. Method

a. The following temperature program is used: 60ºC initial, increase by 20°C/min to
100ºC, increase by 50ºC/min to 220ºC, and hold for 1 min. The sample was injected
at a spit ratio of 40:1 with a helium flow of 1 mL/min. The mass spectrometer is
operated in electron impact mode (70eV).

b. Inject 1ul sample into GC-MS
c. Selective ion monitoring of mass-to-charge ratios (m/z) 58 (M) and 59 (M + 1) was conducted
using a dwell time of 10 ms per ion. 2H acetone elutes at between 1.7-1.85 min.
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1. Linear Standard Curve Preparation
First Create a stock solution of 5% 2H2O (5.0 ml of 2H20 + 95 ml of ultrapure diH2O) and then
make the following dilutions:
%

ml of

ml of

total ml

labeled

stock

diH2O

5.0

1.0

0

1.0

2.5

0.5

0.5

1.0

1.25

0.25

0.75

1.0

1.0

0.20

0.8

1.0

0.5

0.10

0.9

1.0

0.25

0.05

0.95

1.0

0.125

0.025

0.975

1.0

0

0

1.0

1.0

Standards should be prepared and ran in the same manner as the plasma samples above.
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Product Numbers:
Acetone (CH3COCH3)

EMD, AX0120-8

Acetonitrile (CH3CN)

Fisher, A998-4

GC-MS glass vials

Agilent, 5182-0714

GC-MS vial inserts

Agilent, 5182-0549

GC-MS vial screw top caps

Agilent, 5185-5820

Chloroform (CH3Cl3)

Fisher, C298

Sodium hydroxide (NaOH)

Fisher, 5612-3

Sodium Sulfate (Na2SO4)

Fisher, S414

Trichloroacetic acid (TCA-Cl3CCOOH)

EMD, TX1045-5

Methyl-8 (N,N-Dimethylformamide dimethyl acetal) Sigma 394963
Analyzing Plasma Sample Data
1. Open the Enhanced Data Analysis Program that was provided by Agilent.
2. In the left window pane, find and select the data file you want to analyze. Left click on the
data file and select Load.
This will make the data file appear Bolded. All files that you have opened in the current
session of Data Analysis will remain bolded
3. Along the top menu toolbar, select Chromatogram → Extract Ion Chromatogram
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4. In the pop up box that appears Enter 1.7 - 1.85 into the Time Range fields,
This range will change slightly based on many different factors including Column Length,
Column Age, and different machines. It should be relatively close to that range.
5. Enter 58 in Ion 1, this corresponds to m, or in this case Acetone.
6. Enter 59 in Ion 2, this corresponds to m+1, or in this case 2H-Acetone.
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7. This creates the screen where the top peak is for M and the bottom peak is for M+1. You

may choose to merge the peaks if you want to view just one graph.

8. The goal of this measurement is to get a ratio of M+1:M, To get this go to Chromatogram →
Percent Report. This will open up a text box. Copy and Paste the Peak Heights for both of
the peaks in to Excel and get a ratio of M+1:M. *Notice that time times are virtually identical
in the column labeled R.T. min. Sometimes you can get multiple peak numbers for m+1.
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Always take the one with the time closest to the peak for M.

Muscle Preparation:
1. Weight out 30 ± 5 mg of muscle 60mg if assessing myofibrillar fraction as it makes up
50% of the mixed muscle homogenate).

2. Place into 2.0 ml microcentrifuge tubes and add 0.400 ml of 10% TCA (Cl3CCOOH) on
ice.

a. For Myofibrillar FSR:
i. weight out ~60 mg of mixed muscle and add 400ul of Norris buffer with
1% Triton.
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ii. Homogenize using a polytron homogenizer at full speed and allow settling
on ice for a minimum of 1 h. Visibly check to make sure there are no
large ‘chunks’ of muscle in the vial

iii. Centrifuge at 14,000 rpm for 30 min at 4ºC. Decant supernatant and add
0.3 ml of 10% TCA on ice.
iv. The remainders of the steps are the same as the mixed muscle
homogenate.
v. To conserve tissue sample, it is possible to prep samples for western
blotting and myofibrillar FSR. If you use the ‘unrefined’ separation of
adding triton to Norris buffer and centrifuging at 14,00 rpm to obtain the
cytosolic and membrane fraction, you can then use the myofibrillar pellet
that we typically discard. This fraction contains more than just
myofibrillar proteins. It also contains nuclear, microsomal, mitochondrial,
connective tissue. Therefore, it should probably be termed myofibrillar
rich fraction since that is the predominant fraction of the pellet.

3. Homogenize using a polytron homogenizer at full speed, centrifuge at 3,800 rpm, decant
supernatant and add 0.3 ml of 10%TCA on ice. TCA is a weak acid that causes the
proteins to fall out of solution, therefore all free amino acids should be washed out in the
supernatant.
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4. Repeat step 3 three additional times, always decanting TCA after centrifugation.

5. Add 0.3 ml of 6 N HCl, vortex and place into 2.0 ml screw top tubes.
a. HCL and heating breaks the proteins into amino acids so we can measure alanine
with the GC/MS. You must use screw tops to prevent evaporation in the sample.
Snap caps will not work.

6. Incubate at 100ºC for 24 h.
a. Vortex the samples periodically throughout the heating process to remove all the
black chunks of tissue. I like to vortex about 15mins after they are first put on the
heating block, then at 1hr, maybe at 2-3hrs, let samples sit for overnight and then
vortex first thing in the morning and finally about 1hr before the end of the 24hrs.
b. Hydrolysate should turn from clear at the beginning to a very dark brown after
heating.

7. Pipette between 50 and 100 ul of hydrolysate into a 1.5-2.0ml microcentrifuge tube place
in heating block at heat at 100ºC with top off for 1 h to allow HCL to evaporate.
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a. Sample could alternatively be placed under a low stream of N2 to dry or could be
dried using a freeze drier. The MBL uses the heating block method because of its
ease and relatively short time frame. Freeze the remainder of the hydrolysate in
the -80° C Freezer.
b. Currently the MBL has gone to using 50ul of hydrolysate and 50 of 3:2:1 solution
(below)
c.

Sample Must Be Completely DRY! Check by thumping or rotating the tube to
see if any liquid still remains.

8. Make a 3:2:1 solution of Methyl-8 (N,N-Dimethylformamide dimethyl acetal), methanol
(CH3OH) and acetonitrile (CH3CN).
a. As a rule of thumb we make a little extra than the 100ul needed for all the
samples, but not too much so we are not wasting reagent. For example to run 24
samples, you need 2.4 ml of the 3:2:1 solution, but I would recommend making
2.6 ml.
b. This is 3 parts Methyl-8, 2 parts methanol and 1 part acetonitrile
9. Pipette equal volume from step 7 (50 - 100ul) of the 3:2:1 Methyl-8, methanol (CH3OH)
and acetonitrile into the dried samples.
a. If the sample was not completely dry, addition of the the methyl-8 solution will
‘smoke’ (releases visible vapors) and the methyl-8 will be inactivated. If this
occurs the reaction will not occur and there will be no peaks if ran on the GC/MS.
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10. Heat samples in heating block at ~70ºC for one hour, vortexing intermittently, to ensure
the dried hydrolysate dissolves into solution.

11. Place sample into GC-MS vial inserts and place into the GC-MS glass vials and cap.
Label the samples on the cap and place them into the auto-injection loader.

Gas Chromatography Mass Spectrometry (GC-MS)
1. System:
a. Agilent 5973N-MSD equipped with an Agilent 6890 GC system.
b. DB17-MS capillary column (30 m × 0.25 mm × 0.25 µm).

2. Settings:
a. The following temperature program was used: 90ºC initial, hold for 5 min, increase by
5°C/min to 130ºC, increase by 40ºC/min o 240ºC, and hold for 5 min. The sample was
injected at a spit ratio of 20:1 (5:1 for human tissue) with a helium flow of 1 ml/min. The
mass spectrometer was operated in electron impact mode (70eV).
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b. Selective ion monitoring of mass-to-charge ratios (m/z) 99 (M) and 100 (M + 1) was
conducted using a dwell time of 10 ms per ion. 2H alanine elutes at ~ 12 min (9 min on
our system).
c. For Muscle 80:1 splitting is probably a better starting point and even then may still have
to be diluted in acetonitrile (50 ul dilution will probably work).

3. Linear Standard Curve Preparation
a. Solution A - Stock Solution of L-alanine (C3H7NO2):
i. Place 10 mg L-alanine into 1.0 ml of ultrapure dH2O (Solution A).
b. Solution B - Stock Solution of L-alanine-2-d (CH3CD(NH2)CO2H):
i. Place 1 mg of L-alanine-2-d into 1.0 ml of ultrapure dH2O (Solution B).
% labeled

Sol A (ml)

Sol B (ml)

H2O (ml)

total (ml)

2.0

1.0

0.2

0.8

2.0

1.0

1.0

0.1

0.9

2.0

0.75

1.0

0.075

0.925

2.0

0.5

1.0

0.050

0.950

2.0

0.25

1.0

0.025

0.975

2.0

0

1.0

0

1.0

2.0
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c. Take 0.1 ml of each standard and place into GC-MS glass vials and dry under a low
stream of N2 (can place in heating block at heat at 100ºC with top off for 1 h). Freeze the
remainder of the hydrolysate.
a. Add a 3:2:1 solution of Methyl-8, methanol (CH3OH) and acetonitrile (CH3CN); cap and
vortex vigorously.
b. Place sample into GC-MS vial inserts and place into the GC-MS glass vials and cap.

*The goal is to have the peaks for your standards look the same as for your tissue samples, so
peak heights should correspond pretty well. The goal for peak heights on samples is 200,000 –
400,000, so you would not want peak heights on your standards in the 1 million ranges. The
steps above suggest 100ul of each standard, but that is assuming a split of 1:20. As you decrease
your split, you should also decrease the amount of standard you use. 800,000 is typically the
maximal accepted limit.
*Standards should be run with each new run on the GC-MS. They should also be analyzed
exactly the same way as the tissue. In other words, if you are changing split ratios on the GCMS, you need to re-run the standards.
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Analyzing Muscle Sample Data
1. Open the Enhanced Data Analysis Program that was provided by Agilent.
2. In the left window pane, find and select the data file you want to analyze. Left click on the
data file and select Load.
This will make the data file appear Bolded. All files that you have opened in the current
session of Data Analysis will remain bolded
3. Along the top menu toolbar, select Chromatogram → Extract Ion Chromatogram

4. In the pop up box that appears Enter 8 – 12 minute into the Time Range fields,
This range will change slightly based on many different factors including Column Length,
Column Age, and different machines. It should be relatively close to that range.
5. Enter 99 in Ion 1, this corresponds to m, or in this case Alanine.
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6. Enter 100 in Ion 2, this corresponds to m+1, or in this case 2H-Alanine.

7. When analyzing muscle peak heights, we take only a small portion of the curve. We have
designated that all measurements will be taken between 25 and 50% of the peak height.
a. Peak height can be determined either by choosing peak height from the menu similar
to what is done in step 8 of analyzing plasma samples. To get this go to
Chromatogram → Percent Report. This will open up a text box. Copy and Paste the
Peak Heights for both of the peaks in to Excel. Use a simple formula to calculate 25
and 50%.
b. In the past, we have also chosen to get peak height by the eyeball method. Simply
zoom in on the peak by left clicking and drawing a box around the top of the peak
until you can get a very good opinion on the peak height
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c. Don’t be surprised if the two methods give different peaks; just be CONSISTENT in
which method you choose and stick with it.
8. To get the area under the curve (AUC) between 25-50% of the peak height. Right Click and
hold while your cursor is located ON THE CURVE where the value on the y-axis
corresponds to the value you calculated for 25%. Drag the cursor to the value ON THE
CURVE corresponding to 50% and release your click. You box should look similar to the
picture below.
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9.

This will pop up a box with the 99 and 100 AUC.

10. To get the values, go to Spectrum→Tabulate.
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11. Copy and paste into Excel. It is up to you how you want to set up your spreadsheet but I
have provided an example below.
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12. MPE is determined by solving for X in your equation determined by your standard curve.
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Respiration and ROS Methodology
RCR Measurements


Vacuum out chamber and add 965 microliters of Creatine Buffer



Hit “Go”



Add tissue and cap. Wait for the line to stabilize.



Mark “mito” and then add 10 microliters of malate and10 microliters of pyruvate and
mark “mp”



Adjust the cap so that the fluid is just at the well



Wait two minutes from the mark of MP and add 5 microliters of ADP. Mark “adp”



Wait 5 minutes from the mark of adp and then add 10 microliters of Oligo. Mark “oligo”



Wait 10 minutes from the mark oligo and then stop the recording and save the data.



Wash two times with dH2O and then add dH2O. Go to step one when the next tissues are
ready.

Clean for Storage


Vacuum out chambers and disconnect. Do everything like “cleaning” accept place
electrodes in electrode box instead of adding a new membrane.



Place stir rods in tube and place also in electrode box along with gaskets.



Remove plungers from syringes and wash with dH2O unless it is the oligo syringe which
needs to be washed with ET-OH. Run the plunger through with either dH2O or ET-OH
depending on the syringe and then place separate in the “syringe box”.

Analyzing the RCR Data – Permeabilized Fibers


Open the software and then open the File you want. –Click Rate- show rate cursors
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Click the red line button and adjust the start and end lines to be 30 sec apart.



Move the lines to the ADP mark.



Slide it slowly along the line until you find the highest number. This will be your state 3.



For the state 4 you need to adjust your start and end line for 2 min apart then move them
past the oligo mark. Search for the lowest value and this will be your state 4.



The state 3 divided by the state 4 is the RCR.



IN the event that the RCR is significantly lower or higher than normal (about 6-8) adjust
the start and the end lines to be 1 min apart, find the middle value of the state 4 and use
that. If it is still wrong find the middle between the middle and the lowest or the highest
and then middle.
RCR = (state 3) / (state 4)
State 3 / 40 μL of mitochondria x [protein] = rate per unit mass
State 4 / 40 μL of mitochondria x [protein] = rate per unit mass

SOP for Mitochondria Oxygraph (Cleaning/Calibration/Measurements)
Cleaning


Turn on surge protector to vacuum out the chambers and disconnect the line on the
bottom left



1=4 2=2 3=3



Unscrew the chambers by turning them to the right. Remove stir rod, black rings, and
membrane.

195



Wash with dH2O, get electrode polish and a Q-tip, polish the silver ring and electrode
hard, wash with dH2O



KCl made from each project 17.5g/100mL of dH2O. When a project is done, clean and
put stir rod in tube and store in electrode box.



Put 200 microliters of KCl on electrode before membrane



To change membrane, use black tool from electrode box.



Chem wipe. Don’t touch, cut and put the rest back.



Membrane, touch edge, flip and cut. Make sure inside is facing up.



Use KCl 4 or 5 drops on silver with one drop on top.



Paper first then plastic. Black O ring. Slowly place tool then quickly press.



Replace large black O ring and replace the electrode on chamber.



Replace wire anddH2O and stir bar.



Turn on.

Calibration


Check air pressure from rat room and convert to KPa



Turn upside down to eliminate air



Turn on surge protector to vacuum out the chambers. DON’T GO TO THE BOTTOM!
Just touch stir rod!



Add 2 ml Buffer Z (put tip on wall) replace in H2O bath.



Open software. User, Oxigraph+, OK 3times, calibrate, liquid phase, cal, channel1, temp
37, pressure in KPa, OK 2times



Watch for the rate. If you have rate click OK.
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Add sodium hydrosulfite wait for override to say OK. Click OK and save. Turn off stir
rod.



Wash with Et-OH 3X & then fill with dH2O



If there is a problem, wash with Et-OH 3x & then use dH2O 3X and try again.

SOP for Mitochondrial Substrates


5mg of Oligomyacin (Sigma) into 5 mL of Ethanol
o 4 mL in bottle of Oligomyacin
o Add 1 mL and pour into 5 mL tube and vortex



Aliquot into 10 .5 mL tubes



Write “O” on tubes and freeze in the -20 freezer at the bottom (should last a long time!)



Day before use, thaw buffer X and Z in the -4 glass fridge



Make sure these three substrates are made. Usually once a week.



Pyruvate 55mg/ 1 mL of Tris HCL Changed to 22mg -> Online protocol uses 44mg



Malate 35.6mg/ 1 mL of Tris HCL



ADP 21.4mg/ 1 mL Tris HCL



100mMol Tris HCL 1.576g in 100 mL



91mg/35 mL -> Creatine (made fresh daily) 13mg/5 mL buffer Z (975
microliters/chamber/tissue) Place in H2O bath for later use (e.g., 5 animals with 4 tissues
each would need 20mL buffer Z and 52mg Creatine)
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Saponin (made fresh daily) .5mg/ 1mL of dH2O (Good for 2 animals) use 5m. Measure
powder and then add dH2O to powder. Mix and then pour into tube. Place in white
fridge.



Need 4 2mL tubes per piece of tissue



Add 1mL of buffer X to the first tube and then add 34 microliters directly before adding
tissue for 30 min perm.



Add 1.5mL of Z to the other three tubes for the 5 min washes.

Respiration Quick Reference
Make these Fresh Daily:


Creatine 13mg/5mL



Malate 22mg/ mL



Pyruvate 35.6mg/ mL



ADP 21.4mg/ mL



Saponin 0.5mg/ mL

Order of Substrates:


Add mito & lid



Add 10 μL Malate & Pyruvate. Wait 2 min



Add 5 μL ADP. Wait 5 min



Add 10 μL Oligo. Wait 10 min

(1mL) Buffer X (initial pH 7.3) – Used for separating fibers and for permibilizing
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Amount Need for (RCR + ROS) per animals/day
Buffer X 5 mL for separation 1.5 mL / fiber – usually 4 = 6 mL =11
Buffer Z 60 mL 1.5 mL x 3 wash x 4 fibers = 18mL
Calibration = 12mL /day
Respiration = 4 mL/animal
Amplex Red = 1mL/fiber
4 animals/day
Reagent

K-MES

MW(g/mol) Conc

233.33

200mL

500mL

(mM)

(g)

(g)

60

2.8000

6.9999

1L (g)

Product #

13.9998

Sigma
M0895

KCl

74.56

35

0.5219

1.3048

2.6096

K2EGTA

100mM

7.23

5.54mL

13.86mL

27.7mL

CaK2EGTA

200mM

2.77

14.45mL

36.15mL

72.3mL

Imidazole

68.08

20

0.2723

0.6808

1.3616

Sigma 10125

Dithiothreitol 154.1

0.5

0.0154

0.0385

0.0771

Santa Cruz

(DDT)
Taurine

Sigma P4504

sc-29089
125.15

20

0.5006
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1.2515

2.5030

Sigma T8691

ATP

551.1

5.7

0.6283

1.5706

3.1413

Sigma A2383
(order)

PCr

327.2

15

0.9815

2.4540

4.9080

Roche
(order)
10621714001

MgCl 6H2O

203.3

3mM

1.4018

pH 7.1, 295 mosmol/kg H2O initial pH 3.86 pH 3.12 (w.o KOH) pH 5.58 (w/KOH)
K2EGTA=7.608g EGTA + 2.3g KOH in 200 mL dH2O – pH 7.4 with KOH – pH ??????
CaK2EGTA=7.608g EGTA (order) +2.002g CaCO3 in 200mL dH2O at 80° C + then add
2.3g KOH in the 200mL. pH 7.4
EGTA 0.3804 in 10mL

KOH

0.115 in 10mL

CaCO3 0.1001 in 10mL

For per. RCR
Initial pH 7.5 (5/2)
(1.5 mL) Buffer Z – used for washes, respiration, base for Amplex Red
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Reagent

K-MES

MW

Conc

200mL

500mL

(g/mol)

(mM)

(g)

(g)

233.33

110

2.1333

12.8332

1 L (g)

Product # 1.5L

25.6663

Sigma

38.4996

M0895
KCl

74.56

35

0.5219

1.3048

26096

Sigma

3.9144

P4504
EGTA

280.35

1

0.0761

0.1902

0.3804

Sigma

0.5706

E4378
K2HPO4

174.18

5

0.1742

0.4355

0.8709

Fisher

1.3065

P380
MgCl2 *

203.3

5

0.2085

0.50825

1.0165

6 H2O
Glutamate

Sigma

1.5248

M2670
169.11

0.005

Sigma

75 μL

G8415
(50 μL)
Malate

134.09

0.002

Sigma

300 μL

M6773
(200 μL)
BSA

0.05%

0.1

0.25

0.5

Sigma
A6003

201

0.75

pH 7.1, 295 mosmol/kg H2O (pH @ room temp per powers lab history)
Sigma G5889 – Glutamate 0.073g/5mL of dH2O (=0.1M x 147.13g (MW) x 0.005L) 1M
stock -> 15 mL = 2.5367g Glutamate
 0.01mL (10 μL)/200mL of Buffer Z (=10 μL/20mL of Buffer Z) – boiling when
putting glutamate it should be warm or hot to get in solution pH 7.4
Sigma M7397 – Malate 0.089g/5mL of dH2O (=0.1M x 178.05g(MW) x 0.005L)
 0.04mL (40 μL)/200mL of Buffer Z (=4 μL/20mL of Buffer Z) 1M stock -> 15mL =
2.0114g Malate – pH 7.4

Glutamate 0.5 μL in 10 mL

Malate 2 μL in 10mL

Freeze Glutammate & Malate @ -20°C – Aliquot in small vials

500 mL = 600 μL 114.12 mg ECTA

Preparation of 10uM Amplex Ultra Red stock 1 (regular stock for state 4 H202 assay):
Goal: H202 assay buffer stock 1: Buffer Z <w. 0.5 mg/ml BSA) +1mM EGTA + 25μM
blebbstatin + 10μM Amplex Ultra Red + 25U

202

1. Make 5mM Amplex Ultra Red (AUR). Add 666.6ul of DMSO to 1mg Amplex Ultra Red
(Invitrogen # A36006), vortex. 5 vials 600μL in 300μL
2. Prepare 10uM Amplex Red. Add 160.6mL Buffer Z (0.5mg/ml BSA) + 325μL 5mM
AUR + (3.25μL 0.5M EGTA) already in buffer Z + 406μL 10mM Bleb
3. Prepare in black tubes. 1.05ml Aliquot in the dark. Store in -80.
Typically only run state 4
Preparation of 10uM Amplex Ultra Red stock 2 (for state 3 H202 assay with ADP clamp):
Goal: H202 assay buffer stock 2: Buffer Z (w/ 0.5mg/ml BSA) + 20mM Cr + 1mM
EGTA + 25μM blebbstatin + 10μM Amplex Ultra Red + 25U/ml CuZn-SOD + 5mM DOG +
2U/ml HK
1. Prepare 10uM AUR stock. Add 80.3 mL Buffer Z (0.5mg/ml BSA) + 0.24237g of
creatine monohydrate + 0.0667mg 2-DOG + 406.25μL of 400U/ml HK + 162.5μL 5mM
AUR + 162.5μL 0.5M EGTA + 406.25μL 5000 IU/ml SOD + 203μL 10mM Bleb
2. Prepare in black tubes. 1.05ml Aliquot in the dark. Store in -80.
Preparation of Amplex Red (used for PDN 58)
1. Remove 1 vial from freezer. As of 11/09, one vial contains 154ug of Amplex Red.
DOUBLE CHECK THE CONTENT LISTING ON THE LABEL AS THESE
AMOUNTS CAN BE CHANGED BY THE MANUFACTURER!
2. Make 10mM Stock. The MW of Amplex Red is 257.25g/mol. Dissolve in DMSO. This
requires 59.864 ul of DMSO, or simply 59.9 ul, added directly to the vial. Vortex well
but not too much as vigorous vortexing can denature certain compounds.
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3. Dilute stock to 10uM and store in separate aliquots. This is a 1000 fold dilution, therefore
the final volume will be 59.864 ml. Dilute using 0.5mg/ml BSA in Buffer Z (double
check that the pH of Z is at 7.40). DO NOT USE PURE WATER!
TIP: The vial will hold approximately 700 ul volume. Add ~500 ul of Buffer Z to
vial, pipette up and down to ensure proper mixing, and then transfer to small beaker
or 50 ml plastic tube. Add another 500 ul and repeat. Do this at least 4 times to ensure
that ALL Amplex red has been removed from vial. DO NOT SIMPLY PIPETTE
OUT AMPLEX RED DISSOLVED IN DMSO AS THE SMALLEST DROP
MISSED CAN AFFECT YOUR FINAL CONCENTRATION – especially
considering the 1000 fold dilution!
4. Add 120 ul 0.5M EGTA final concentration.
5. Bring final volume up to 59.864 ml, or whatever is appropriate for the mass in your
original vial.
TIP: If using a 50 ml plastic tube, bring final volume up to 25-30 ml (RECORD
WHAT FINAL VOLUME IS!) and add the remaining Z to the 2nd tube, so long as the
total volume in both tubes is 59.864 including the original 59.864 ul of
DMSO/AMPLEX RED. Then pour some of the solution from the 1st tube into the 2nd
and then back and forth. Do so several times to get complete mixing. Otherwise just
use a small beaker!
6. Aliquot in 925 ul volumes into black 1.5 ml Eppendorf tubes. This volume permits 3
experiments of 300ul each, with a bit of extra to ease pipetting for the 3rd experiment.
You may have to spin it down. In general, do not aliquot any more than you need – this
saves money in the long run.
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Succinate (sodium succinate dibasic hexahydrate)
Make stock solution of 0.5 m succinate = 2.026g in 15 mL of Buffer Z. Add 20ul to ROS
chamber for final concentration of 10mM.
HRP buffer
Sigma P8375 – 1KU
To make 300u/mL, dissolve contents of both in 3.33 mL of Buffer Z.
You will be adding 3.33uL into the ROS chamber per sample so aliquot this into small
amounts 30-50uL or smaller.

Protocol 5 – Max Succinate
Substrate

Event Code

STOCK

Titration

Final

Volume (ul)

Concentration in
Chamber

AmplexRed

10mM

1000

25uM

300U/ml

3.33

1U/ml

Assay Buffer
HRP

ADD FIBER AND GET BACKGROUND FOR 8 MINUTES
Succinate

S

0.5M

20

10mM

Auranofin

AF

1m M

1

1uM
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Reagent

#

Supplier

Amplex Red

A36006

Thermofisher

HRP

P8375

Sigma

Auranofin

A6733

Sigma

1 KU = 1000
300u/m
H2O2 Standard Curve Protocol
1. Make H2O2 standards via serial dilution:
Make H2O2 stock by serial dilution
Vial

Vol. of ddH2O

3% (v/v) Vol. of

[H2O2] stock.

added in uL

[H2O2] added in

uM

uL
A

4310

100

20000

B

3980

20 uL of A

100

C

3200

800 ul of B

20

D

2000

2000 ul of C

10

206

E

2000

2000 ul of D

5

2. Perform H2O2 titration in buffers containing all substrates/inhibitors
[H2O2] stock uM

[H2O2] stock

Vol. of [H2O2]

Total pmol of

pmol/ul

added in uL

H2O2 added (ul)

E

5

3

15

5

3

30

10

3

60

10

4

100

20

3

160

20

5

260

20

8

420

5
E
5
D
10
D
10
C
20
C
20
C
20

583uM
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Stir Bar 6

Setting for Ocean Optics Device

Setup – Integration Time – 500mSec
Strip Chart – Update every 10 scans
Integrate 583 -> 587

581-587

Make sure Cuvette is facing correct way… Slotted side facing LED.
Strip Chart Wiz – Update every scan integrate 581-587
Stir speed – 6/10

*In order to lengthen time of acquisition on strip chart, go to “schematic Window” tab,
and double-click “Trend_#” icon. Default Buffer size = 1,000 (about 10 minutes). Can
increase this value to increase acquisition duration.
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